<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Minigene Splicing Assays Identify 12 Spliceogenic Variants of BRCA2 Exons 14 and 15</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":5.477727,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpSAwwEEloAFx9SSkYMVgoHEkkZTAJXVlZXSwdWU1hIA1NRAAAXVBBZCg==","queueTime":0,"ttGuid":"db0d3e19bf8f0a74"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/full">
<meta property="description" name="description" content="A relevant fraction of BRCA2 variants is associated with splicing alterations and with an increased risk of hereditary breast and ovarian cancer (HBOC). In t...">
<meta property="og:title" name="title" content="Frontiers | Minigene Splicing Assays Identify 12 Spliceogenic Variants of BRCA2 Exons 14 and 15">
<meta property="og:description" name="description" content="A relevant fraction of BRCA2 variants is associated with splicing alterations and with an increased risk of hereditary breast and ovarian cancer (HBOC). In t...">
<meta name="keywords" content="breast  cancer,BRCA2,DNA variants,Aberrant splicing,Minigenes">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="10">
<meta name="citation_journal_title" content="Frontiers in Genetics">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Genet.">
<meta name="citation_issn" content="1664-8021">
<meta name="citation_doi" content="10.3389/fgene.2019.00503">
<meta name="citation_firstpage" content="452814">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Minigene Splicing Assays Identify 12 Spliceogenic Variants of BRCA2 Exons 14 and 15">
<meta name="citation_keywords" content="breast  cancer; BRCA2; DNA variants; Aberrant splicing; Minigenes">
<meta name="citation_abstract" content="A relevant fraction of BRCA2 variants is associated with splicing alterations and with an increased risk of hereditary breast and ovarian cancer (HBOC). In this work, we have carried out a thorough study of variants from BRCA2 exons 14 and 15 reported at mutation databases.A total of 294 variants from exons 14 and 15 and flanking intronic sequences were analysed with the online splicing tools NNSplice and Human Splicing Finder. Fifty-three out of these 294 variants were selected as candidate splicing variants. All variants but one, were introduced into the minigene MGBR2_ex14-20 (with exons 14 to 20) by site-directed mutagenesis and assayed in MCF-7 cells. Twelve of the remaining 52 variants (23.1%) impaired splicing at different degrees, yielding from 5% to 100% of aberrant transcripts. Nine variants affected the natural acceptor or donor sites of both exons and three affected putative enhancers or silencers. Fluorescent capillary electrophoresis revealed at least ten different anomalous transcripts: (E14q5),  (E14p10), (E14p246), (E14q256), (E14), (E15p12), (E15p13), (E15p83), (E15) and a 942-nt fragment of unknown structure. All transcripts, except for (E14q256) and (E15p12), are expected to truncate the BRCA2 protein. Nine variants induced severe splicing aberrations with more than 90% of abnormal transcripts. Thus, according to the guidelines of the American College of Medical Genetics and Genomics, eight variants should be classified as pathogenic (c.7008-2A>T, c.7008-1G>A, c.7435+1G>C, c.7436-2A>T, c.7436-2A>G, c.7617+1G>A, c.7617+1G>T and c.7617+2T>G), one as likely pathogenic (c.7008-3C>G) and three remain as variants of uncertain clinical significance or VUS (c.7177A>G, c.7447A>G and c.7501C>T).In conclusion, functional assays by minigenes constitute a valuable strategy to primarily check the splicing impact of DNA variants and their clinical interpretation. While bioinformatics predictions of splice site variants were accurate, those of enhancer or silencer variants were poor (only 3/23 spliceogenic variants) which showed weak impacts on splicing (~5 to 16% of aberrant isoforms). So, the Exonic Splicing Enhancer and Silencer (ESE and ESS, respectively) prediction algorithms require further improvement.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2019/05/07">
<meta name="citation_publication_date" content="2019/05/28">
<meta name="citation_author" content="Fraile-Bethencourt, Eugenia ">
<meta name="citation_author_institution" content="Splicing and Genetic Susceptibility to Cancer, Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain">
<meta name="citation_author" content="Valenzuela-Palomo, Alberto ">
<meta name="citation_author_institution" content="Splicing and Genetic Susceptibility to Cancer, Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain">
<meta name="citation_author" content="Dez-Gmez, Beatriz ">
<meta name="citation_author_institution" content="Splicing and Genetic Susceptibility to Cancer, Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain">
<meta name="citation_author" content="Caloca, Mara Jos ">
<meta name="citation_author_institution" content="Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain">
<meta name="citation_author" content="Gmez-Barrero, Susana ">
<meta name="citation_author_institution" content="VISAVET-Universidad Complutense de Madrid, Spain">
<meta name="citation_author" content="Velasco, Eladio A. ">
<meta name="citation_author_institution" content="Splicing and Genetic Susceptibility to Cancer, Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain">
<meta name="dc.identifier" content="doi:10.3389/fgene.2019.00503">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Minigene Splicing Assays Identify 12 Spliceogenic Variants of BRCA2 Exons 14 and 15","author":[{"@type":"Person","name":"Eugenia Fraile-Bethencourt","affiliation":["Splicing and Genetic Susceptibility to Cancer, Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain"]},{"@type":"Person","name":"Alberto Valenzuela-Palomo","affiliation":["Splicing and Genetic Susceptibility to Cancer, Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain"]},{"@type":"Person","name":"Beatriz Dez-Gmez","affiliation":["Splicing and Genetic Susceptibility to Cancer, Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain"]},{"@type":"Person","name":"Mara Jos Caloca","affiliation":["Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain"]},{"@type":"Person","name":"Susana Gmez-Barrero","affiliation":["VISAVET-Universidad Complutense de Madrid, Spain"]},{"@type":"Person","name":"Eladio A. Velasco","affiliation":["Splicing and Genetic Susceptibility to Cancer, Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain"]}],"datePublished":"2019-05-28","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2019","isPartOf":{"@type":"PublicationVolume","volumeNumber":"10","isPartOf":{"@type":"Periodical","name":"Frontiers in Genetics"}}},"citation":["https://doi.org/10.3389/fgene.2019.00503"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/genetics" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=30&amp;specialtyid=0&amp;entitytype=2&amp;entityid=240" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/genetics" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/applied-genetic-epidemiology" data-event="iBarJournal-sections-a_id_549">Applied Genetic Epidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/behavioral-and-psychiatric-genetics" data-event="iBarJournal-sections-a_id_536">Behavioral and Psychiatric Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cancer-genetics-and-oncogenomics" data-event="iBarJournal-sections-a_id_2030">Cancer Genetics and Oncogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/computational-genomics" data-event="iBarJournal-sections-a_id_551">Computational Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cytogenomics" data-event="iBarJournal-sections-a_id_2512">Cytogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/elsi-in-science-and-genetics" data-event="iBarJournal-sections-a_id_650">ELSI in Science and Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/epigenomics-and-epigenetics" data-event="iBarJournal-sections-a_id_455">Epigenomics and Epigenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/evolutionary-and-population-genetics" data-event="iBarJournal-sections-a_id_535">Evolutionary and Population Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-aging" data-event="iBarJournal-sections-a_id_596">Genetics of Aging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-common-and-rare-diseases" data-event="iBarJournal-sections-a_id_635">Genetics of Common and Rare Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomic-assay-technology" data-event="iBarJournal-sections-a_id_557">Genomic Assay Technology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomics-of-plants-and-the-phytoecosystem" data-event="iBarJournal-sections-a_id_1520">Genomics of Plants and the Phytoecosystem</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/human-and-medical-genomics" data-event="iBarJournal-sections-a_id_1419">Human and Medical Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/immunogenetics" data-event="iBarJournal-sections-a_id_2237">Immunogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/livestock-genomics" data-event="iBarJournal-sections-a_id_241">Livestock Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/neurogenomics" data-event="iBarJournal-sections-a_id_19">Neurogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/nutritional-genomics" data-event="iBarJournal-sections-a_id_3423">Nutritional Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/predictive-toxicology-and-exposomics" data-event="iBarJournal-sections-a_id_556">Predictive Toxicology and Exposomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/rna" data-event="iBarJournal-sections-a_id_555">RNA</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/statistical-genetics-and-methodology" data-event="iBarJournal-sections-a_id_454">Statistical Genetics and Methodology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/stem-cell-research" data-event="iBarJournal-sections-a_id_685">Stem Cell Research</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=30&amp;specialtyid=0&amp;entitytype=2&amp;entityid=240" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/genetics" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/applied-genetic-epidemiology" data-event="iBarJournal-sections-a_id_549">Applied Genetic Epidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/behavioral-and-psychiatric-genetics" data-event="iBarJournal-sections-a_id_536">Behavioral and Psychiatric Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cancer-genetics-and-oncogenomics" data-event="iBarJournal-sections-a_id_2030">Cancer Genetics and Oncogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/computational-genomics" data-event="iBarJournal-sections-a_id_551">Computational Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cytogenomics" data-event="iBarJournal-sections-a_id_2512">Cytogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/elsi-in-science-and-genetics" data-event="iBarJournal-sections-a_id_650">ELSI in Science and Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/epigenomics-and-epigenetics" data-event="iBarJournal-sections-a_id_455">Epigenomics and Epigenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/evolutionary-and-population-genetics" data-event="iBarJournal-sections-a_id_535">Evolutionary and Population Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-aging" data-event="iBarJournal-sections-a_id_596">Genetics of Aging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-common-and-rare-diseases" data-event="iBarJournal-sections-a_id_635">Genetics of Common and Rare Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomic-assay-technology" data-event="iBarJournal-sections-a_id_557">Genomic Assay Technology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomics-of-plants-and-the-phytoecosystem" data-event="iBarJournal-sections-a_id_1520">Genomics of Plants and the Phytoecosystem</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/human-and-medical-genomics" data-event="iBarJournal-sections-a_id_1419">Human and Medical Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/immunogenetics" data-event="iBarJournal-sections-a_id_2237">Immunogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/livestock-genomics" data-event="iBarJournal-sections-a_id_241">Livestock Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/neurogenomics" data-event="iBarJournal-sections-a_id_19">Neurogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/nutritional-genomics" data-event="iBarJournal-sections-a_id_3423">Nutritional Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/predictive-toxicology-and-exposomics" data-event="iBarJournal-sections-a_id_556">Predictive Toxicology and Exposomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/rna" data-event="iBarJournal-sections-a_id_555">RNA</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/statistical-genetics-and-methodology" data-event="iBarJournal-sections-a_id_454">Statistical Genetics and Methodology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/stem-cell-research" data-event="iBarJournal-sections-a_id_685">Stem Cell Research</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/genetics" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/applied-genetic-epidemiology" data-event="iBarJournal-sections-a_id_549">Applied Genetic Epidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/behavioral-and-psychiatric-genetics" data-event="iBarJournal-sections-a_id_536">Behavioral and Psychiatric Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cancer-genetics-and-oncogenomics" data-event="iBarJournal-sections-a_id_2030">Cancer Genetics and Oncogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/computational-genomics" data-event="iBarJournal-sections-a_id_551">Computational Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cytogenomics" data-event="iBarJournal-sections-a_id_2512">Cytogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/elsi-in-science-and-genetics" data-event="iBarJournal-sections-a_id_650">ELSI in Science and Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/epigenomics-and-epigenetics" data-event="iBarJournal-sections-a_id_455">Epigenomics and Epigenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/evolutionary-and-population-genetics" data-event="iBarJournal-sections-a_id_535">Evolutionary and Population Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-aging" data-event="iBarJournal-sections-a_id_596">Genetics of Aging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-common-and-rare-diseases" data-event="iBarJournal-sections-a_id_635">Genetics of Common and Rare Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomic-assay-technology" data-event="iBarJournal-sections-a_id_557">Genomic Assay Technology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomics-of-plants-and-the-phytoecosystem" data-event="iBarJournal-sections-a_id_1520">Genomics of Plants and the Phytoecosystem</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/human-and-medical-genomics" data-event="iBarJournal-sections-a_id_1419">Human and Medical Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/immunogenetics" data-event="iBarJournal-sections-a_id_2237">Immunogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/livestock-genomics" data-event="iBarJournal-sections-a_id_241">Livestock Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/neurogenomics" data-event="iBarJournal-sections-a_id_19">Neurogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/nutritional-genomics" data-event="iBarJournal-sections-a_id_3423">Nutritional Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/predictive-toxicology-and-exposomics" data-event="iBarJournal-sections-a_id_556">Predictive Toxicology and Exposomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/rna" data-event="iBarJournal-sections-a_id_555">RNA</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/statistical-genetics-and-methodology" data-event="iBarJournal-sections-a_id_454">Statistical Genetics and Methodology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/stem-cell-research" data-event="iBarJournal-sections-a_id_685">Stem Cell Research</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=30&amp;specialtyid=0&amp;entitytype=2&amp;entityid=240" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Genet.</span><span>, 28 May 2019</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. RNA</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 10 - 2019 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fgene.2019.00503">https://doi.org/10.3389/fgene.2019.00503</a></p><!----></div><!----><p class="ArticleLayoutHeader__isPartOfRT"><span class="ArticleLayoutHeader__isPartOfRT__label">This article is part of the Research Topic</span><span class="ArticleLayoutHeader__isPartOfRT__title">RNA Splicing and Backsplicing: Disease and Therapy</span><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View all 18 articles" href="https://www.frontiersin.org/research-topics/9566/rna-splicing-and-backsplicing-disease-and-therapy/magazine" target="_self" data-event="customLink-linkType-a_viewAll18Articles"><span>View all 18 articles</span></a></span></p></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Minigene Splicing Assays Identify 12 Spliceogenic Variants of <i>BRCA2</i> Exons 14 and 15</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract">
<a id="h1" name="h1"></a>
<div class="authors"><span class="author-wrapper notranslate">
<a href="https://loop.frontiersin.org/people/496376" class="user-id-496376"><img class="pr5" src="https://loop.frontiersin.org/images/profile/496376/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="
Eugenia Fraile-Bethencourt">Eugenia Fraile-Bethencourt</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/514162" class="user-id-514162"><img class="pr5" src="https://loop.frontiersin.org/images/profile/514162/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Alberto Valenzuela-Palomo">Alberto Valenzuela-Palomo</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/563485" class="user-id-563485"><img class="pr5" src="https://loop.frontiersin.org/images/profile/563485/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Beatriz D&#xED;ez-G&#xF;mez">Beatriz D&#x00ED;ez-G&#x00F3;mez</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/682766" class="user-id-682766"><img class="pr5" src="https://loop.frontiersin.org/images/profile/682766/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Mar&#xED;a Jos&#xE; Caloca">Mar&#x00ED;a Jos&#x00E9; Caloca</a><sup>2</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/717658" class="user-id-717658"><img class="pr5" src="https://loop.frontiersin.org/images/profile/717658/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Susana G&#xF;mez-Barrero">Susana G&#x00F3;mez-Barrero</a><sup>3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/496947" class="user-id-496947"><img class="pr5" src="https://loop.frontiersin.org/images/profile/496947/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Eladio A. Velasco*">Eladio A. Velasco</a><sup>1*</sup></span></div>
<ul class="notes">
<li><span><sup>1</sup></span>Splicing and Genetic Susceptibility to Cancer, Instituto de Biolog&#x00ED;a y Gen&#x00E9;tica Molecular (CSIC-UVa), Valladolid, Spain</li>
<li><span><sup>2</sup></span>Instituto de Biolog&#x00ED;a y Gen&#x00E9;tica Molecular (CSIC-UVa), Valladolid, Spain</li>
<li><span><sup>3</sup></span>VISAVET-Universidad Complutense de Madrid, Madrid, Spain</li>
</ul>
<p class="mb0">A relevant fraction of <i>BRCA2</i> variants is associated with splicing alterations and with an increased risk of hereditary breast and ovarian cancer (HBOC). In this work, we have carried out a thorough study of variants from BRCA2 exons 14 and 15 reported at mutation databases. A total of 294 variants from exons 14 and 15 and flanking intronic sequences were analyzed with the online splicing tools NNSplice and Human Splicing Finder. Fifty-three out of these 294 variants were selected as candidate splicing variants. All variants but one, were introduced into the minigene MGBR2_ex14-20 (with exons 14&#x2013;20) by site-directed mutagenesis and assayed in MCF-7 cells. Twelve of the remaining 52 variants (23.1%) impaired splicing at different degrees, yielding from 5 to 100% of aberrant transcripts. Nine variants affected the natural acceptor or donor sites of both exons and three affected putative enhancers or silencers. Fluorescent capillary electrophoresis revealed at least 10 different anomalous transcripts: <img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-i001.jpg" id="I1" alt="www.frontiersin.org">(E14q5), &#x0394; (E14p10), &#x0394;(E14p246), &#x0394;(E14q256), &#x0394;(E14), &#x0394;(E15p12), &#x0394;(E15p13), &#x0394;(E15p83), &#x0394;(E15) and a 942-nt fragment of unknown structure. All transcripts, except for &#x0394;(E14q256) and &#x0394;(E15p12), are expected to truncate the BRCA2 protein. Nine variants induced severe splicing aberrations with more than 90% of abnormal transcripts. Thus, according to the guidelines of the American College of Medical Genetics and Genomics, eight variants should be classified as pathogenic (c.7008-2A &#x003E; T, c.7008-1G &#x003E; A, c.7435+1G &#x003E; C, c.7436-2A &#x003E; T, c.7436-2A &#x003E; G, c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G), one as likely pathogenic (c.7008-3C &#x003E; G) and three remain as variants of uncertain clinical significance or VUS (c.7177A &#x003E; G, c.7447A &#x003E; G and c.7501C &#x003E; T). In conclusion, functional assays by minigenes constitute a valuable strategy to primarily check the splicing impact of DNA variants and their clinical interpretation. While bioinformatics predictions of splice site variants were accurate, those of enhancer or silencer variants were poor (only 3/23 spliceogenic variants) which showed weak impacts on splicing (&#x223C;5&#x2013;16% of aberrant isoforms). So, the Exonic Splicing Enhancer and Silencer (ESE and ESS, respectively) prediction algorithms require further improvement.</p>
<div class="clear"></div>
</div>
<div class="JournalFullText">
<a id="h2" name="h2"></a><h2>Introduction</h2>
<p class="mb15">Since the discovery of the breast cancer genes <i>BRCA1</i> (OMIM #113705) and <i>BRCA2</i> (OMIM #600185) (<a href="#B27">Miki et al., 1994</a>; <a href="#B47">Wooster et al., 1995</a>), nearly 17,000 different variants of both genes have been recorded at the ClinVar database<sup id="footnotesuper1"><a id="note1a"></a><a class="footnoteanchor" href="#note1">1</a></sup> (date last accessed; November 2018). Germline inactivating variants in <i>BRCA1</i> and <i>BRCA2</i> confer high lifetime risks of breast and ovarian cancers (<a href="#B26">Mavaddat et al., 2013</a>). Also, other cancer types, such as prostate, pancreatic and melanoma, are associated with pathogenic variants in these genes (<a href="#B31">Petrucelli et al., 2013</a>). Despite the high penetrance of <i>BRCA</i> pathogenic variants, they are responsible for only &#x223C;15&#x2013;20% of hereditary breast and ovarian cancer (HBOC) (<a href="#B42">Stratton and Rahman, 2008</a>). In fact, HBOC is a highly genetically heterogeneous disease with about 25 known or proposed susceptibility genes (<a href="#B30">Nielsen et al., 2016</a>). Apart from the BRCA genes, <i>PALB2</i> (OMIM #610355), <i>ATM</i> (OMIM #607585), and <i>CHEK2</i> (OMIM #604373) have a prominent contribution since, in a recent study, more than 30% of pathogenic variants were found in these genes (<a href="#B6">Buys et al., 2017</a>).</p>
<p class="mb15">Commonly, the variants are classified attending to their predicted effect on the protein so that truncating variants (frameshift and nonsense) are directly classified as pathogenic, while intronic, missense and synonymous variants are usually considered to be variants of uncertain clinical significance (VUS). In fact, VUS are identified by a relevant proportion of BRCA genetic tests (&#x223C;20%), which hamper genetic counseling and subsequent preventive or therapeutic actions, since risk assessment is solely based on family history (<a href="#B32">Radice et al., 2011</a>; <a href="#B13">Eccles et al., 2015</a>; <a href="#B36">Ricks et al., 2015</a>).</p>
<p class="mb15">Furthermore, other upstream gene-expression processes, such as transcription or splicing, can be impaired if regulatory motifs are targeted by nucleotide variations (<a href="#B46">Wang and Cooper, 2007</a>). Splicing is the process by which introns are removed from a pre-mRNA and exons are consecutively joined. This mechanism is performed in the nucleus by the spliceosome, a macrocomplex constituted by 5 small nuclear ribonucleoproteins (snRNPs) and many other associated proteins (<a href="#B10">De Conti et al., 2012</a>). The spliceosome recognizes in the pre-mRNA specific sequences which define the exons/introns boundaries and other elements needed to carry out the process. These sequences are: the acceptor or 3&#x2032; splice site (3&#x2032;ss), the donor or 5&#x2032; splice site (5&#x2032;ss), the branch point, the polypyrimidine tract and the auxiliary <i>cis</i> sequences known as splicing regulatory elements (SREs) where enhancer or silencer <i>trans</i> factors can bind. Therefore, any change in the sequence may disrupt splicing (<a href="#B7">Cartegni et al., 2002</a>). Splicing variants usually break the 3&#x2032;ss or 5&#x2032;ss leading to abnormal splicing events such as exon skipping, alternative site usage or intron retention. However, they may also create new splicing sites or strengthen cryptic ones that would then be recognized. Other mechanism that may alter splicing is the disruption of exonic/intronic splicing enhancers (ESEs/ISEs) or the creation of exonic/intronic splicing silencers (ESSs/ISSs) (<a href="#B1">Abramowicz and Gos, 2018</a>). Nevertheless, it is extremely difficult to identify active SREs and predict the impact of the DNA variants on splicing given the low accuracy of SRE-detection softwares. Therefore, splicing variants can induce abnormal transcripts that either introduce premature termination codons (PTC), in-frame loss of essential protein domains or even inclusion of new translated sequences. Consequently, variants with impact on splicing (or <i>spliceogenic</i> variants) may be associated with an increased risk of a given disease. This ethiopathogenic mechanism has been so far underestimated, even though some authors have suggested that spliceogenic variants may represent more than 60% of disease-causing mutations (<a href="#B23">L&#x00F3;pez-Bigas et al., 2005</a>).</p>
<p class="mb15">Previous studies have shown that a significant number of splicing variants have been detected in <i>BRCA2</i> (<a href="#B40">Spurdle et al., 2008</a>; <a href="#B34">Rebbeck et al., 2018</a>). In fact, previous results from our group showed that more than 50% of tested variants of <i>BRCA2</i> exons 16&#x2013;27 impaired splicing (<a href="#B3">Acedo et al., 2012</a>, <a href="#B2">2015</a>; <a href="#B16">Fraile-Bethencourt et al., 2017</a>, <a href="#B17">2018</a>). Likewise, at least 24 different BRCA2 alternative transcripts have been identified. They are helpful to interpret the splicing outcomes of genetic variations (<a href="#B14">Fackenthal et al., 2016</a>) and suggest a fine regulation of <i>BRCA2</i> exon processing. This feature is supported by the fact that several ESE-rich regions have been functionally mapped by exonic deletions throughout most <i>BRCA2</i> exons. Thus, these motifs would be involved in precise exon recognition and alternative splicing events (<a href="#B2">Acedo et al., 2015</a>; <a href="#B16">Fraile-Bethencourt et al., 2017</a>). Moreover, we showed that functional mapping is an optimal approach that improves ESE-software predictions and facilitates the identification of spliceogenic mutations of this sort of <i>cis</i>-elements.</p>
<p class="mb0">In this work, we have extended our analysis to <i>BRCA2</i> exons 14 and 15 by carrying out an in-depth study of candidate spliceogenic variants. We have explored the presence of splicing enhancers in exons 14 and 15 and have undertaken RNA assays of 52 selected variants from both exons.</p>
<a id="h3" name="h3"></a><h2>Materials and Methods</h2>
<p class="mb0">Ethical approval for this study was obtained from the Ethics Review Committee of the Hospital Universitario R&#x00ED;o Hortega de Valladolid (6/11/2014).</p>
<h3>Bioinformatics: Databases and <i>in silico</i> Analysis</h3>
<p class="mb15">We collected <i>BRCA2</i> variants from the main databases: ClinVar<sup id="footnotesuper2"><a id="note2a"></a><a class="footnoteanchor" href="#note2">2</a></sup>, the BRCA Share Database (UMD<sup id="footnotesuper3"><a id="note3a"></a><a class="footnoteanchor" href="#note3">3</a></sup>) (<a href="#B5">Beroud et al., 2016</a>) and the Breast Cancer Information Core (BIC<sup id="footnotesuper4"><a id="note4a"></a><a class="footnoteanchor" href="#note4">4</a></sup>) (<a href="#h10">Supplementary Table S1</a>). Variants and transcripts were annotated according to the Human Genome Variation Society (HGVS) guidelines on basis of the <i>BRCA2</i> GenBank sequence NM000059.1. In order to simplify, we identified transcripts with a shortened code that combines the following symbols (<a href="#B24">Lopez-Perolio et al., 2019</a>): &#x0394; (skipping of reference exonic sequences), <img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-i001.jpg" id="I2" alt="www.frontiersin.org"> (inclusion of reference intronic sequences), E (exon), p (acceptor shift), q (donor shift). When necessary, the exact number of skipped or retained nucleotides is indicated. For example, transcript &#x0394;(E14p10) indicates the use of an alternative acceptor site 10-nt downstream that causes a 10-nt deletion.</p>
<p class="mb0"><i>In silico</i> analysis was made with the online softwares: NNSplice<sup id="footnotesuper5"><a id="note5a"></a><a class="footnoteanchor" href="#note5">5</a></sup> (<a href="#B35">Reese et al., 1997</a>) and Human Splicing Finder version 3.1 (HSF<sup id="footnotesuper6"><a id="note6a"></a><a class="footnoteanchor" href="#note6">6</a></sup>) that contain several prediction algorithms of different splicing motifs (<a href="#B12">Desmet et al., 2009</a>). The following matrices were used: MaxEntScan (MES) (<a href="#B48">Yeo and Burge, 2004</a>), the HSF branch point detection tool, ESE-finder (<a href="#B8">Cartegni et al., 2003</a>), the HSF matrices for 9G8 and Tra2&#x03B2; and the HSF matrix for hnRNPA1. All the analyses were carried out with the default threshold values of NNSplice and HSF (NNSplice, 0.4; MES, 3.0; Branch point &#x2013; no cut-off-; SRE (0&#x2013;100 scale): SF2/ASF, 72.98; SF2/ASF (IgM &#x2013; BRCA1), 70.51; SC35, 75.05; SRp40, 78.08; SRp55 73.86; 9G8, 59.245; Tra2&#x03B2;, 75.964 and hnRNPA1, 65.476.</p>
<h3>Minigene Construction and Mutations</h3>
<p class="mb0">The minigene MGBR2_14-20 was built as previously reported (<a href="#B16">Fraile-Bethencourt et al., 2017</a>). A total of 52 variants and 8 microdeletions were introduced into the wild type (wt) minigene by site-directed mutagenesis with the QuikChange Lightning Kit (Agilent, Santa Clara, CA, United States), following the manufacturer&#x2019;s instructions (<a href="#h10">Supplementary Table S2</a>). All mutant clones were confirmed by sequencing (Macrogen, Madrid, Spain).</p>
<h3>MCF-7 Transfections</h3>
<p class="mb0">Approximately 2 &#x00D7; 10<sup>5</sup> MCF-7 cells (human breast adenocarcinoma cell line) were plated in four-well plates (Nunc, Roskilde, Denmark). They were grown to 90% confluency in 0.5 mL of medium (MEME, 10% fetal bovine serum, 2 mM glutamine, 1% non-essential amino acids and 1% penicillin/streptomycin). Then, 1 &#x03BC;g of minigene was transfected into MCF-7 cells using low toxicity Lipofectamine (Life Technologies, Carlsbad, CA, United States) in Gibco<sup>TM</sup> Opti-Mem<sup>TM</sup> medium (Thermo Fisher Scientific, Waltham, MA, United States). Cells were incubated during 48h and then treated with cycloheximide 300 &#x03BC;g/ml (Sigma-Aldrich, St. Louis, MO, United States) for 4 h to inhibit the nonsense-mediated mRNA decay (NMD). The RNA was purified with the Genematrix Universal RNA Purification Kit (EURx, Gda&#x0144;sk, Poland) with on-column DNAse I digestion.</p>
<h3>siRNA Assays</h3>
<p class="mb0">SR proteins were silenced in MCF7 cells by small interfering RNAs (siRNA) against the main SR proteins: SRSF1 (SF2), SRSF2 (SC35), SRSF3 (SRp20), SRSF5 (SRp40), SRSF7 (9G8), SRSF9 (SRp30c), and Tra2&#x03B2; (<a href="#h10">Supplementary Table S3</a>), using anti-Luciferase siRNA as negative control. Approximately 1.5 &#x00D7; 10<sup>5</sup> cells were subjected to a two-hit transfection in Optimem medium (Gibco &#x2013; Life Technologies, Carlsbad, CA, United States) with 3 &#x03BC;l of Oligofectamine (Thermo Fisher Scientific) and the specific siRNA at a final concentration of 0.08 &#x03BC;M on day 2. Then, 2 &#x03BC;g of the wt minigene were transfected with low toxicity Lipofectamine (Thermo Fisher Scientific) on day 4, and RNA was extracted on day 5. Silencing was confirmed by qPCR using 10 ng of cDNA in 25 &#x03BC;l reaction (<a href="#h10">Supplementary Table S3</a>). Amplification was made with SG qPCR Master Mix (Eurx, Gda&#x0144;sk, Poland). Each siRNA/minigene transfection as well as all the qPCR experiments were carried out in duplicate.</p>
<h3>RT-PCR and Transcripts Amplification</h3>
<p class="mb15">Retrotranscription was carried out with 400 ng of RNA and the RevertAid First Strand cDNA Synthesis Kit (Life Technologies), using the specific minigene primer RTPSPL3-RV (5&#x2032;-TGAGGAGTGAATTGGTCGAA-3&#x2032;). Samples were incubated at 42&#x00B0;C for 1 h, followed by 5 min at 70&#x00B0;C. Transcripts were amplified with Platinum Taq DNA polymerase (Life Technologies) using 40 ng of cDNA and the primers pMAD_607FW (Patent P201231427, CSIC) and RTBR2_ex17RV2 (5&#x2032;-GGCTTAGGCATCTATTAGCA-3&#x2032;). PCR consisted of: denaturation step at 94&#x00B0;C for 2 min, followed by 35 cycles 94&#x00B0;C-30 s, 60&#x00B0;C-30 s and 72&#x00B0;C-1 min/kb, and a final extension step at 72&#x00B0;C for 5 min. Transcripts were sequenced at the Macrogen Spain facility.</p>
<p class="mb0">In order to relatively quantify all transcripts, semi-quantitative fluorescent RT-PCRs were undertaken in triplicate with the primers pMAD_607FW (FAM-labeled) and RTBR2_ex17RV2 and Platinum Taq DNA polymerase (Life Technologies) under standard conditions except that 26 cycles were herein applied (<a href="#B2">Acedo et al., 2015</a>). FAM-labeled products were run with LIZ-1200 Size Standard at the Macrogen facility and analyzed with the Peak Scanner software V1.0 (Life Technologies). Only peak heights &#x2265; 50 RFU (Relative Fluorescence Units) were considered.</p>
<a id="h4" name="h4"></a><h2>Results</h2>
<h3 class="pt0">Minigene Construction and ESE Mapping</h3>
<p class="mb0">The minigene MGBR2_14-20 had previously been used to study variants of exons 16, 17, and 18, proving that it is a reliable and robust tool to functionally assay splicing variants (<a href="#B16">Fraile-Bethencourt et al., 2017</a>, <a href="#B17">2018</a>; <a href="#B29">Montalban et al., 2018</a>). The MGBR2_14-20 is a 10.7 Kb construct which, after transfection in MCF-7 cells, produces a transcript with the following structure: V1-BRCA2_exons from 14 to 20-V2 (1,806 nt) (<a href="#F1">Figure 1</a>). To study exons 14 and 15, cDNA was amplified with a forward primer located in V1 (pMAD_607FW) and a reverse primer located in exon 17 (RTBR2_Ex17RV2), with an expected transcript size of 1028 nt (<a href="#F1">Figures 1B,C</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg" name="figure1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg" alt="www.frontiersin.org" id="F1" loading="lazy">
  </picture>
</a>
<p><strong>Figure 1.</strong> Minigene MGBR2_14-20. <b>(A)</b> Schematic representation of MGBR2_14-20. BRCA2 exons 14&#x2013;20 are represented in blue boxes. Red lines represented the shortened introns. <b>(B)</b> Expected MGBR2_14-20 transcript (1,806 nt) and the amplified RT-PCR product. Specific amplification primers are shown as red arrows. <b>(C)</b> Capillary electrophoresis result of the functional assay of the wild type MGBR2_14-20 in MCF-7 cells. The full-length transcript is shown as a blue peak. The Genescan Liz-1200 size standard is shown as orange/faint peaks. Fragment sizes (nt) and relative fluorescent units are indicated on the <i>x</i>- and <i>y</i>-axes, respectively.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">To map ESEs, 30-nt overlapping microdeletions were performed along the first and the last 55-nt of exons 14 and 15 (<a href="#B2">Acedo et al., 2015</a>), always preserving the splice site conserved positions (the first 2 nt and the last 3 nt of the exon). None of the deletions but one altered splicing, suggesting the absence of <i>cis</i>-regulatory motifs within these segments. Only exon 15 deletion c.7463_7492 impaired splicing generating a major aberrant transcript (62%) with a deletion of 83 nt [&#x0394;(E15p83)]. This transcript was caused by use of a cryptic 3&#x2032;ss 83-nt downstream, which is stronger than the canonical one, according to Max Ent Scan (MES; 6.18 vs. 5.16) (<a href="#F2">Figure 2</a>). To determine which ESEs were implied in exon 15 recognition, siRNA experiments against the main splicing factors (SFSR1, SFSR2, SFSR3, SFSR5, SRSF7, SFSR9, and Tra2&#x03B2;) were accomplished (<a href="#h10">Supplementary Figure S1</a>). However, none of them affected the recognition of exons 14 and 15.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg" name="figure2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg" alt="www.frontiersin.org" id="F2" loading="lazy">
  </picture>
</a>
<p><strong>Figure 2.</strong> Exon 15 ESE mapping: functional assay of c.7463_7492del positive microdeletion. <b>(A)</b> Schematic representation of BRCA2 exons 14 and 15 and the eight microdeletions: 1, c.7010_7039del; 2, c.7035_7064del; 3, c.7378_7407del; 4, c.7402_7432del; 5, c.7438_7467del; 6, c.7463_7492del; 7, c.7561_7590del; 8, c.7586_7615del. <b>(B)</b> Capillary electrophoresis and sequence results of functional assays of microdeletion c.7463_7492del in MCF-7 cells.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<h3>Variant Collection and Bioinformatics Analysis</h3>
<p class="mb0">A total of 294 different variants, spread throughout exons 14 and 15 and flanking introns, were collected from the main databases (ClinVar, UMD and BIC) (<a href="#h10">Supplementary Table S1</a>). They were analyzed <i>in silico</i> with MES and NNSplice for splice site prediction, and with ESE/ESS estimation algorithms integrated in Human Splicing Finder (HSF). Potential splicing variants were selected following these criteria: creation or disruption of splice sites (according to MES or NNSplice); disruption of the branch point; disruption of the polypyrimidine tract; elimination of enhancers or creation of silencers. Some of the selected variants had a combined effect, for example, they were predicted to simultaneously create an ESS and removed an ESE. A total of 53 candidate variants (&#x223C;18%) that included 19 intronic, 18 missense, 5 nonsense, 8 synonymous, and 3 frameshift variants were selected (<a href="#T1">Table 1</a>). According to their previous clinical classification, the selection contained: 8 benign or likely benign variants, 30 VUS and 15 pathogenic or likely pathogenic variants.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg" name="table1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy">
  </picture>
</a>
<p><strong>Table 1.</strong> Bioinformatics analysis of <i>BRCA2</i> exons 14 and 15 selected variants.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Bioinformatics indicated that 13 variants disrupted the natural splice sites, three decreased their scores (one disrupted the polypyrimidine tract), 11 created new splice sites, one decreased the branch point score (HSF: 79.34&#x2192;55.5), three altered intronic splicing elements (ISEs and ISSs) and 22 altered exonic splicing elements (ESEs and ESSs) (<a href="#T1">Table 1</a>). Exceptionally, variants c.7008-5T &#x003E; C (ivs13-5T &#x003E; C) and c.7435+5T &#x003E; C (ivs14+5T &#x003E; C) were also selected because, even though the bioinformatics did not show significant score changes (MES: 10.37&#x2192;8.48 and 5.64&#x2192;5.56, respectively), these positions are relevant for exon recognition. Thus, c.7008-5T &#x003E; C is the closest position of the polypyrimidine tract to the canonical acceptor site, and c.7435+5T &#x003E; C is part of the consensus 5&#x2032;ss sequence and +5 changes were previously associated with disease (<a href="#B37">Sharma et al., 2014</a>; <a href="#B29">Montalban et al., 2018</a>).</p>
<h3>Functional Splicing Assays Using the Minigene MGBR2_14-20</h3>
<p class="mb0">A total of 52 variants were genetically engineered in the wt MGBR2_14-20 by using specific primers (<a href="#h10">Supplementary Table S2</a>). Despite 53 variants were initially selected, mutagenesis experiments did not work for c.7598C &#x003E; G variant. The 52 mutant minigenes were checked by Sanger sequencing and assayed in MCF-7 cells. Results showed that 12 of them (23%) altered splicing (<a href="#T2">Table 2</a> and <a href="#F3">Figure 3</a>), seven of which had previously been classified as pathogenic and five as VUS (<a href="#T3">Table 3</a>). Among these 12 variants, there were 9 intronic, 2 missense and 1 nonsense changes. Functionally, the 9 intronic variants (c.7008-3C &#x003E; G, c.7008-2A &#x003E; T, c.7008-1G &#x003E; A, c.7435+1G &#x003E; C, c.7436-2A &#x003E; T, c.7436-1G &#x003E; A, c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G) disrupted the natural splice sites, the two missense changes (c.7177A &#x003E; G and c.7447A &#x003E; G) triggered the use of <i>de novo</i> splice sites and originated other transcripts, and the nonsense one (c.7501C &#x003E; T) probably altered SREs despite it was primarily selected because of the creation of a new 5&#x2032;ss (<a href="#T1">Table 1</a>). According to <a href="#B43">Vall&#x00E9;e et al. (2016)</a>, nine variants induced severe splicing disruptions as they produced more than 60% of aberrant transcripts, ranging from 92.8 to 100% (<a href="#T3">Table 3</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg" name="table2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg" alt="www.frontiersin.org" id="T2" loading="lazy">
  </picture>
</a>
<p><strong>Table 2.</strong> Quantification of the transcripts found by capillary electrophoresis after functional assays of <i>BRCA2</i> exons 14 and 15 variants.</p>
</div>
<div class="clear"></div>
<div class="DottedLine mb15"></div>
<div class="Imageheaders">FIGURE 3</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg" name="figure3" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg" alt="www.frontiersin.org" id="F3" loading="lazy">
  </picture>
</a>
<p><strong>Figure 3.</strong> Functional assays of the BRCA2 exons 14 and 15 variants using the MGBR2_14-minigene. <b>(A)</b> Exon 14 variants. <b>(B)</b> Exon 15 variants. On the left, capillary electropherograms are shown. Transcripts were amplified using pMAD_607FW-FAM and RTBR2_Ex17RV2. Labeled transcripts are shown as blue peaks, LIZ1200 was used as size standard (orange peaks). The expected size of the full length transcript is 1028 nt (1018&#x2013;1019 nt according to Peak Scanner). On the right, splicing patterns are represented. While blue boxes are natural exons, red boxes represent aberrant exons; dashed black and red lines show canonical and aberrant splicing events, respectively.</p>
</div>
<div class="clear"></div>
<div class="DottedLine mb15"></div>
<div class="Imageheaders">TABLE 3</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg" name="table3" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg" alt="www.frontiersin.org" id="T3" loading="lazy">
  </picture>
</a>
<p><strong>Table 3.</strong> Classification of spliceogenic variants.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<h4>Acceptor Site Variants</h4>
<p class="mb15">Exon 14 3&#x2032;ss was affected by c.7008-3C &#x003E; G, c.7008-2A &#x003E; T, and c.7008-1G &#x003E; A, whereas c.7008-5T &#x003E; C only produced the canonical transcript (<a href="#T2">Table 2</a>). Curiously, while the main outcome of c.7008-3C &#x003E; G was exon skipping (&#x0394;E14), the variants c.7008-2A &#x003E; T and c.7008-1G &#x003E; A produced mostly the aberrant transcript &#x0394;(E14p10), in which a cryptic 3&#x2032;ss was recognized by the spliceosome 10-nt downstream. This cryptic 3&#x2032;ss was not detected by NNSplice or MES tools. The loss of 10-nt at the beginning of exon 14 would generate a PTC 27 codons downstream (p.Thr2337Asnfs<sup>&#x2217;</sup>27). Our results also revealed the use of another cryptic 3&#x2032;ss (MES = 4.44) within exon 14, located 246-nt downstream the natural one, originating the transcript &#x0394;(E14p246) (13%) in the c.7008-3C &#x003E; G assay (<a href="#T2">Table 2</a>). The transcript &#x0394;(E14p246) led to an in-frame deletion of 82 amino acids from position p.2337 to p.2418 (p.Thr2337_Arg2418del).</p>
<p class="mb0">The branch point (c.7436-22C &#x003E; T), polypyrimidine tract (c.7436-14T &#x003E; G) and &#x2212;4 (c.7436-4A &#x003E; G, c.7436-4A &#x003E; T) variants of exon 15 did not impair splicing. Other exon 15 acceptor variants, such as c.7436-2A &#x003E; T and c.7436-1G &#x003E; A, mainly caused isoform &#x0394;(E15p13) through use of a cryptic acceptor 13-nt downstream (<a href="#T2">Table 2</a>). The use of this cryptic acceptor would provoke a frameshift deletion, leading to a PTC in the protein (p.Asp2479Valfs<sup>&#x2217;</sup>41). Like exon 14 cryptic acceptor, this exon 15 cryptic 3&#x2032;ss was not detected by NNSplice or MES. Variant c.7436-1G &#x003E; A also produced the minor transcript &#x0394;E15p83 (3.7%) a 83-nt deletion that introduced a frameshift (p.Asp2479Alafs<sup>&#x2217;</sup>32) and a PTC 32 codons downstream. This transcript was generated by a cryptic acceptor site 83-nt downstream (MES = 6.28). In summary, we found 5 variants (c.7008-3C &#x003E; G, c.7008-2A &#x003E; T, c.7008-1G &#x003E; A, c.7436-2A &#x003E; T, and c.7436-1G &#x003E; A) that altered 3&#x2032;ss recognition of exons 14 and 15, leading to aberrant splicing (<a href="#T2">Table 2</a>). Remarkably, all of them showed the total absence of canonical transcript, except for c.7008-3C &#x003E; G that produced 7% of the full-length transcript. Moreover, our results unveiled exon 14 and 15 cryptic splice sites that are only recognized when natural acceptors are disrupted.</p>
<h4>Donor Site Variants</h4>
<p class="mb0">Seven variants were predicted to disrupt donor sites: c.7435+1G &#x003E; C, c.7435+3A &#x003E; G, c.7435+5T &#x003E; C, and c.7435+6G &#x003E; A (exon 14) and c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G (exon 15; <a href="#T1">Table 1</a>). Among the exon 14 variants, only c.7435+1G &#x003E; C impaired splicing (<a href="#T2">Table 2</a>) producing a single transcript with a 5-nt insertion [<img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-i001.jpg" id="I3" alt="www.frontiersin.org">(E14q5)], due to the recognition of a cryptic 5&#x2032;ss in ivs14. The <img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-i001.jpg" id="I4" alt="www.frontiersin.org">(E14q5) is an aberrant splicing isoform which leads to PTC (p.Asp2479Glyfs<sup>&#x2217;</sup>4). Surprisingly, this cryptic donor was not detected by NNSplice software as the canonical one was. Regarding exon 15 donor variants, our results showed that all of them (c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G) produced &#x0394;(E15) as unique transcript (<a href="#T2">Table 2</a>), which generates a PTC eight codons downstream (p.Asp2479Alafs<sup>&#x2217;</sup>8).</p>
<h4>Splicing Regulatory Element-Variants</h4>
<p class="mb0">A total of 26 SRE variants were selected according to the criteria above described and assayed in MCF-7 cells (<a href="#T1">Table 1</a>). Only c.7177A &#x003E; G altered weakly splicing resulting in about 5% of aberrant transcripts (<a href="#T2">Table 2</a>). This matches with the creation of a new donor site that was not detected by the splicing prediction software. Conversely, none of the exon 15 SRE-variants impaired splicing even though microdeletion tests had revealed a presumed ESE interval (c.7463_7492).</p>
<h4>New Splice Site Variants</h4>
<p class="mb0">We have assayed 10 variants of this type, six in exon 14 (c.7030A &#x003E; G, c.7180A &#x003E; T, c.7182A &#x003E; G, c.7203A &#x003E; G, c.7266T &#x003E; A, and c.7418G &#x003E; A) and four in exon 15 (c.7447A &#x003E; G, c.7466A &#x003E; G, c.7501C &#x003E; T, and c.7611_7615delTAAAC) (<a href="#T1">Table 1</a>). Results showed that two exon 15 variants (c.7447A &#x003E; G and c.7501C &#x003E; T) slightly disrupted splicing (<a href="#T2">Table 2</a>). The variant c.7447A &#x003E; G generated a new acceptor but most of its outcome was a full-length transcript (<a href="#T2">Table 2</a>). The variant c.7501C &#x003E; T was predicted to create a new strong donor (NNSplice: &#x003C; 0.4&#x2192;0.96 and MES: 2.44&#x2192;10.19) (<a href="#T1">Table 1</a>). However, only 16% of the transcripts made use of this cryptic donor 83-nt upstream of the natural one (<a href="#T2">Table 2</a>).</p>
<h3>Analysis of Transcripts</h3>
<p class="mb0">The so called full-length or canonical transcript (expected size: 1028-nt) was amplified with primers placed on vector exon V1 and BRCA2 exon 17. Apart from the canonical transcript, we have detected other ten different ones (<a href="#F3">Figure 3</a>). Aberrant exon 14 splicing produced six different isoforms, but only five of them were characterized: &#x0394;(E14), &#x0394;(E14p10), &#x0394;(E14p246), &#x0394;(E14q256), and <img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-i001.jpg" id="I5" alt="www.frontiersin.org">(E14q5). A 942-nt transcript of unknown structure could also be detected by capillary electrophoresis. All exon 14 isoforms, except for &#x0394;(E14p246), introduced PTCs into the mRNA. The isoform &#x0394;(E14p246) was seen in up to 13% of the c.7008-3C &#x003E; G transcripts (<a href="#T2">Table 2</a>). Exon 15 variants produced 4 different isoforms besides the canonical one: &#x0394;(E15p12), &#x0394;(E15p13), &#x0394;(E15q83), and &#x0394;(E15). The &#x0394;(E15p13), &#x0394;(E15q83) and &#x0394;(E15) isoforms created PTCs while &#x0394;(E15p12) (new acceptor 12-nt downstream) kept the reading frame, although this isoform only accounted for 10% of the transcripts (<a href="#T2">Table 2</a>).</p>
<a id="h5" name="h5"></a><h2>Discussion</h2>
<p class="mb0">Due to the implementation of Next Generation Sequencing in the clinical setting (<a href="#B39">Slavin et al., 2015</a>), a large number of variants have been detected in disease-responsible genes. HBOC and the breast cancer susceptibility genes are not exceptions, where thousands of different variants have been reported although many of them are considered as VUS (<a href="#B41">Spurdle et al., 2012</a>; <a href="#B38">Slavin et al., 2017</a>). In this context, the functional and clinical classifications pose a challenge for Medical Genetics. We have herein functionally assayed 52 <i>BRCA2</i> variants using the minigene MGBR2_14-20, whose reliability had been previously proven (<a href="#B16">Fraile-Bethencourt et al., 2017</a>, <a href="#B17">2018</a>; <a href="#B29">Montalban et al., 2018</a>). We found 12 variants that altered splicing, nine of which would severely alter the protein. This study forms part of a comprehensive study of our group concerning potential splicing <i>BRCA2</i> variants, where 22 exons and up to 335 variants have been assayed using three minigenes: MGBR2_2-9 (<a href="#B18">Fraile-Bethencourt et al., 2019</a>), MGBR2_14-20 (<a href="#B16">Fraile-Bethencourt et al., 2017</a>, <a href="#B17">2018</a>) and MGBR2_19-27 (<a href="#B3">Acedo et al., 2012</a>, <a href="#B2">2015</a>). The following advantages of the minigene technology should be underlined: (i) analysis of a single allele outcome without the interference of the wt counterpart of a patient sample; (ii) simple and fast quantification of generated transcripts by fluorescent capillary electrophoresis with minimum hands-on time versus other proposed methods (<a href="#B15">Farber-Katz et al., 2018</a>); (iii) versatility, one single multi-exon minigene allows to assay variants from different exons; (iv) capability of analysis in many cell types to check effects derived from tissue-specific alternative splicing; (v) high reproducibility of splicing physiological/pathological patterns. In fact, we have previously provided many examples of the minigene reproducibility. In the case of <i>BRCA2</i> exons 14 and 15, variants c.7008-2A &#x003E; T, c.7617+1G &#x003E; A, and c.7617+2T &#x003E; G displayed similar patterns in patient RNA and minigene assays (<a href="#B45">Vreeswijk et al., 2009</a>; <a href="#B9">Colombo et al., 2013</a>; <a href="#B11">de Garibay et al., 2014</a>). Moreover, another 31 variants of this and other constructs replicated previously reported patient splicing outcomes (<a href="#B2">Acedo et al., 2015</a>; <a href="#B16">Fraile-Bethencourt et al., 2017</a>, <a href="#B17">2018</a>, <a href="#B18">2019</a>), confirming that splicing reporters are robust and valuable tools to test the impact of variants on splicing, especially when patient RNA is not available.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 4</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg" name="table4" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg" alt="www.frontiersin.org" id="T4" loading="lazy">
  </picture>
</a>
<p><strong>Table 4.</strong> Summary of spliceogenic variants tested in minigene MGBR2_14-20.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Here, we have shown that nine variants drastically disrupted the splicing pattern. We found five 3&#x2032;ss disrupting variants, one of which (c.7008-3C &#x003E; G) provoked exon 14 skipping, whereas the rest of them induced the use of cryptic sites (c.7008-2A &#x003E; T, c.7008-1G &#x003E; A, c.7436-2A &#x003E; T, and c.7436-1G &#x003E; A). Moreover, variant c.7435+1G &#x003E; C, which disrupt the exon 14 donor site, provoked the use of a cryptic donor. Curiously, neither c.7435+3A &#x003E; G, c.7435+5T &#x003E; C nor c.7435+6G &#x003E; A, which are also part of the consensus 5&#x2032;ss, affected splicing. This may be due to the low frequency of +5T and +6G at these positions, so that any nucleotide change only equals or improves splice site strength. Conversely, +3A is the main nucleotide at this position (71%) but +3G is also relatively frequent (24%) (<a href="#B49">Zhang, 1998</a>). Thus, a substitution A to G might have a reduced or no splicing impact, as it is the case of the c.7435+3A &#x003E; G variant. As a matter of fact, variant c.9501+3A &#x003E; T produced 87% of the canonical transcript (<a href="#B2">Acedo et al., 2015</a>). On the other hand, the three variants of exon 15 donor site c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G resulted in exon skipping. In this regard, it was recently recommended the use of a combination of the computational tools HSF plus Splice Site Finder-like to select candidate splice site variants with high sensitivity and specificity (<a href="#B28">Moles-Fern&#x00E1;ndez et al., 2018</a>). According to HSF, variants c.7435+3A &#x003E; G, c.7435+5T &#x003E; C, and c.7435+6G &#x003E; A showed only minimal changes of the splice site scores (&#x00B1;1%) so that they should have been excluded from subsequent functional tests.</p>
<p class="mb0">Concerning other splicing motifs, minigenes also allow the identification of regulatory sequences (splicing enhancers and silencers) and splicing factors involved in the specific regulation (<a href="#B4">Baralle and Buratti, 2017</a>). Indeed, the SRE mapping constitutes an interesting experimental approach since it identifies critical regions for exon recognition. In this context, our group previously found exonic variants that disrupted splicing through elimination of ESEs or creation of <i>de novo</i> silencers, such as <i>BRCA2</i> variants c.7985C &#x003E; G (predicted missense p.Thr2662Arg) or c.8009C &#x003E; A (predicted nonsense p.Ser2670<sup>&#x2217;</sup>) (<a href="#B16">Fraile-Bethencourt et al., 2017</a>). The splicing assays showed how both variants elicited complete splicing aberrations (mainly exon 18 skipping). However, they were <i>a priori</i> classified as missense and nonsense variants, respectively, due to their predicted protein effect. After microdeletion mapping, we have identified a putative ESE-region in exon 15 (c.7463_7492). These ESEs might be involved in exon 15 3&#x2032;ss recognition since their loss produced the use of a cryptic acceptor 83-nt downstream (<a href="#F2">Figure 2</a>). Curiously, we did not find any ESE-variants that affected pre-mRNA processing. Only, c.7501C &#x003E; T, which lays near to this presumed ESE interval, provoked a similar outcome to that of r.7463_7492 deletion (<a href="#T2">Table 2</a>). In summary, we have tested a total of 117 different variants in minigene MGBR2_14-20, from exons 14&#x2013;18 (<a href="#T4">Table 4</a>), 51 of which (43.6%) induced abnormal splicing patterns: 31 disrupted the natural splice sites (16 3&#x2032;ss and 15 5&#x2032;ss), 11 affected SREs, six created <i>de novo</i> splice sites and three altered the polypyrimidine tract.</p>
<h3>Transcript Interpretation</h3>
<p class="mb0">The <i>BRCA2</i> exons 14 (c.7008_7435) and 15 (c.7436_7617) encode for amino acids 2336 to p.2539, which are part of the DNA Binding Domain (DBD; p.2459_p.3190). The DBD is the largest conserved region of BRCA2 and is composed of a helical domain (HD), three oligonucleotide binding sites (OB) and a tower domain (TD) (<a href="#B19">Guidugli et al., 2014</a>). Specifically, exons 14 and 15 are part of the HD (p.2481_2667) that binds to the protein DSS1 (deleted in split-hand/split-foot syndrome) in the region comprised by the residues 2472&#x2013;2957 (<a href="#B25">Marston et al., 1999</a>). Among these residues, a total of 125 are strictly conserved from human to sea urchin. DSS1 is important for BRCA2 stability, since its loss leads to a reduction of BRCA2 levels in human cells (<a href="#B22">Li et al., 2006</a>). Moreover, exons 14 and 15 coding region is also recognized by FANCD2 (Fanconi anemia group D2) protein, which binds to the BRCA2 protein between codons 2350 and 2545 (<a href="#B20">Hussain et al., 2004</a>). FANCD2, like BRCA2, is one of the 16 proteins that form the Fanconi Anemia complex, aimed to repair DNA interstrand crosslinks. However, it was shown that BRCA2-FANCD2 association has an independent function in the Fanconi Anemia pathway. The BRCA2-FANCD2 complex is involved in the restart of the replication fork, by protecting the nascent DNA strands from degradation (<a href="#B33">Raghunandan et al., 2015</a>). Taken together, exons 14 and 15 contain crucial sequences of <i>BRCA2</i>, owing to its function in homologous recombination and other relevant biological processes. Moreover, the biological relevance of exons 14 and 15 is supported by the presence of numerous pathological nonsense and frameshift variants at the mutation databases. Hence, the exon 14&#x2013;15 spliceogenic variants that induce PTC-transcripts may be associated with an increased risk of HBOC.</p>
<h3>Clinical Interpretation of Spliceogenic Variants</h3>
<p class="mb15">Twelve variants altered splicing with different patterns. While some variants caused the total absence of canonical transcript, others originated just &#x223C;5% of aberrant transcripts (<a href="#T2">Table 2</a>). Variants c.7008-2A &#x003E; T, c.7008-1G &#x003E; A, c.7435+1G &#x003E; C, c.7436-2A &#x003E; T, c.7436-1G &#x003E; A, c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G did not produce the canonical transcript. Moreover, all the transcripts generated by these variants were frameshift transcripts. Thus, following the criteria of the American College of Medical Genetics and Genomics (ACMG), these eight variants should be classified as pathogenic variants (<a href="#T3">Table 3</a>). Variant c.7008-3C &#x003E; G produced &#x0394;(E14) as the major transcript, but the full-length (&#x223C;7%) and the in-frame transcript &#x0394;(E14p246) (&#x223C;13%) were also identified. The &#x0394;(E14p246) isoform contains a deletion of 82 non-conserved amino acids (p.Thr2337_Arg2418del) that form part of the FANCD2 binding site (p.Thr2350_Val2545). At the UMD database, c.7008-3C &#x003E; G is classified as a &#x201C;causal&#x201D; variant because of the skipping of exon 14, but ClinVar shows it as VUS. According to the ACMG criteria, this variant should be cataloged as likely pathogenic (<a href="#T3">Table 3</a>). On the other hand, according to the guidelines of the ENIGMA consortium<sup id="footnotesuper7"><a id="note7a"></a><a class="footnoteanchor" href="#note7">7</a></sup> eight variants should be classified as Class 4 (Likely pathogenic), three as VUS and one as pathogenic, though this is due to its predicted nonsense effect (<a href="#T3">Table 3</a>).</p>
<p class="mb15">On the other hand, missense variants c.7177A &#x003E; G (p.Met2393Val) and c.7447A &#x003E; G (p.Ser2483Gly) produced the canonical transcript as the main outcome and only 5 and 10% of aberrant isoforms, respectively (<a href="#T2">Table 2</a>). The canonical transcript generated by these two variants carried missense changes, but <i>in silico</i> predictions with the PolyPhen tool<sup id="footnotesuper8"><a id="note8a"></a><a class="footnoteanchor" href="#note8">8</a></sup> suggested that p.Met2393Val and p.Ser2483Gly were both benign changes. So, following the ACMG criteria, c.7177A &#x003E; G and c.7447A &#x003E; G remain as VUS (<a href="#T3">Table 3</a>). Finally, variant c.7501C &#x003E; T generated mainly the canonical transcript (84%) that includes a nonsense change (pathogenic according to ClinVar) so this change should be classified as pathogenic under a combined splicing-protein viewpoint. Altogether, we have re-classified three variants (c.7008-3C &#x003E; G, c.7008-1G &#x003E; A, and c.7436-1G &#x003E; A) from VUS to pathogenic or likely pathogenic, and we have provided further support for the classification of six spliceogenic variants (c.7008-2A &#x003E; T, c.7435+1G &#x003E; C, c.7436-2A &#x003E; T, c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G). Interestingly, c.7617G &#x003E; A is classified as &#x201C;causal&#x201D; in the UMD database<sup id="footnotesuper9"><a id="note9a"></a><a class="footnoteanchor" href="#note9">9</a></sup> and indicated that causes exon 15 skipping but no functional proofs were provided. However, the functional assay of MGBR2_14-20-c.7617G &#x003E; A only showed the canonical transcript (<a href="#h10">Supplementary Figure S2</a>). In fact, NNSplice, HSF and MES estimated just a small decrease (&#x2212;19, &#x2212;11.6, and &#x2212;24%, respectively) of the donor site score. Therefore, c.7617G &#x003E; A behaves as a neutral variant from the splicing perspective. Finally, the minigene MGBR2_14-20 results of 5 exons suggest that a total of 39 spliceogenic variants should be classified as pathogenic or likely pathogenic (<a href="#T4">Table 4</a>), lending further support to this strategy for the clinical interpretation of variants.</p>
<p class="mb0">In summary, splicing is a finely regulated mechanism which can be altered by any change in the sequence. The disruption of this process might cause serious effects on the protein, from the loss of important domains to the generation of a PTC. Thus, splicing alteration is a common mechanism of gene inactivation, which is often involved in human disease. Here, we have revealed 12 spliceogenic variants of <i>BRCA2</i> exons 14 and 15. The minigene based assays offer a relevant information about effects of splicing variants, since they allow to functionally assay almost any DNA change, to quantify all generated transcripts, including very rare ones, and to initially study the splicing regulation. Moreover, we have detected an ESE region that seems to be regulating exon 15 splicing, and therefore constitutes a hypothetical hotspot for putative ESE-mutations. Indeed, pSAD-based minigenes have constituted an invaluable technology to functionally test variants of other disease genes such as <i>GRN</i> (Frontotemporal Dementia), <i>SERPINA1</i> (Severe alpha-1 antitrypsin deficiency) and <i>CHD7</i> (Charge Syndrome) genes (<a href="#B21">Lara et al., 2014</a>; <a href="#B44">Villate et al., 2018</a>). Altogether, these results highlight, once more, the importance of RNA assays to know the splicing effects of DNA variants to give support to their clinical interpretation and consequently to activate preventive and/or therapeutic interventions.</p>
<a id="h6" name="h6"></a><h2>Author Contributions</h2>
<p class="mb0">EF-B contributed to the bioinformatics analysis, minigene construction, manuscript writing, and performed most of the splicing functional assays. BD-G and AV-P participated in minigene construction, mutagenesis experiments, and functional assays. SG-B and MC carried out the data collection of variants and their computer analysis, as well as manuscript editing. EV conceived the study and the experimental design, supervised all the experiments, and wrote the manuscript. All authors contributed to data interpretation, revisions of the manuscript, and approved the final version of the manuscript.</p>
<a id="h7" name="h7"></a><h2>Funding</h2>
<p class="mb0">EV&#x2019;s lab was supported by grants from the Spanish Ministry of Science, Innovation and Universities, Plan Nacional de I+D+I 2013-2016, Instituto de Salud Carlos III (PI13/01749 and PI17/00227) co-funded by FEDER from Regional Development European Funds (European Union), and grants CSI090U14 (ORDEN EDU/122/2014) and CSI242P18 (actuaci&#x00F3;n cofinanciada P.O. FEDER 2014-2020 de Castilla y Le&#x00F3;n) from the Consejer&#x00ED;a de Educaci&#x00F3;n, Junta de Castilla y Le&#x00F3;n. EF-B was supported by a predoctoral fellowship from the University of Valladolid and Banco de Santander (2015&#x2013;2019). AV-P was supported by a predoctoral fellowship from Consejer&#x00ED;a de Educaci&#x00F3;n, Junta de Castilla y Le&#x00F3;n (2018&#x2013;2022).</p>
<a id="h8" name="h8"></a><h2>Conflict of Interest Statement</h2>
<p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<a id="h9" name="h9"></a><h2>Acknowledgments</h2>
<p class="mb0">We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).</p>
<a id="h10" name="h10"></a><h2>Supplementary Material</h2>
<p class="mb0">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fgene.2019.00503/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fgene.2019.00503/full#supplementary-material</a></p>
<a id="h11" name="h11"></a><h2>Footnotes</h2>
<ol>
<li id="note1"><strong><a style="color:gray;" class="footnotetextanchor" href="#note1a" title="">^</a></strong> <a style="color:gray;" href="https://www.ncbi.nlm.nih.gov/clinvar">https://www.ncbi.nlm.nih.gov/clinvar</a></li>
<li id="note2"><strong><a style="color:gray;" class="footnotetextanchor" href="#note2a" title="">^</a></strong> <a style="color:gray;" href="https://www.ncbi.nlm.nih.gov/clinvar/">https://www.ncbi.nlm.nih.gov/clinvar/</a></li>
<li id="note3"><strong><a style="color:gray;" class="footnotetextanchor" href="#note3a" title="">^</a></strong> <a style="color:gray;" href="http://www.umd.be/BRCA2/">http://www.umd.be/BRCA2/</a></li>
<li id="note4"><strong><a style="color:gray;" class="footnotetextanchor" href="#note4a" title="">^</a></strong> <a style="color:gray;" href="https://research.nhgri.nih.gov/projects/bic/index.shtml">https://research.nhgri.nih.gov/projects/bic/index.shtml</a></li>
<li id="note5"><strong><a style="color:gray;" class="footnotetextanchor" href="#note5a" title="">^</a></strong> <a style="color:gray;" href="http://www.fruitfly.org/seq_tools/splice.html">http://www.fruitfly.org/seq_tools/splice.html</a></li>
<li id="note6"><strong><a style="color:gray;" class="footnotetextanchor" href="#note6a" title="">^</a></strong> <a style="color:gray;" href="http://www.umd.be/HSF3/">http://www.umd.be/HSF3/</a></li>
<li id="note7"><strong><a style="color:gray;" class="footnotetextanchor" href="#note7a" title="">^</a></strong> <a style="color:gray;" href="https://enigmaconsortium.org/library/general-documents/enigma-classification-criteria/">https://enigmaconsortium.org/library/general-documents/enigma-classification-criteria/</a></li>
<li id="note8"><strong><a style="color:gray;" class="footnotetextanchor" href="#note8a" title="">^</a></strong> <a style="color:gray;" href="http://genetics.bwh.harvard.edu/pph2/">http://genetics.bwh.harvard.edu/pph2/</a></li>
<li id="note9"><strong><a style="color:gray;" class="footnotetextanchor" href="#note9a" title="">^</a></strong> <a style="color:gray;" href="https://goo.gl/bG2V4n">https://goo.gl/bG2V4n</a></li>
</ol>
<a id="h12" name="h12"></a><h2>References</h2>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B1" id="B1"></a>Abramowicz, A., and Gos, M. (2018). Splicing mutations in human genetic disorders: examples, detection, and confirmation. <i>J. Appl. Genet.</i> 59, 253&#x2013;268. doi: 10.1007/s13353-018-0444-447</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1007/s13353-018-0444-447" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Splicing+mutations+in+human+genetic+disorders%3A+examples%2C+detection%2C+and+confirmation%2E&#x0026;journal=J%2E+Appl%2E+Genet%2E&#x0026;author=Abramowicz+A.&#x0026;author=and+Gos+M.&#x0026;publication_year=2018&#x0026;volume=59&#x0026;pages=253-268" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B2" id="B2"></a>Acedo, A., Hern&#x00E1;ndez-Moro, C., Curiel-Garc&#x00ED;a, &#x00C1;, D&#x00ED;ez-G&#x00F3;mez, B., and Velasco, E. A. ( (2015). Functional classification of BRCA2 DNA variants by splicing assays in a large minigene with 9 exons. <i>Hum. Mutat.</i> 36, 210&#x2013;221. doi: 10.1002/humu.22725</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=25382762" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.22725" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Functional+classification+of+BRCA2+DNA+variants+by+splicing+assays+in+a+large+minigene+with+9+exons%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Acedo+A.&#x0026;author=Hern&#x00E1;ndez-Moro+C.+Curiel-Garc&#x00ED;a&#x0026;author=&#x00C1;+D&#x00ED;ez-G&#x00F3;mez+B.&#x0026;author=and+Velasco+E.+A.&#x0026;publication_year=2015&#x0026;volume=36&#x0026;pages=210-221" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B3" id="B3"></a>Acedo, A., Sanz, D. J., Dur&#x00E1;n, M., Infante, M., P&#x00E9;rez-Cabornero, L., Miner, C., et al. (2012). Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes. <i>Breast Cancer Res.</i> 14:R87. doi: 10.1186/bcr3202</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=22632462" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/bcr3202" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Comprehensive+splicing+functional+analysis+of+DNA+variants+of+the+BRCA2+gene+by+hybrid+minigenes%2E&#x0026;journal=Breast+Cancer+Res%2E&#x0026;author=Acedo+A.&#x0026;author=Sanz+D.+J.&#x0026;author=Dur&#x00E1;n+M.&#x0026;author=Infante+M.&#x0026;author=P&#x00E9;rez-Cabornero+L.&#x0026;author=Miner+C.&#x0026;publication_year=2012" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B4" id="B4"></a>Baralle, D., and Buratti, E. (2017). RNA splicing in human disease and in the clinic. <i>Clin. Sci.</i> 131, 356&#x2013;368. doi: 10.1042/CS20160211</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=28202748" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1042/CS20160211" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=RNA+splicing+in+human+disease+and+in+the+clinic%2E&#x0026;journal=Clin%2E+Sci%2E&#x0026;author=Baralle+D.&#x0026;author=and+Buratti+E.&#x0026;publication_year=2017&#x0026;volume=131&#x0026;pages=356-368" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B5" id="B5"></a>Beroud, C., Letovsky, S. I., Braastad, C. D., Caputo, S. M., Beaudoux, O., Bignon, Y. J., et al. (2016). BRCA share: a collection of clinical BRCA gene variants. <i>Hum. Mutat.</i> 37, 1318&#x2013;1328. doi: 10.1002/humu.23113</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=27633797" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.23113" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA+share%3A+a+collection+of+clinical+BRCA+gene+variants%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Beroud+C.&#x0026;author=Letovsky+S.+I.&#x0026;author=Braastad+C.+D.&#x0026;author=Caputo+S.+M.&#x0026;author=Beaudoux+O.&#x0026;author=Bignon+Y.+J.&#x0026;publication_year=2016&#x0026;volume=37&#x0026;pages=1318-1328" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B6" id="B6"></a>Buys, S. S., Sandbach, J. F., Gammon, A., Patel, G., Kidd, J., Brown, K. L., et al. (2017). A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. <i>Cancer</i> 123, 1721&#x2013;1730. doi: 10.1002/cncr.30498</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=28085182" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/cncr.30498" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+study+of+over+35%2C000+women+with+breast+cancer+tested+with+a+25-gene+panel+of+hereditary+cancer+genes%2E&#x0026;journal=Cancer&#x0026;author=Buys+S.+S.&#x0026;author=Sandbach+J.+F.&#x0026;author=Gammon+A.&#x0026;author=Patel+G.&#x0026;author=Kidd+J.&#x0026;author=Brown+K.++L.&#x0026;publication_year=2017&#x0026;volume=123&#x0026;pages=1721-1730" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B7" id="B7"></a>Cartegni, L., Chew, S. L., and Krainer, A. R. (2002). Listening to silence and understanding nonsense: exonic mutations that affect splicing. <i>Nat. Rev. Genet.</i> 3, 285&#x2013;298. doi: 10.1038/nrg775</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=11967553" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nrg775" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Listening+to+silence+and+understanding+nonsense%3A+exonic+mutations+that+affect+splicing%2E&#x0026;journal=Nat%2E+Rev%2E++Genet%2E&#x0026;author=Cartegni+L.&#x0026;author=Chew+S.+L.&#x0026;author=and+Krainer+A.+R.&#x0026;publication_year=2002&#x0026;volume=3&#x0026;pages=285-298" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B8" id="B8"></a>Cartegni, L., Wang, J., Zhu, Z., Zhang, M. Q., and Krainer, A. R. (2003). ESEfinder: a web resource to identify exonic splicing enhancers. <i>Nucleic Acids Res.</i> 31, 3568&#x2013;3571.</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=12824367" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=ESEfinder%3A+a+web+resource+to+identify+exonic+splicing+enhancers%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Cartegni+L.&#x0026;author=Wang+J.&#x0026;author=Zhu+Z.&#x0026;author=Zhang+M.+Q.&#x0026;author=and+Krainer+A.+R.&#x0026;publication_year=2003&#x0026;volume=31&#x0026;pages=3568-3571" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B9" id="B9"></a>Colombo, M., De Vecchi, G., Caleca, L., Foglia, C., Ripamonti, C. B., Ficarazzi, F., et al. (2013). Comparative in vitro and in silico analyses of variants in splicing regions of brca1 and brca2 genes and characterization of novel pathogenic mutations. <i>PLoS One</i> 8:e57173. doi: 10.1371/journal.pone.0057173</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=23451180" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pone.0057173" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Comparative+in+vitro+and+in+silico++analyses+of+variants+in+splicing+regions+of+brca1+and+brca2+genes+and+characterization+of+novel+pathogenic+mutations%2E&#x0026;journal=PLoS+One&#x0026;author=Colombo+M.&#x0026;author=De+Vecchi+G.&#x0026;author=Caleca+L.&#x0026;author=Foglia+C.&#x0026;author=Ripamonti+C.++B.&#x0026;author=Ficarazzi+F.&#x0026;publication_year=2013" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B10" id="B10"></a>De Conti, L., Baralle, M., and Buratti, E. (2012). Exon and intron definition in pre-mRNA splicing. <i>Wiley Interdiscip. Rev. RNA</i> 4, 49&#x2013;60. doi: 10.1002/wrna.1140</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=23044818" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/wrna.1140" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Exon+and+intron+definition+in+pre-mRNA+splicing%2E&#x0026;journal=Wiley+Interdiscip%2E+Rev%2E+RNA&#x0026;author=De+Conti+L.&#x0026;author=Baralle+M.&#x0026;author=and+Buratti+E.&#x0026;publication_year=2012&#x0026;volume=4&#x0026;pages=49-60" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B11" id="B11"></a>de Garibay, G. R., Acedo, A., Garc&#x00ED;a-Casado, Z., Guti&#x00E9;rrez-Enr&#x00ED;quez, S., Tosar, A., Romero, A., et al. (2014). Capillary electrophoresis analysis of conventional splicing assays: IARC analytical and clinical classification of 31 BRCA2 genetic variants. <i>Hum. Mutat.</i> 35, 53&#x2013;57. doi: 10.1002/humu.22456</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=24123850" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.22456" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Capillary+electrophoresis+analysis+of+conventional+splicing+assays%3A+IARC+analytical+and+clinical+classification+of+31+BRCA2+genetic+variants%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=de+Garibay+G.+R.&#x0026;author=Acedo+A.&#x0026;author=Garc&#x00ED;a-Casado+Z.&#x0026;author=Guti&#x00E9;rrez-Enr&#x00ED;quez+S.&#x0026;author=Tosar+A.&#x0026;author=Romero+A.&#x0026;publication_year=2014&#x0026;volume=35&#x0026;pages=53-57" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B12" id="B12"></a>Desmet, F. O., Hamroun, D., Lalande, M., Collod-Beroud, G., Claustres, M., and Beroud, C. (2009). Human Splicing Finder: an online bioinformatics tool to predict splicing signals. <i>Nucleic Acids Res.</i> 37:e67. doi: 10.1093/nar/gkp215</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=19339519" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gkp215" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Human+Splicing+Finder%3A+an+online+bioinformatics+tool+to+predict+splicing+signals%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Desmet+F.+O.&#x0026;author=Hamroun+D.&#x0026;author=Lalande+M.&#x0026;author=Collod-Beroud+G.&#x0026;author=Claustres+M.&#x0026;author=and+Beroud+C.&#x0026;publication_year=2009" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B13" id="B13"></a>Eccles, D. M., Mitchell, G., Monteiro, A. N. A., Schmutzler, R., Couch, F. J., Spurdle, A. B., et al. (2015). BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. <i>Ann. Oncol.</i> 26, 2057&#x2013;2065. doi: 10.1093/annonc/mdv278</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=26153499" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/annonc/mdv278" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA1+and+BRCA2+genetic+testing-pitfalls+and+recommendations+for+managing+variants+of+uncertain+clinical+significance%2E&#x0026;journal=Ann%2E+Oncol%2E&#x0026;author=Eccles+D.+M.&#x0026;author=Mitchell+G.&#x0026;author=Monteiro+A.+N.+A.&#x0026;author=Schmutzler+R.&#x0026;author=Couch+F.++J.&#x0026;author=Spurdle+A.+B.&#x0026;publication_year=2015&#x0026;volume=26&#x0026;pages=2057-2065" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B14" id="B14"></a>Fackenthal, J. D., Yoshimatsu, T., Zhang, B., de Garibay, G. R., Colombo, M., De Vecchi, G., et al. (2016). Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples. <i>J. Med. Genet.</i> 53, 548&#x2013;558. doi: 10.1136/jmedgenet-2015-103570</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=27060066" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/jmedgenet-2015-103570" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Naturally+occurring+BRCA2+alternative+mRNA+splicing+events+in+clinically+relevant+samples%2E&#x0026;journal=J%2E+Med%2E+Genet%2E&#x0026;author=Fackenthal+J.+D.&#x0026;author=Yoshimatsu+T.&#x0026;author=Zhang+B.&#x0026;author=de+Garibay+G.+R.&#x0026;author=Colombo+M.&#x0026;author=De+Vecchi+G.&#x0026;publication_year=2016&#x0026;volume=53&#x0026;pages=548-558" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B15" id="B15"></a>Farber-Katz, S., Hsuan, V., Wu, S., Landrith, T., Vuong, H., Xu, D., et al. (2018). Quantitative Analysis of BRCA1 and BRCA2 Germline Splicing Variants Using a Novel RNA-Massively Parallel Sequencing Assay. <i>Front. Oncol.</i> 8:286. doi: 10.3389/fonc.2018.00286</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=30101128" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fonc.2018.00286" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Quantitative+Analysis+of+BRCA1+and+BRCA2+Germline+Splicing+Variants+Using+a+Novel+RNA-Massively+Parallel+Sequencing+Assay%2E&#x0026;journal=Front%2E++Oncol%2E&#x0026;author=Farber-Katz+S.&#x0026;author=Hsuan+V.&#x0026;author=Wu+S.&#x0026;author=Landrith+T.&#x0026;author=Vuong+H.&#x0026;author=Xu+D.&#x0026;publication_year=2018" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B16" id="B16"></a>Fraile-Bethencourt, E., D&#x00ED;ez-G&#x00F3;mez, B., Vel&#x00E1;squez-Zapata, V., Acedo, A., Sanz, D. J., and Velasco, E. A. (2017). Functional classification of DNA variants by hybrid minigenes: identification of 30 spliceogenic variants of BRCA2 exons 17 and 18. <i>PLoS Genet.</i> 13:e1006691. doi: 10.1371/journal.pgen.1006691</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=28339459" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pgen.1006691" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Functional+classification+of+DNA+variants+by+hybrid+minigenes%3A+identification+of+30+spliceogenic+variants+of+BRCA2+exons+17+and+18%2E&#x0026;journal=PLoS+Genet%2E&#x0026;author=Fraile-Bethencourt+E.&#x0026;author=D&#x00ED;ez-G&#x00F3;mez+B.&#x0026;author=Vel&#x00E1;squez-Zapata+V.&#x0026;author=Acedo+A.&#x0026;author=Sanz+D.++J.&#x0026;author=and+Velasco+E.++A.&#x0026;publication_year=2017" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B17" id="B17"></a>Fraile-Bethencourt, E., Valenzuela-Palomo, A., D&#x00ED;ez-G&#x00F3;mez, B., Acedo, A., and Velasco, E. A. (2018). Identification of Eight Spliceogenic Variants in BRCA2 Exon 16 by Minigene Assays. <i>Front. Genet.</i> 9:188. doi: 10.3389/fgene.2018.00188</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=29881398" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fgene.2018.00188" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Identification+of+Eight+Spliceogenic+Variants+in+BRCA2+Exon+16+by+Minigene+Assays%2E&#x0026;journal=Front%2E++Genet%2E&#x0026;author=Fraile-Bethencourt+E.&#x0026;author=Valenzuela-Palomo+A.&#x0026;author=D&#x00ED;ez-G&#x00F3;mez+B.&#x0026;author=Acedo+A.&#x0026;author=and+Velasco+E.+A.&#x0026;publication_year=2018" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B18" id="B18"></a>Fraile-Bethencourt, E., Valenzuela-Palomo, A., D&#x00ED;ez-G&#x00F3;mez, B., Goina, E., Acedo, A., Buratti, E., et al. (2019). Mis-splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assays. <i>J. Pathol.</i> doi: 10.1002/path.5268 [Epub ahead of print].</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=30883759" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/path.5268 [Epub ahead of print]." target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Mis-splicing+in+breast+cancer%3A+identification+of+pathogenic+BRCA2+variants+by+systematic+minigene+assays%2E&#x0026;journal=J%2E+Pathol%2E&#x0026;author=Fraile-Bethencourt+E.&#x0026;author=Valenzuela-Palomo+A.&#x0026;author=D&#x00ED;ez-G&#x00F3;mez+B.&#x0026;author=Goina+E.&#x0026;author=Acedo+A.&#x0026;author=Buratti+E.&#x0026;publication_year=2019" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B19" id="B19"></a>Guidugli, L., Carreira, A., Caputo, S. M., Ehlen, A., Galli, A., Monteiro, A. N., et al. (2014). Functional assays for analysis of variants of uncertain significance in BRCA2. <i>Hum. Mutat.</i> 35, 151&#x2013;164. doi: 10.1002/humu.22478</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=24323938" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.22478" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Functional+assays+for+analysis+of+variants+of+uncertain+significance+in+BRCA2%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Guidugli+L.&#x0026;author=Carreira+A.&#x0026;author=Caputo+S.+M.&#x0026;author=Ehlen+A.&#x0026;author=Galli+A.&#x0026;author=Monteiro+A.+N.&#x0026;publication_year=2014&#x0026;volume=35&#x0026;pages=151-164" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B20" id="B20"></a>Hussain, S., Wilson, J. B., Medhurst, A. L., Hejna, J., Witt, E., Ananth, S., et al. (2004). Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. <i>Hum. Mol. Genet.</i> 13, 1241&#x2013;1248. doi: 10.1093/hmg/ddh135</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=15115758" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/hmg/ddh135" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Direct+interaction+of+FANCD2+with+BRCA2+in+DNA+damage+response+pathways%2E&#x0026;journal=Hum%2E++Mol%2E++Genet%2E&#x0026;author=Hussain+S.&#x0026;author=Wilson+J.++B.&#x0026;author=Medhurst+A.++L.&#x0026;author=Hejna+J.&#x0026;author=Witt+E.&#x0026;author=Ananth+S.&#x0026;publication_year=2004&#x0026;volume=13&#x0026;pages=1241-1248" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B21" id="B21"></a>Lara, B., Mart&#x00ED;nez, M. T., Blanco, I., Hern&#x00E1;ndez-Moro, C., Velasco, E. A., Ferrarotti, I., et al. (2014). Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadrid. <i>Respir. Res.</i> 15, 125. doi: 10.1186/s12931-014-0125-y</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=25287719" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12931-014-0125-y" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Severe+alpha-1+antitrypsin+deficiency+in+composite+heterozygotes+inheriting+a+new+splicing+mutation+QOMadrid%2E&#x0026;journal=Respir%2E+Res%2E&#x0026;author=Lara+B.&#x0026;author=Mart&#x00ED;nez+M.+T.&#x0026;author=Blanco+I.&#x0026;author=Hern&#x00E1;ndez-Moro+C.&#x0026;author=Velasco+E.+A.&#x0026;author=Ferrarotti+I.&#x0026;publication_year=2014&#x0026;volume=15&#x0026;issue=125" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B22" id="B22"></a>Li, J., Zou, C., Bai, Y., Wazer, D. E., Band, V., and Gao, Q. (2006). DSS1 is required for the stability of BRCA2. <i>Oncogene</i> 25, 1186&#x2013;1194. doi: 10.1038/sj.onc.1209153</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=16205630" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/sj.onc.1209153" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=DSS1+is+required+for+the+stability+of+BRCA2%2E&#x0026;journal=Oncogene&#x0026;author=Li+J.&#x0026;author=Zou+C.&#x0026;author=Bai+Y.&#x0026;author=Wazer+D.++E.&#x0026;author=Band+V.&#x0026;author=and+Gao+Q.&#x0026;publication_year=2006&#x0026;volume=25&#x0026;pages=1186-1194" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B23" id="B23"></a>L&#x00F3;pez-Bigas, N., Audit, B., Ouzounis, C., Parra, G., and Guig&#x00F3;, R. (2005). Are splicing mutations the most frequent cause of hereditary disease? <i>FEBS Lett.</i> 579, 1900&#x2013;1903. doi: 10.1016/j.febslet.2005.02.047</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=15792793" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.febslet.2005.02.047" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Are+splicing+mutations+the+most+frequent+cause+of+hereditary+disease%B4&#x0026;journal=FEBS+Lett%2E&#x0026;author=L&#x00F3;pez-Bigas+N.&#x0026;author=Audit+B.&#x0026;author=Ouzounis+C.&#x0026;author=Parra+G.&#x0026;author=and+Guig&#x00F3;+R.&#x0026;publication_year=2005&#x0026;volume=579&#x0026;pages=1900-1903" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B24" id="B24"></a>Lopez-Perolio, I., Leman, R., Behar, R., Lattimore, V., Pearson, J. F., Cast&#x00E9;ra, L., et al. (2019). Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report. <i>J. Med. Genet.</i> 2019, 1&#x2013;9. doi: 10.1136/jmedgenet-2018-105834</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=30890586" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/jmedgenet-2018-105834" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Alternative+splicing+and+ACMG-AMP-2015-based+classification+of+PALB2+genetic+variants%3A+an+ENIGMA+report%2E&#x0026;journal=J%2E+Med%2E+Genet%2E&#x0026;author=Lopez-Perolio+I.&#x0026;author=Leman+R.&#x0026;author=Behar+R.&#x0026;author=Lattimore+V.&#x0026;author=Pearson+J.++F.&#x0026;author=Cast&#x00E9;ra+L.&#x0026;publication_year=2019&#x0026;volume=2019&#x0026;pages=1-9" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B25" id="B25"></a>Marston, N. J., Richards, W. J., Hughes, D., Bertwistle, D., Marshall, C. J., and Ashworth, A. (1999). Interaction between the Product of the Breast Cancer Susceptibility Gene <i>BRCA2</i> and DSS1, a Protein Functionally Conserved from Yeast to Mammals. <i>Mol. Cell. Biol.</i> 19, 4633&#x2013;4642. doi: 10.1128/MCB.19.7.4633</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=10373512" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1128/MCB.19.7.4633" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Interaction+between+the+Product+of+the+Breast+Cancer+Susceptibility+Gene+BRCA2+and+DSS1%2C+a+Protein+Functionally+Conserved+from+Yeast+to+Mammals%2E&#x0026;journal=Mol%2E++Cell%2E++Biol%2E&#x0026;author=Marston+N.++J.&#x0026;author=Richards+W.++J.&#x0026;author=Hughes+D.&#x0026;author=Bertwistle+D.&#x0026;author=Marshall+C.++J.&#x0026;author=and+Ashworth+A.&#x0026;publication_year=1999&#x0026;volume=19&#x0026;pages=4633-4642" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B26" id="B26"></a>Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., et al. (2013). Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. <i>J. Natl. Cancer Inst.</i> 105, 812&#x2013;822. doi: 10.1093/jnci/djt095</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=23628597" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/jnci/djt095" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Cancer+risks+for+BRCA1+and+BRCA2+mutation+carriers%3A+results+from++prospective+analysis+of+EMBRACE%2E&#x0026;journal=J%2E+Natl%2E+Cancer+Inst%2E&#x0026;author=Mavaddat+N.&#x0026;author=Peock+S.&#x0026;author=Frost+D.&#x0026;author=Ellis+S.&#x0026;author=Platte+R.&#x0026;author=Fineberg+E.&#x0026;publication_year=2013&#x0026;volume=105&#x0026;pages=812-822" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B27" id="B27"></a>Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. <i>Science</i> 266, 66&#x2013;71.</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=7545954" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+strong+candidate+for+the+breast+and+ovarian+cancer+susceptibility+gene+BRCA1%2E&#x0026;journal=Science&#x0026;author=Miki+Y.&#x0026;author=Swensen+J.&#x0026;author=Shattuck-Eidens+D.&#x0026;author=Futreal+P.+A.&#x0026;author=Harshman+K.&#x0026;author=Tavtigian+S.&#x0026;publication_year=1994&#x0026;volume=266&#x0026;pages=66-71" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B28" id="B28"></a>Moles-Fern&#x00E1;ndez, A., Duran-Lozano, L., Montalban, G., Bonache, S., L&#x00F3;pez-Perolio, I., Men&#x00E9;ndez, M., et al. (2018). Computational tools for splicing defect prediction in breast/ovarian cancer genes: how efficient are they at predicting rna alterations? <i>Front. Genet.</i> 9:366. doi: 10.3389/fgene.2018.00366</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=30233647" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fgene.2018.00366" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Computational+tools+for+splicing+defect+prediction+in+breast%2Fovarian+cancer+genes%3A+how+efficient+are+they+at+predicting+rna+alterations%B4&#x0026;journal=Front%2E++Genet%2E&#x0026;author=Moles-Fern&#x00E1;ndez+A.&#x0026;author=Duran-Lozano+L.&#x0026;author=Montalban+G.&#x0026;author=Bonache+S.&#x0026;author=L&#x00F3;pez-Perolio+I.&#x0026;author=Men&#x00E9;ndez+M.&#x0026;publication_year=2018" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B29" id="B29"></a>Montalban, G., Fraile-Bethencourt, E., L&#x00F3;pez-Perolio, I., P&#x00E9;rez-Segura, P., Infante, M., Dur&#x00E1;n, M., et al. (2018). Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.<i>7976</i>+5G &#x003E; T as a case study. <i>Hum. Mutat.</i> 39, 1155&#x2013;1160. doi: 10.1002/humu.23583</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=29969168" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.23583" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Characterization+of+spliceogenic+variants+located+in+regions+linked+to+high+levels+of+alternative+splicing%3A+BRCA2+c%2E7976%2B5G+>+T+as+a+case+study%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Montalban+G.&#x0026;author=Fraile-Bethencourt+E.&#x0026;author=L&#x00F3;pez-Perolio+I.&#x0026;author=P&#x00E9;rez-Segura+P.&#x0026;author=Infante+M.&#x0026;author=Dur&#x00E1;n+M.&#x0026;publication_year=2018&#x0026;volume=39&#x0026;pages=1155-1160" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B30" id="B30"></a>Nielsen, F. C., van Overeem Hansen, T., and S&#x00F8;rensen, C. S. (2016). Hereditary breast and ovarian cancer: new genes in confined pathways. <i>Nat. Rev. Cancer</i> 16, 599&#x2013;612. doi: 10.1038/nrc.2016.72</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=27515922" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nrc.2016.72" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Hereditary+breast+and+ovarian+cancer%3A+new+genes+in+confined+pathways%2E&#x0026;journal=Nat%2E++Rev%2E+Cancer&#x0026;author=Nielsen+F.++C.&#x0026;author=van+Overeem+Hansen+T.&#x0026;author=and+S&#x00F8;rensen+C.++S.&#x0026;publication_year=2016&#x0026;volume=16&#x0026;pages=599-612" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B31" id="B31"></a>Petrucelli, N., Daly, M. B., and Feldman, G. L. (2013). &#x201C;BRCA1 and BRCA2 hereditary breast and ovarian cancer&#x201D;. <i>GeneReviews<sup>&#x00AE;</sup>[Internet]</i> eds MP., Adam, H. H., Ardinger Seattle, WA: University of Washington, Seattle 1&#x2013;11.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=%22BRCA1+and+BRCA2+hereditary+breast+and+ovarian+cancer%22%2E&#x0026;journal=GeneReviews&#xAE;%3B%5BInternet%5D&#x0026;author=Petrucelli+N.&#x0026;author=Daly+M.++B.&#x0026;author=and+Feldman+G.++L.&#x0026;publication_year=2013&#x0026;pages=1-11" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B32" id="B32"></a>Radice, P., De, S. S., Caleca, L., and Tommasi, S. (2011). Unclassified variants in BRCA genes: guidelines for interpretation. <i>Ann.Oncol.</i> 22(Suppl. 1), i18&#x2013;i23. doi: 10.1093/annonc/mdq661</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=21285146" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/annonc/mdq661" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Unclassified+variants+in+BRCA+genes%3A+guidelines+for+interpretation%2E&#x0026;journal=Ann%2EOncol%2E&#x0026;author=Radice+P.&#x0026;author=De+S.+S.&#x0026;author=Caleca+L.&#x0026;author=and+Tommasi+S.&#x0026;publication_year=2011&#x0026;pages=i18-i23" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B33" id="B33"></a>Raghunandan, M., Chaudhury, I., Kelich, S. L., Hanenberg, H., and Sobeck, A. (2015). FANCD2. FANCJ and BRCA2 cooperate to promote replication fork recovery independently of the Fanconi Anemia core complex. <i>Cell Cycle</i> 14, 342&#x2013;353. doi: 10.4161/15384101.2014.987614</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=25659033" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4161/15384101.2014.987614" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=FANCD2%2E+FANCJ+and+BRCA2+cooperate+to+promote+replication+fork+recovery+independently+of+the+Fanconi+Anemia+core+complex%2E&#x0026;journal=Cell+Cycle&#x0026;author=Raghunandan+M.&#x0026;author=Chaudhury+I.&#x0026;author=Kelich+S.+L.&#x0026;author=Hanenberg+H.&#x0026;author=and+Sobeck+A.&#x0026;publication_year=2015&#x0026;volume=14&#x0026;pages=342-353" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B34" id="B34"></a>Rebbeck, T. R., Friebel, T. M., Friedman, E., Hamann, U., Huo, D., Kwong, A., et al. (2018). Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Hum. Mutat.</i> 39, 593&#x2013;620. doi: 10.1002/humu.23406</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=29446198" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.23406" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Mutational+spectrum+in+a+worldwide+study+of+29%2C700+families+with+BRCA1+or+BRCA2+mutations%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Rebbeck+T.++R.&#x0026;author=Friebel+T.++M.&#x0026;author=Friedman+E.&#x0026;author=Hamann+U.&#x0026;author=Huo+D.&#x0026;author=Kwong+A.&#x0026;publication_year=2018&#x0026;volume=39&#x0026;pages=593-620" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B35" id="B35"></a>Reese, M. G., Eeckman, F. H., Kulp, D., and Haussler, D. (1997). Improved splice site detection in Genie. <i>J. Comput. Biol.</i> 4, 311&#x2013;323. doi: 10.1089/cmb.1997.4.311</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=9278062" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1089/cmb.1997.4.311" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Improved+splice+site+detection+in+Genie%2E&#x0026;journal=J%2E+Comput%2E+Biol%2E&#x0026;author=Reese+M.++G.&#x0026;author=Eeckman+F.++H.&#x0026;author=Kulp+D.&#x0026;author=and+Haussler+D.&#x0026;publication_year=1997&#x0026;volume=4&#x0026;pages=311-323" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B36" id="B36"></a>Ricks, T. K., Chiu, H.-J., Ison, G., Kim, G., McKee, A. E., Kluetz, P., et al. (2015). Successes and challenges of PARP inhibitors in cancer therapy. <i>Front. Oncol.</i> 5:222. doi: 10.3389/fonc.2015.00222</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=26528434" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fonc.2015.00222" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Successes+and+challenges+of+PARP+inhibitors+in+cancer+therapy%2E&#x0026;journal=Front%2E++Oncol%2E&#x0026;author=Ricks+T.+K.&#x0026;author=Chiu+H.-J.&#x0026;author=Ison+G.&#x0026;author=Kim+G.&#x0026;author=McKee+A.+E.&#x0026;author=Kluetz+P.&#x0026;publication_year=2015" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B37" id="B37"></a>Sharma, N., Sosnay, P. R., Ramalho, A. S., Douville, C., Franca, A., Gottschalk, L. B., et al. (2014). Experimental assessment of splicing variants using expression minigenes and comparison with in silico predictions. <i>Hum. Mutat.</i> 35,1249&#x2013;1259. doi: 10.1002/humu.22624</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=25066652" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.22624" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Experimental+assessment+of+splicing+variants+using+expression+minigenes+and+comparison+with+in+silico+predictions%2E&#x0026;journal=Hum%2E++Mutat%2E&#x0026;author=Sharma+N.&#x0026;author=Sosnay+P.++R.&#x0026;author=Ramalho+A.++S.&#x0026;author=Douville+C.&#x0026;author=Franca+A.&#x0026;author=Gottschalk+L.+B.&#x0026;publication_year=2014&#x0026;volume=35&#x0026;pages=1249-1259" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B38" id="B38"></a>Slavin, T. P., Maxwell, K. N., Lilyquist, J., Vijai, J., Neuhausen, S. L., Hart, S. N., et al. (2017). The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. <i>NPJ Breast Cancer</i> 3, 22. doi: 10.1038/s41523-017-0024-8</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=29119134" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41523-017-0024-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=The+contribution+of+pathogenic+variants+in+breast+cancer+susceptibility+genes+to+familial+breast+cancer+risk%2E&#x0026;journal=NPJ+Breast+Cancer&#x0026;author=Slavin+T.+P.&#x0026;author=Maxwell+K.+N.&#x0026;author=Lilyquist+J.&#x0026;author=Vijai+J.&#x0026;author=Neuhausen+S.+L.&#x0026;author=Hart+S.+N.&#x0026;publication_year=2017&#x0026;volume=3&#x0026;issue=22" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B39" id="B39"></a>Slavin, T. P., Niell-Swiller, M., Solomon, I., Nehoray, B., Rybak, C., Blazer, K. R., et al. (2015). Clinical application of multigene panels: challenges of next-generation counseling and cancer risk management. <i>Front. Oncol.</i> 5:208. doi: 10.3389/fonc.2015.00208</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=26484312" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fonc.2015.00208" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Clinical+application+of+multigene+panels%3A+challenges+of+next-generation+counseling+and+cancer+risk+management%2E&#x0026;journal=Front%2E+Oncol%2E&#x0026;author=Slavin+T.+P.&#x0026;author=Niell-Swiller+M.&#x0026;author=Solomon+I.&#x0026;author=Nehoray+B.&#x0026;author=Rybak+C.&#x0026;author=Blazer+K.+R.&#x0026;publication_year=2015" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B40" id="B40"></a>Spurdle, A. B., Couch, F. J., Hogervorst, F. B. L., Radice, P., and Sinilnikova, O. M. (2008). Prediction and assessment of splicing alterations: implications for clinical testing. <i>Hum. Mutat.</i> 29, 1304&#x2013;1313. doi: 10.1002/humu.20901</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=18951448" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.20901" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Prediction+and+assessment+of+splicing+alterations%3A+implications+for+clinical+testing%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Spurdle+A.+B.&#x0026;author=Couch+F.+J.&#x0026;author=Hogervorst+F.+B.+L.&#x0026;author=Radice+P.&#x0026;author=and+Sinilnikova+O.+M.&#x0026;publication_year=2008&#x0026;volume=29&#x0026;pages=1304-1313" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B41" id="B41"></a>Spurdle, A. B., Healey, S., Devereau, A., Hogervorst, F. B. L., Monteiro, A. N. A., Nathanson, K. L., et al. (2012). ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. <i>Hum. Mutat.</i> 33, 2&#x2013;7. doi: 10.1002/humu.21628</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=21990146" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.21628" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=ENIGMA-evidence-based+network+for+the+interpretation+of+germline+mutant+alleles%3A+an+international+initiative+to+evaluate+risk+and+clinical+significance+associated+with+sequence+variation+in+BRCA1+and+BRCA2+genes%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Spurdle+A.+B.&#x0026;author=Healey+S.&#x0026;author=Devereau+A.&#x0026;author=Hogervorst+F.+B.+L.&#x0026;author=Monteiro+A.+N.++A.&#x0026;author=Nathanson+K.+L.&#x0026;publication_year=2012&#x0026;volume=33&#x0026;pages=2-7" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B42" id="B42"></a>Stratton, M. R., and Rahman, N. (2008). The emerging landscape of breast cancer susceptibility. <i>Nat. Genet.</i> 40, 17&#x2013;22.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=The+emerging+landscape+of+breast+cancer+susceptibility%2E&#x0026;journal=Nat%2E+Genet%2E&#x0026;author=Stratton+M.+R.&#x0026;author=and+Rahman+N.&#x0026;publication_year=2008&#x0026;volume=40&#x0026;pages=17-22" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B43" id="B43"></a>Vall&#x00E9;e, M. P., Di Sera, T. L., Nix, D. A., Paquette, A. M., Parsons, M. T., Bell, R., et al. (2016). Adding in silico assessment of potential splice aberration to the integrated evaluation of brca gene unclassified variants. <i>Hum. Mutat.</i> 37, 627&#x2013;639. doi: 10.1002/humu.22973</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=26913838" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.22973" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Adding+in+silico+assessment+of+potential+splice+aberration+to+the+integrated+evaluation+of+brca+gene+unclassified+variants%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Vall&#x00E9;e+M.+P.&#x0026;author=Di+Sera+T.+L.&#x0026;author=Nix+D.+A.&#x0026;author=Paquette+A.+M.&#x0026;author=Parsons+M.+T.&#x0026;author=Bell+R.&#x0026;publication_year=2016&#x0026;volume=37&#x0026;pages=627-639" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B44" id="B44"></a>Villate, O., Ibarluzea, N., Fraile-Bethencourt, E., Valenzuela, A., Velasco, E. A., Grozeva, D., et al. (2018). Functional analyses of a novel splice variant in the CHD7 gene. found by next generation sequencing, confirm its pathogenicity in a spanish patient and diagnose him with CHARGE syndrome. <i>Front. Genet.</i> 9, 26&#x2013;31. doi: 10.3389/fgene.2018.00007</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=29434620" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fgene.2018.00007" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Functional+analyses+of+a+novel+splice+variant+in+the+CHD7+gene%2E+found+by+next+generation+sequencing%2C+confirm+its+pathogenicity+in+a+spanish+patient+and+diagnose+him+with+CHARGE+syndrome%2E&#x0026;journal=Front%2E+Genet%2E&#x0026;author=Villate+O.&#x0026;author=Ibarluzea+N.&#x0026;author=Fraile-Bethencourt+E.&#x0026;author=Valenzuela+A.&#x0026;author=Velasco+E.++A.&#x0026;author=Grozeva+D.&#x0026;publication_year=2018&#x0026;volume=9&#x0026;pages=26-31" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B45" id="B45"></a>Vreeswijk, M. P. G., Kraan, J. N., van der Klift, H. M., Vink, G. R., Cornelisse, C. J., Wijnen, J. T., et al. (2009). Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. <i>Hum. Mutat.</i> 30, 107&#x2013;114. doi: 10.1002/humu.20811</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=18693280" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.20811" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Intronic+variants+in+BRCA1+and+BRCA2+that+affect+RNA+splicing+can+be+reliably+selected+by+splice-site+prediction+programs%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Vreeswijk+M.++P.++G.&#x0026;author=Kraan+J.++N.&#x0026;author=van+der+Klift+H.++M.&#x0026;author=Vink+G.++R.&#x0026;author=Cornelisse+C.+J.&#x0026;author=Wijnen+J.+T.&#x0026;publication_year=2009&#x0026;volume=30&#x0026;pages=107-114" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B46" id="B46"></a>Wang, G.-S., and Cooper, T. A. (2007). Splicing in disease: disruption of the splicing code and the decoding machinery. <i>Nat. Rev. Genet.</i> 8, 749&#x2013;761. doi: 10.1038/nrg2164</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=17726481" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nrg2164" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Splicing+in+disease%3A+disruption+of+the+splicing+code+and+the+decoding+machinery%2E&#x0026;journal=Nat%2E+Rev%2E+Genet%2E&#x0026;author=Wang+G.-S.&#x0026;author=and+Cooper+T.+A.&#x0026;publication_year=2007&#x0026;volume=8&#x0026;pages=749-761" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B47" id="B47"></a>Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. <i>Nature</i> 378, 789&#x2013;792. doi: 10.1038/378789a0</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=8524414" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/378789a0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Identification+of+the+breast+cancer+susceptibility+gene+BRCA2%2E&#x0026;journal=Nature&#x0026;author=Wooster+R.&#x0026;author=Bignell+G.&#x0026;author=Lancaster+J.&#x0026;author=Swift+S.&#x0026;author=Seal+S.&#x0026;author=Mangion+J.&#x0026;publication_year=1995&#x0026;volume=378&#x0026;pages=789-792" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B48" id="B48"></a>Yeo, G., and Burge, C. B. (2004). Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. <i>J. Comput. Biol.</i> 11, 377&#x2013;394. doi: 10.1089/1066527041410418</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=15285897" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1089/1066527041410418" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Maximum+entropy+modeling+of+short+sequence+motifs+with+applications+to+RNA+splicing+signals%2E&#x0026;journal=J%2E+Comput%2E+Biol%2E&#x0026;author=Yeo+G.&#x0026;author=and+Burge+C.++B.&#x0026;publication_year=2004&#x0026;volume=11&#x0026;pages=377-394" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B49" id="B49"></a>Zhang, M. Q. (1998). Statistical features of human exons and their flanking regions. <i>Hum. Mol. Genet.</i> 7, 919&#x2013;932. doi: 10.1093/hmg/7.5.919</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=9536098" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/hmg/7.5.919" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Statistical+features+of+human+exons+and+their+flanking+regions%2E&#x0026;journal=Hum%2E+Mol%2E+Genet%2E&#x0026;author=Zhang+M.+Q.&#x0026;publication_year=1998&#x0026;volume=7&#x0026;pages=919-932" target="_blank">Google Scholar</a></p>
</div>
</div>
<div class="thinLineM20"></div>
<div class="AbstractSummary">
<p><span>Keywords</span>: breast cancer, BRCA2, DNA variants, splicing, hybrid minigenes</p>
<p><span>Citation:</span> Fraile-Bethencourt E, Valenzuela-Palomo A, D&#x00ED;ez-G&#x00F3;mez B, Caloca MJ, G&#x00F3;mez-Barrero S and Velasco EA (2019) Minigene Splicing Assays Identify 12 Spliceogenic Variants of <i>BRCA2</i> Exons 14 and 15. <i>Front. Genet.</i> 10:503. doi: 10.3389/fgene.2019.00503</p>
<p id="timestamps">
<span>Received:</span> 05 February 2019; <span>Accepted:</span> 07 May 2019;<br><span>Published:</span> 28 May 2019.</p>
<div>
<p>Edited by:</p>
<a href="https://loop.frontiersin.org/people/143042/overview">Naoyuki Kataoka</a>, The University of Tokyo, Japan</div>
<div>
<p>Reviewed by:</p>
<a href="https://loop.frontiersin.org/people/302927/overview">Logan Walker</a>, University of Otago, New Zealand<br>
<a href="https://loop.frontiersin.org/people/132589/overview">Katarzyna Gaweda-Walerych</a>, Mossakowski Medical Research Centre (PAN), Poland<br>
<a href="https://loop.frontiersin.org/people/290253/overview">Mads Thomassen</a>, Odense University Hospital, Denmark</div>
<p><span>Copyright</span> &#x00A9; 2019 Fraile-Bethencourt, Valenzuela-Palomo, D&#x00ED;ez-G&#x00F3;mez, Caloca, G&#x00F3;mez-Barrero and Velasco. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>*Correspondence:</span> Eladio A. Velasco, <a id="encmail">ZWF2ZWxzYW1AaWJnbS51dmEuZXM=</a></p>
<div class="clear"></div>
</div>
</div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fgene.2019.00503" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">16,7K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">3,7K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">31</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/452814#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fgene.2019.00503" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fgene.2019.00503" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/143042/overview" data-event="editorInfo-a-naoyukiKataoka" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">N</span><span class="notranslate">K</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Naoyuki  Kataoka</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">The University of Tokyo, Japan</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/132589/overview" data-event="editorInfo-a-katarzynaGawedaWalerych" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">K</span><span class="notranslate">G</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Katarzyna  Gaweda-Walerych</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Mossakowski Medical Research Institute, Polish Academy of Sciences, Poland</div></div></a><a href="https://loop.frontiersin.org/people/290253/overview" data-event="editorInfo-a-madsThomassen" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">M</span><span class="notranslate">T</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Mads  Thomassen</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Odense University Hospital, Denmark</div></div></a><a href="https://loop.frontiersin.org/people/302927/overview" data-event="editorInfo-a-loganWalker" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">L</span><span class="notranslate">W</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Logan  Walker</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">University of Otago, New Zealand</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal">
<li><a href="#h1">Abstract</a></li>
<li><a href="#h2">Introduction</a></li>
<li><a href="#h3">Materials and Methods</a></li>
<li><a href="#h4">Results</a></li>
<li><a href="#h5">Discussion</a></li>
<li><a href="#h6">Author Contributions</a></li>
<li><a href="#h7">Funding</a></li>
<li><a href="#h8">Conflict of Interest Statement</a></li>
<li><a href="#h9">Acknowledgments</a></li>
<li><a href="#h10">Supplementary Material</a></li>
<li><a href="#h11">Footnotes</a></li>
<li><a href="#h12">References</a></li>
</ul>
</div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fgene.2019.00503" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/genetics/articles/10.3389/fgene.2019.00503/full",["Reactive",16],{"main":17,"user":514,"article":515,"articleHub":801,"mainHeader":805},{"ibar":18,"footer":276,"newsletterComponent":-1,"snackbarItem":358,"toggleShowSnackbar":359,"contentfulJournal":360,"graphJournal":414,"settingsFeaturesSwitchers":418,"templateToggleBanner":419,"tenantConfig":479},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":207,"aboutJournal":208,"mainLinks":257,"journalLinks":264,"helpCenterLink":273},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=1&fieldid=30&specialtyid=0&entitytype=2&entityid=240",{"id":115,"name":116,"slug":117,"sections":118},240,"Frontiers in Genetics","genetics",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203],{"id":120,"name":121,"slug":122},549,"Applied Genetic Epidemiology","applied-genetic-epidemiology",{"id":124,"name":125,"slug":126},536,"Behavioral and Psychiatric Genetics","behavioral-and-psychiatric-genetics",{"id":128,"name":129,"slug":130},2030,"Cancer Genetics and Oncogenomics","cancer-genetics-and-oncogenomics",{"id":132,"name":133,"slug":134},551,"Computational Genomics","computational-genomics",{"id":136,"name":137,"slug":138},2512,"Cytogenomics","cytogenomics",{"id":140,"name":141,"slug":142},650,"ELSI in Science and Genetics","elsi-in-science-and-genetics",{"id":144,"name":145,"slug":146},455,"Epigenomics and Epigenetics","epigenomics-and-epigenetics",{"id":148,"name":149,"slug":150},535,"Evolutionary and Population Genetics","evolutionary-and-population-genetics",{"id":152,"name":153,"slug":154},596,"Genetics of Aging","genetics-of-aging",{"id":156,"name":157,"slug":158},635,"Genetics of Common and Rare Diseases","genetics-of-common-and-rare-diseases",{"id":160,"name":161,"slug":162},557,"Genomic Assay Technology","genomic-assay-technology",{"id":164,"name":165,"slug":166},1520,"Genomics of Plants and the Phytoecosystem","genomics-of-plants-and-the-phytoecosystem",{"id":168,"name":169,"slug":170},1419,"Human and Medical Genomics","human-and-medical-genomics",{"id":172,"name":173,"slug":174},2237,"Immunogenetics","immunogenetics",{"id":176,"name":177,"slug":178},241,"Livestock Genomics","livestock-genomics",{"id":180,"name":181,"slug":182},19,"Neurogenomics","neurogenomics",{"id":184,"name":185,"slug":186},3423,"Nutritional Genomics","nutritional-genomics",{"id":188,"name":189,"slug":190},198,"Pharmacogenetics and Pharmacogenomics","pharmacogenetics-and-pharmacogenomics",{"id":192,"name":193,"slug":194},556,"Predictive Toxicology and Exposomics","predictive-toxicology-and-exposomics",{"id":196,"name":197,"slug":198},555,"RNA","rna",{"id":200,"name":201,"slug":202},454,"Statistical Genetics and Methodology","statistical-genetics-and-methodology",{"id":204,"name":205,"slug":206},685,"Stem Cell Research","stem-cell-research","Sections",[209,233],{"title":210,"links":211},"Scope",[212,215,218,221,224,227,230],{"text":213,"url":214,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/genetics/about#about-editors",{"text":216,"url":217,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/genetics/about#about-scope",{"text":219,"url":220,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/genetics/about#about-facts",{"text":222,"url":223,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/genetics/about#about-submission",{"text":225,"url":226,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/genetics/about#about-open",{"text":228,"url":229,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/genetics/about#copyright-statement",{"text":231,"url":232,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/genetics/about#about-quality",{"title":234,"links":235},"For authors",[236,239,242,245,248,251,254],{"text":237,"url":238,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/genetics/for-authors/why-submit",{"text":240,"url":241,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/genetics/for-authors/article-types",{"text":243,"url":244,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines",{"text":246,"url":247,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines",{"text":249,"url":250,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees",{"text":252,"url":253,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist",{"text":255,"url":256,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office",[258,261],{"text":259,"url":260,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":262,"url":263,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[265,268,270],{"text":266,"url":267,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":269,"target":27,"ariaLabel":28},"research-topics",{"text":271,"url":272,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":274,"url":275,"target":77,"ariaLabel":274},"Help center","https://helpcenter.frontiersin.org",{"blocks":277,"socialLinks":331,"copyright":355,"termsAndConditionsUrl":356,"privacyPolicyUrl":357},[278,292,302,316],{"title":279,"links":280},"Guidelines",[281,283,286,289,291],{"text":243,"url":282,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":284,"url":285,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":287,"url":288,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":246,"url":290,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":293,"links":294},"Explore",[295,296,299,301],{"text":266,"url":263,"target":27,"ariaLabel":28},{"text":297,"url":298,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":300,"url":260,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":303,"links":304},"Outreach",[305,308,311,315],{"text":306,"url":92,"target":77,"ariaLabel":307},"Frontiers Forum ","Frontiers Forum website",{"text":309,"url":310,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":312,"url":313,"target":77,"ariaLabel":314},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":317,"links":318},"Connect",[319,320,324,327,330],{"text":274,"url":275,"target":77,"ariaLabel":274},{"text":321,"url":322,"target":77,"ariaLabel":323},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":325,"url":111,"target":27,"ariaLabel":326},"Contact us ","Subscribe to newsletter",{"text":328,"url":329,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[332,340,345,350],{"link":333,"type":336,"color":337,"icon":338,"size":339,"hiddenText":13},{"text":334,"url":335,"target":77,"ariaLabel":334},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":341,"type":336,"color":337,"icon":344,"size":339,"hiddenText":13},{"text":342,"url":343,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":346,"type":336,"color":337,"icon":349,"size":339,"hiddenText":13},{"text":347,"url":348,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":351,"type":336,"color":337,"icon":354,"size":339,"hiddenText":13},{"text":352,"url":353,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":361,"identifier":115,"name":116,"slug":117,"banner":362,"description":407,"mission":408,"palette":409,"impactFactor":410,"citeScore":411,"citations":412,"showTagline":28,"twitter":413},"Journal",[363],{"id":364,"src":365,"name":366,"type":367,"width":368,"height":369,"idHash":370,"archive":371,"brandId":372,"limited":371,"fileSize":373,"isPublic":374,"original":375,"copyright":19,"extension":376,"thumbnails":378,"dateCreated":386,"description":19,"orientation":387,"userCreated":388,"watermarked":371,"dateModified":386,"datePublished":389,"ecsArchiveFiles":390,"propertyOptions":391,"property_Channel":396,"property_Sub-Type":398,"property_Asset_Type":400,"activeOriginalFocusPoint":402,"property_Office_Department":405},"12AFEC62-10F2-4A9B-900C8422E4B53D54","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/webimage-A09D2065-D257-435D-987C43E79D7FBDFD.png","FGENE_Main Visual_Purple_Website","image",6016,4016,"3b54103c3aad636f",0,"22C10171-81B3-4DA6-99342F272A32E8BB",10275124,1,"https://brand.frontiersin.org/m/3b54103c3aad636f/original/FGENE_Main-Visual_Purple_Website.jpg",[377],"jpg",{"mini":379,"thul":380,"webimage":365,"Guidelines":381,"WebsiteJpg_XL":382,"WebsiteWebP_L":383,"WebsiteWebP_M":384,"WebsiteWebP_XL":385},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/mini-8741E412-02C1-4126-84DDA81B97389D5E.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/thul-D176A038-2FDA-438D-B9A7E98CF3926BBE.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/Guidelines-FGENE_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteJpg_XL-FGENE_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteWebP_L-FGENE_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteWebP_M-FGENE_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteWebP_XL-FGENE_Main Visual_Purple_Website.webp","2022-06-27T09:59:48Z","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[392,393,394,395],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[397],"frontiersin_org",[399],"Main_Visual",[401],"Photography",{"x":403,"y":404},3008,2008,[406],"Publishing","Explore research from the world's most cited genetics and heredity journal, advancing our understanding of genes from humans to plants and other model organisms.","\u003Cp>Frontiers in Genetics publishes research on genes and genomes relating to all the domains of life, from humans to livestock, and plants to other model organisms.\u003C/p>\n\n\u003Cp>Led by Field Chief Editor Enrico Domenici (Department of Cellular, Computational and Integrated Biology, University of Trento, Italy) Frontiers in Genetics is indexed in PubMed Central (PMC) and Scopus, among others, and explores the full spectrum of genetic and genomic research, encompassing fundamental studies and their clinical applications, while also embracing methodological advancements and exploring their applications and implications. Topics of interest include, but are not limited to:\u003C/p>\n\n\u003Cdiv> &bull; how genes or genomes relate to traits and humanpathophysiology\u003C/div>\n\u003Cdiv> &bull; advances in genomic data technology and analysis\u003C/div>\n\u003Cdiv> &bull; gene flow among species and populations\u003C/div>\n\u003Cdiv> &bull; livestock genome research Interactions between organisms, theirenvironment, and xenobiotics\u003C/div>\n\u003Cdiv> &bull; molecular and cellular genetics\u003C/div>\n\u003Cdiv> &bull; societal implicationsof genetic research.\u003C/div>\n\u003Cbr>\n\u003Cp>Submissions that emphasize advancement in the understanding of the function and variability of the genome, the use of genetic and genomic tools, and the analysis of the genetic underpinnings of biological processes are of particular interest to this journal.\u003Cp>\n\u003Cp>Furthermore, the journal actively welcomes submissions which support and advance the UNs Sustainable Development Goals (SDGs), notably SDG 3: good health and well-being.\u003C/p>\n\u003Cp>Manuscripts that focus solely on clinical outcomes, patient management, or therapeutic interventions without a clear genetic or genomic component are not suitable for publication in this journal. Studies that are purely epidemiological or observational, without a foundation in genetic or genomic mechanisms, are also not within the scope of this journal. Manuscripts consisting solely of bioinformatics, computational analyses of public data which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo) or are not highly innovative are not suitable for publication in this journal. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,Standards%20for%20research%20methodology,-Experiments\">Frontiers Standards for research methodology policy\u003C/a>, for more information.\u003C/p>\n\u003Cp>Frontiers in Genetics is committed to advancing developments in the field of genetics and genomics by allowing unrestricted access to articles, and communicating scientific knowledge to both researchers and the public, to enable the scientific breakthroughs of the future.\u003C/p>","purple","3.7","5.2","277710","@FrontGenetics",{"id":115,"name":116,"slug":117,"abbreviation":415,"isOnline":13,"isOpenForSubmissions":13,"citeScore":416,"impactFactor":417},"fgene",6.2,2.8,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":359},{"isPublic":13,"allowCompanyUsers":359,"whiteListEmails":420,"enableAllJournals":13,"whiteListJournals":442},[421,422,423,424,425,426,427,428,429,426,430,431,432,433,434,435,436,437,438,439,440,441],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[443,444,445,446,447,448,374,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":374,"name":374,"availableJournalPages":480,"announcement":484},[267,272,269,481,482,483],"volumes","about","community-reviewers",{"__typename":485,"sys":486,"preHeader":42,"title":488,"description":489,"image":490,"link":512},"Announcement",{"id":487},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[491],{"archive":371,"brandId":372,"copyright":28,"dateCreated":492,"dateModified":493,"datePublished":494,"description":28,"extension":495,"fileSize":497,"height":498,"id":499,"isPublic":371,"limited":371,"name":500,"orientation":387,"original":28,"thumbnails":501,"type":367,"watermarked":371,"width":508,"videoPreviewURLs":509,"tags":510,"textMetaproperties":511,"src":502},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[496],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":502,"thul":503,"mini":504,"WebsiteWebP_L":505,"WebsiteWebP_M":506,"Guidelines":507},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":513,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":516,"isPreviewPage":359,"hasSupplementalData":359,"showCrossmarkWidget":13,"articleTemplate":671,"currentArticlePageMetaInfo":672,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":517,"doi":518,"title":519,"acceptanceDate":520,"receptionDate":521,"publicationDate":522,"lastModifiedDate":523,"isPublished":13,"abstract":524,"researchTopic":525,"articleType":531,"stage":534,"keywords":535,"authors":541,"editors":588,"reviewers":598,"journal":626,"section":633,"impactMetrics":635,"volume":639,"articleVolume":640,"relatedArticles":641,"isPublishedV2":359,"contents":642,"files":646},452814,"10.3389/fgene.2019.00503","Minigene Splicing Assays Identify 12 Spliceogenic Variants of BRCA2 Exons 14 and 15",["Date","2019-05-07T13:24:57.000Z"],["Date","2019-02-05T07:58:16.000Z"],["Date","2019-05-28T00:00:00.000Z"],["Date","2025-11-25T04:59:12.752Z"],"A relevant fraction of BRCA2 variants is associated with splicing alterations and with an increased risk of hereditary breast and ovarian cancer (HBOC). In this work, we have carried out a thorough study of variants from BRCA2 exons 14 and 15 reported at mutation databases.\nA total of 294 variants from exons 14 and 15 and flanking intronic sequences were analysed with the online splicing tools NNSplice and Human Splicing Finder. Fifty-three out of these 294 variants were selected as candidate splicing variants. All variants but one, were introduced into the minigene MGBR2_ex14-20 (with exons 14 to 20) by site-directed mutagenesis and assayed in MCF-7 cells. Twelve of the remaining 52 variants (23.1%) impaired splicing at different degrees, yielding from 5% to 100% of aberrant transcripts. Nine variants affected the natural acceptor or donor sites of both exons and three affected putative enhancers or silencers. Fluorescent capillary electrophoresis revealed at least ten different anomalous transcripts: (E14q5),  (E14p10), (E14p246), (E14q256), (E14), (E15p12), (E15p13), (E15p83), (E15) and a 942-nt fragment of unknown structure. All transcripts, except for (E14q256) and (E15p12), are expected to truncate the BRCA2 protein. Nine variants induced severe splicing aberrations with more than 90% of abnormal transcripts. Thus, according to the guidelines of the American College of Medical Genetics and Genomics, eight variants should be classified as pathogenic (c.7008-2A>T, c.7008-1G>A, c.7435+1G>C, c.7436-2A>T, c.7436-2A>G, c.7617+1G>A, c.7617+1G>T and c.7617+2T>G), one as likely pathogenic (c.7008-3C>G) and three remain as variants of uncertain clinical significance or VUS (c.7177A>G, c.7447A>G and c.7501C>T).\nIn conclusion, functional assays by minigenes constitute a valuable strategy to primarily check the splicing impact of DNA variants and their clinical interpretation. While bioinformatics predictions of splice site variants were accurate, those of enhancer or silencer variants were poor (only 3/23 spliceogenic variants) which showed weak impacts on splicing (~5 to 16% of aberrant isoforms). So, the Exonic Splicing Enhancer and Silencer (ESE and ESS, respectively) prediction algorithms require further improvement.",{"id":526,"title":527,"articlesCount":528,"isMagazinePage":13,"slug":529,"isOpenForSubmission":359,"views":530},9566,"RNA Splicing and Backsplicing: Disease and Therapy",18,"rna-splicing-and-backsplicing-disease-and-therapy",174406,{"id":532,"name":533},24,"Original Research",{"id":528,"name":19},[536,537,538,539,540],"breast  cancer","BRCA2","DNA variants","Aberrant splicing","Minigenes",[542,551,558,565,573,581],{"id":543,"firstName":544,"middleName":19,"lastName":545,"givenNames":546,"isCorresponding":359,"isProfilePublic":13,"userId":543,"email":-1,"affiliations":547},496376,"Eugenia","Fraile-Bethencourt","Eugenia ",[548],{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},"Splicing and Genetic Susceptibility to Cancer, Instituto de Biologa y Gentica Molecular (CSIC-UVa)","Spain",{"id":552,"firstName":553,"middleName":19,"lastName":554,"givenNames":555,"isCorresponding":359,"isProfilePublic":13,"userId":552,"email":-1,"affiliations":556},514162,"Alberto","Valenzuela-Palomo","Alberto ",[557],{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"id":559,"firstName":560,"middleName":19,"lastName":561,"givenNames":562,"isCorresponding":359,"isProfilePublic":13,"userId":559,"email":-1,"affiliations":563},563485,"Beatriz","Dez-Gmez","Beatriz ",[564],{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},{"id":566,"firstName":567,"middleName":19,"lastName":568,"givenNames":569,"isCorresponding":359,"isProfilePublic":13,"userId":566,"email":-1,"affiliations":570},682766,"Mara Jos","Caloca","Mara Jos ",[571],{"organizationName":572,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},"Instituto de Biologa y Gentica Molecular (CSIC-UVa)",{"id":574,"firstName":575,"middleName":19,"lastName":576,"givenNames":577,"isCorresponding":359,"isProfilePublic":13,"userId":574,"email":-1,"affiliations":578},717658,"Susana","Gmez-Barrero","Susana ",[579],{"organizationName":580,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},"VISAVET-Universidad Complutense de Madrid",{"id":582,"firstName":583,"middleName":19,"lastName":584,"givenNames":585,"isCorresponding":359,"isProfilePublic":13,"userId":582,"email":-1,"affiliations":586},496947,"Eladio A.","Velasco","Eladio A. ",[587],{"organizationName":549,"countryName":550,"cityName":19,"stateName":19,"zipCode":19},[589],{"id":590,"firstName":591,"middleName":19,"lastName":592,"givenNames":593,"isCorresponding":359,"isProfilePublic":13,"userId":590,"email":-1,"affiliations":594},143042,"Naoyuki","Kataoka","Naoyuki ",[595],{"organizationName":596,"countryName":597,"cityName":19,"stateName":19,"zipCode":19},"The University of Tokyo","Japan",[599,608,617],{"id":600,"firstName":601,"middleName":19,"lastName":602,"givenNames":603,"isCorresponding":359,"isProfilePublic":13,"userId":600,"email":-1,"affiliations":604},132589,"Katarzyna","Gaweda-Walerych","Katarzyna ",[605],{"organizationName":606,"countryName":607,"cityName":19,"stateName":19,"zipCode":19},"Mossakowski Medical Research Institute, Polish Academy of Sciences","Poland",{"id":609,"firstName":610,"middleName":19,"lastName":611,"givenNames":612,"isCorresponding":359,"isProfilePublic":13,"userId":609,"email":-1,"affiliations":613},290253,"Mads","Thomassen","Mads ",[614],{"organizationName":615,"countryName":616,"cityName":19,"stateName":19,"zipCode":19},"Odense University Hospital","Denmark",{"id":618,"firstName":619,"middleName":19,"lastName":620,"givenNames":621,"isCorresponding":359,"isProfilePublic":13,"userId":618,"email":-1,"affiliations":622},302927,"Logan","Walker","Logan ",[623],{"organizationName":624,"countryName":625,"cityName":19,"stateName":19,"zipCode":19},"University of Otago","New Zealand",{"id":115,"slug":117,"name":116,"shortName":627,"electronicISSN":628,"field":629,"specialtyId":28,"journalSectionPaths":631},"Front. Genet.","1664-8021",{"id":630,"domainId":374},30,[632],{"section":633},{"id":196,"name":197,"slug":198,"specialtyId":634},1270,{"views":636,"downloads":637,"citations":638},16653,3675,31,10,"Volume 10 - 2019",[],{"titleHtml":643,"fullTextHtml":644,"menuHtml":645},"Minigene Splicing Assays Identify 12 Spliceogenic Variants of \u003Ci>BRCA2\u003C/i> Exons 14 and 15","\u003Cdiv class=\"JournalAbstract\">\r\n\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\r\n\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\r\n\u003Ca href=\"https://loop.frontiersin.org/people/496376\" class=\"user-id-496376\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/496376/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"\r\nEugenia Fraile-Bethencourt\">Eugenia Fraile-Bethencourt\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/514162\" class=\"user-id-514162\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/514162/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Alberto Valenzuela-Palomo\">Alberto Valenzuela-Palomo\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/563485\" class=\"user-id-563485\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/563485/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Beatriz D&#xED;ez-G&#xF;mez\">Beatriz D&#x00ED;ez-G&#x00F3;mez\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/682766\" class=\"user-id-682766\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/682766/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Mar&#xED;a Jos&#xE; Caloca\">Mar&#x00ED;a Jos&#x00E9; Caloca\u003C/a>\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/717658\" class=\"user-id-717658\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/717658/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Susana G&#xF;mez-Barrero\">Susana G&#x00F3;mez-Barrero\u003C/a>\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/496947\" class=\"user-id-496947\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/496947/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Eladio A. Velasco*\">Eladio A. Velasco\u003C/a>\u003Csup>1*\u003C/sup>\u003C/span>\u003C/div>\r\n\u003Cul class=\"notes\">\r\n\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Splicing and Genetic Susceptibility to Cancer, Instituto de Biolog&#x00ED;a y Gen&#x00E9;tica Molecular (CSIC-UVa), Valladolid, Spain\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Instituto de Biolog&#x00ED;a y Gen&#x00E9;tica Molecular (CSIC-UVa), Valladolid, Spain\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>VISAVET-Universidad Complutense de Madrid, Madrid, Spain\u003C/li>\r\n\u003C/ul>\r\n\u003Cp class=\"mb0\">A relevant fraction of \u003Ci>BRCA2\u003C/i> variants is associated with splicing alterations and with an increased risk of hereditary breast and ovarian cancer (HBOC). In this work, we have carried out a thorough study of variants from BRCA2 exons 14 and 15 reported at mutation databases. A total of 294 variants from exons 14 and 15 and flanking intronic sequences were analyzed with the online splicing tools NNSplice and Human Splicing Finder. Fifty-three out of these 294 variants were selected as candidate splicing variants. All variants but one, were introduced into the minigene MGBR2_ex14-20 (with exons 14&#x2013;20) by site-directed mutagenesis and assayed in MCF-7 cells. Twelve of the remaining 52 variants (23.1%) impaired splicing at different degrees, yielding from 5 to 100% of aberrant transcripts. Nine variants affected the natural acceptor or donor sites of both exons and three affected putative enhancers or silencers. Fluorescent capillary electrophoresis revealed at least 10 different anomalous transcripts: \u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-i001.jpg\" id=\"I1\" alt=\"www.frontiersin.org\">(E14q5), &#x0394; (E14p10), &#x0394;(E14p246), &#x0394;(E14q256), &#x0394;(E14), &#x0394;(E15p12), &#x0394;(E15p13), &#x0394;(E15p83), &#x0394;(E15) and a 942-nt fragment of unknown structure. All transcripts, except for &#x0394;(E14q256) and &#x0394;(E15p12), are expected to truncate the BRCA2 protein. Nine variants induced severe splicing aberrations with more than 90% of abnormal transcripts. Thus, according to the guidelines of the American College of Medical Genetics and Genomics, eight variants should be classified as pathogenic (c.7008-2A &#x003E; T, c.7008-1G &#x003E; A, c.7435+1G &#x003E; C, c.7436-2A &#x003E; T, c.7436-2A &#x003E; G, c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G), one as likely pathogenic (c.7008-3C &#x003E; G) and three remain as variants of uncertain clinical significance or VUS (c.7177A &#x003E; G, c.7447A &#x003E; G and c.7501C &#x003E; T). In conclusion, functional assays by minigenes constitute a valuable strategy to primarily check the splicing impact of DNA variants and their clinical interpretation. While bioinformatics predictions of splice site variants were accurate, those of enhancer or silencer variants were poor (only 3/23 spliceogenic variants) which showed weak impacts on splicing (&#x223C;5&#x2013;16% of aberrant isoforms). So, the Exonic Splicing Enhancer and Silencer (ESE and ESS, respectively) prediction algorithms require further improvement.\u003C/p>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003C/div>\r\n\u003Cdiv class=\"JournalFullText\">\r\n\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\r\n\u003Cp class=\"mb15\">Since the discovery of the breast cancer genes \u003Ci>BRCA1\u003C/i> (OMIM #113705) and \u003Ci>BRCA2\u003C/i> (OMIM #600185) (\u003Ca href=\"#B27\">Miki et al., 1994\u003C/a>; \u003Ca href=\"#B47\">Wooster et al., 1995\u003C/a>), nearly 17,000 different variants of both genes have been recorded at the ClinVar database\u003Csup id=\"footnotesuper1\">\u003Ca id=\"note1a\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#note1\">1\u003C/a>\u003C/sup> (date last accessed; November 2018). Germline inactivating variants in \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> confer high lifetime risks of breast and ovarian cancers (\u003Ca href=\"#B26\">Mavaddat et al., 2013\u003C/a>). Also, other cancer types, such as prostate, pancreatic and melanoma, are associated with pathogenic variants in these genes (\u003Ca href=\"#B31\">Petrucelli et al., 2013\u003C/a>). Despite the high penetrance of \u003Ci>BRCA\u003C/i> pathogenic variants, they are responsible for only &#x223C;15&#x2013;20% of hereditary breast and ovarian cancer (HBOC) (\u003Ca href=\"#B42\">Stratton and Rahman, 2008\u003C/a>). In fact, HBOC is a highly genetically heterogeneous disease with about 25 known or proposed susceptibility genes (\u003Ca href=\"#B30\">Nielsen et al., 2016\u003C/a>). Apart from the BRCA genes, \u003Ci>PALB2\u003C/i> (OMIM #610355), \u003Ci>ATM\u003C/i> (OMIM #607585), and \u003Ci>CHEK2\u003C/i> (OMIM #604373) have a prominent contribution since, in a recent study, more than 30% of pathogenic variants were found in these genes (\u003Ca href=\"#B6\">Buys et al., 2017\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Commonly, the variants are classified attending to their predicted effect on the protein so that truncating variants (frameshift and nonsense) are directly classified as pathogenic, while intronic, missense and synonymous variants are usually considered to be variants of uncertain clinical significance (VUS). In fact, VUS are identified by a relevant proportion of BRCA genetic tests (&#x223C;20%), which hamper genetic counseling and subsequent preventive or therapeutic actions, since risk assessment is solely based on family history (\u003Ca href=\"#B32\">Radice et al., 2011\u003C/a>; \u003Ca href=\"#B13\">Eccles et al., 2015\u003C/a>; \u003Ca href=\"#B36\">Ricks et al., 2015\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Furthermore, other upstream gene-expression processes, such as transcription or splicing, can be impaired if regulatory motifs are targeted by nucleotide variations (\u003Ca href=\"#B46\">Wang and Cooper, 2007\u003C/a>). Splicing is the process by which introns are removed from a pre-mRNA and exons are consecutively joined. This mechanism is performed in the nucleus by the spliceosome, a macrocomplex constituted by 5 small nuclear ribonucleoproteins (snRNPs) and many other associated proteins (\u003Ca href=\"#B10\">De Conti et al., 2012\u003C/a>). The spliceosome recognizes in the pre-mRNA specific sequences which define the exons/introns boundaries and other elements needed to carry out the process. These sequences are: the acceptor or 3&#x2032; splice site (3&#x2032;ss), the donor or 5&#x2032; splice site (5&#x2032;ss), the branch point, the polypyrimidine tract and the auxiliary \u003Ci>cis\u003C/i> sequences known as splicing regulatory elements (SREs) where enhancer or silencer \u003Ci>trans\u003C/i> factors can bind. Therefore, any change in the sequence may disrupt splicing (\u003Ca href=\"#B7\">Cartegni et al., 2002\u003C/a>). Splicing variants usually break the 3&#x2032;ss or 5&#x2032;ss leading to abnormal splicing events such as exon skipping, alternative site usage or intron retention. However, they may also create new splicing sites or strengthen cryptic ones that would then be recognized. Other mechanism that may alter splicing is the disruption of exonic/intronic splicing enhancers (ESEs/ISEs) or the creation of exonic/intronic splicing silencers (ESSs/ISSs) (\u003Ca href=\"#B1\">Abramowicz and Gos, 2018\u003C/a>). Nevertheless, it is extremely difficult to identify active SREs and predict the impact of the DNA variants on splicing given the low accuracy of SRE-detection softwares. Therefore, splicing variants can induce abnormal transcripts that either introduce premature termination codons (PTC), in-frame loss of essential protein domains or even inclusion of new translated sequences. Consequently, variants with impact on splicing (or \u003Ci>spliceogenic\u003C/i> variants) may be associated with an increased risk of a given disease. This ethiopathogenic mechanism has been so far underestimated, even though some authors have suggested that spliceogenic variants may represent more than 60% of disease-causing mutations (\u003Ca href=\"#B23\">L&#x00F3;pez-Bigas et al., 2005\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Previous studies have shown that a significant number of splicing variants have been detected in \u003Ci>BRCA2\u003C/i> (\u003Ca href=\"#B40\">Spurdle et al., 2008\u003C/a>; \u003Ca href=\"#B34\">Rebbeck et al., 2018\u003C/a>). In fact, previous results from our group showed that more than 50% of tested variants of \u003Ci>BRCA2\u003C/i> exons 16&#x2013;27 impaired splicing (\u003Ca href=\"#B3\">Acedo et al., 2012\u003C/a>, \u003Ca href=\"#B2\">2015\u003C/a>; \u003Ca href=\"#B16\">Fraile-Bethencourt et al., 2017\u003C/a>, \u003Ca href=\"#B17\">2018\u003C/a>). Likewise, at least 24 different BRCA2 alternative transcripts have been identified. They are helpful to interpret the splicing outcomes of genetic variations (\u003Ca href=\"#B14\">Fackenthal et al., 2016\u003C/a>) and suggest a fine regulation of \u003Ci>BRCA2\u003C/i> exon processing. This feature is supported by the fact that several ESE-rich regions have been functionally mapped by exonic deletions throughout most \u003Ci>BRCA2\u003C/i> exons. Thus, these motifs would be involved in precise exon recognition and alternative splicing events (\u003Ca href=\"#B2\">Acedo et al., 2015\u003C/a>; \u003Ca href=\"#B16\">Fraile-Bethencourt et al., 2017\u003C/a>). Moreover, we showed that functional mapping is an optimal approach that improves ESE-software predictions and facilitates the identification of spliceogenic mutations of this sort of \u003Ci>cis\u003C/i>-elements.\u003C/p>\r\n\u003Cp class=\"mb0\">In this work, we have extended our analysis to \u003Ci>BRCA2\u003C/i> exons 14 and 15 by carrying out an in-depth study of candidate spliceogenic variants. We have explored the presence of splicing enhancers in exons 14 and 15 and have undertaken RNA assays of 52 selected variants from both exons.\u003C/p>\r\n\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Materials and Methods\u003C/h2>\r\n\u003Cp class=\"mb0\">Ethical approval for this study was obtained from the Ethics Review Committee of the Hospital Universitario R&#x00ED;o Hortega de Valladolid (6/11/2014).\u003C/p>\r\n\u003Ch3>Bioinformatics: Databases and \u003Ci>in silico\u003C/i> Analysis\u003C/h3>\r\n\u003Cp class=\"mb15\">We collected \u003Ci>BRCA2\u003C/i> variants from the main databases: ClinVar\u003Csup id=\"footnotesuper2\">\u003Ca id=\"note2a\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#note2\">2\u003C/a>\u003C/sup>, the BRCA Share Database (UMD\u003Csup id=\"footnotesuper3\">\u003Ca id=\"note3a\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#note3\">3\u003C/a>\u003C/sup>) (\u003Ca href=\"#B5\">Beroud et al., 2016\u003C/a>) and the Breast Cancer Information Core (BIC\u003Csup id=\"footnotesuper4\">\u003Ca id=\"note4a\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#note4\">4\u003C/a>\u003C/sup>) (\u003Ca href=\"#h10\">Supplementary Table S1\u003C/a>). Variants and transcripts were annotated according to the Human Genome Variation Society (HGVS) guidelines on basis of the \u003Ci>BRCA2\u003C/i> GenBank sequence NM000059.1. In order to simplify, we identified transcripts with a shortened code that combines the following symbols (\u003Ca href=\"#B24\">Lopez-Perolio et al., 2019\u003C/a>): &#x0394; (skipping of reference exonic sequences), \u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-i001.jpg\" id=\"I2\" alt=\"www.frontiersin.org\"> (inclusion of reference intronic sequences), E (exon), p (acceptor shift), q (donor shift). When necessary, the exact number of skipped or retained nucleotides is indicated. For example, transcript &#x0394;(E14p10) indicates the use of an alternative acceptor site 10-nt downstream that causes a 10-nt deletion.\u003C/p>\r\n\u003Cp class=\"mb0\">\u003Ci>In silico\u003C/i> analysis was made with the online softwares: NNSplice\u003Csup id=\"footnotesuper5\">\u003Ca id=\"note5a\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#note5\">5\u003C/a>\u003C/sup> (\u003Ca href=\"#B35\">Reese et al., 1997\u003C/a>) and Human Splicing Finder version 3.1 (HSF\u003Csup id=\"footnotesuper6\">\u003Ca id=\"note6a\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#note6\">6\u003C/a>\u003C/sup>) that contain several prediction algorithms of different splicing motifs (\u003Ca href=\"#B12\">Desmet et al., 2009\u003C/a>). The following matrices were used: MaxEntScan (MES) (\u003Ca href=\"#B48\">Yeo and Burge, 2004\u003C/a>), the HSF branch point detection tool, ESE-finder (\u003Ca href=\"#B8\">Cartegni et al., 2003\u003C/a>), the HSF matrices for 9G8 and Tra2&#x03B2; and the HSF matrix for hnRNPA1. All the analyses were carried out with the default threshold values of NNSplice and HSF (NNSplice, 0.4; MES, 3.0; Branch point &#x2013; no cut-off-; SRE (0&#x2013;100 scale): SF2/ASF, 72.98; SF2/ASF (IgM &#x2013; BRCA1), 70.51; SC35, 75.05; SRp40, 78.08; SRp55 73.86; 9G8, 59.245; Tra2&#x03B2;, 75.964 and hnRNPA1, 65.476.\u003C/p>\r\n\u003Ch3>Minigene Construction and Mutations\u003C/h3>\r\n\u003Cp class=\"mb0\">The minigene MGBR2_14-20 was built as previously reported (\u003Ca href=\"#B16\">Fraile-Bethencourt et al., 2017\u003C/a>). A total of 52 variants and 8 microdeletions were introduced into the wild type (wt) minigene by site-directed mutagenesis with the QuikChange Lightning Kit (Agilent, Santa Clara, CA, United States), following the manufacturer&#x2019;s instructions (\u003Ca href=\"#h10\">Supplementary Table S2\u003C/a>). All mutant clones were confirmed by sequencing (Macrogen, Madrid, Spain).\u003C/p>\r\n\u003Ch3>MCF-7 Transfections\u003C/h3>\r\n\u003Cp class=\"mb0\">Approximately 2 &#x00D7; 10\u003Csup>5\u003C/sup> MCF-7 cells (human breast adenocarcinoma cell line) were plated in four-well plates (Nunc, Roskilde, Denmark). They were grown to 90% confluency in 0.5 mL of medium (MEME, 10% fetal bovine serum, 2 mM glutamine, 1% non-essential amino acids and 1% penicillin/streptomycin). Then, 1 &#x03BC;g of minigene was transfected into MCF-7 cells using low toxicity Lipofectamine (Life Technologies, Carlsbad, CA, United States) in Gibco\u003Csup>TM\u003C/sup> Opti-Mem\u003Csup>TM\u003C/sup> medium (Thermo Fisher Scientific, Waltham, MA, United States). Cells were incubated during 48h and then treated with cycloheximide 300 &#x03BC;g/ml (Sigma-Aldrich, St. Louis, MO, United States) for 4 h to inhibit the nonsense-mediated mRNA decay (NMD). The RNA was purified with the Genematrix Universal RNA Purification Kit (EURx, Gda&#x0144;sk, Poland) with on-column DNAse I digestion.\u003C/p>\r\n\u003Ch3>siRNA Assays\u003C/h3>\r\n\u003Cp class=\"mb0\">SR proteins were silenced in MCF7 cells by small interfering RNAs (siRNA) against the main SR proteins: SRSF1 (SF2), SRSF2 (SC35), SRSF3 (SRp20), SRSF5 (SRp40), SRSF7 (9G8), SRSF9 (SRp30c), and Tra2&#x03B2; (\u003Ca href=\"#h10\">Supplementary Table S3\u003C/a>), using anti-Luciferase siRNA as negative control. Approximately 1.5 &#x00D7; 10\u003Csup>5\u003C/sup> cells were subjected to a two-hit transfection in Optimem medium (Gibco &#x2013; Life Technologies, Carlsbad, CA, United States) with 3 &#x03BC;l of Oligofectamine (Thermo Fisher Scientific) and the specific siRNA at a final concentration of 0.08 &#x03BC;M on day 2. Then, 2 &#x03BC;g of the wt minigene were transfected with low toxicity Lipofectamine (Thermo Fisher Scientific) on day 4, and RNA was extracted on day 5. Silencing was confirmed by qPCR using 10 ng of cDNA in 25 &#x03BC;l reaction (\u003Ca href=\"#h10\">Supplementary Table S3\u003C/a>). Amplification was made with SG qPCR Master Mix (Eurx, Gda&#x0144;sk, Poland). Each siRNA/minigene transfection as well as all the qPCR experiments were carried out in duplicate.\u003C/p>\r\n\u003Ch3>RT-PCR and Transcripts Amplification\u003C/h3>\r\n\u003Cp class=\"mb15\">Retrotranscription was carried out with 400 ng of RNA and the RevertAid First Strand cDNA Synthesis Kit (Life Technologies), using the specific minigene primer RTPSPL3-RV (5&#x2032;-TGAGGAGTGAATTGGTCGAA-3&#x2032;). Samples were incubated at 42&#x00B0;C for 1 h, followed by 5 min at 70&#x00B0;C. Transcripts were amplified with Platinum Taq DNA polymerase (Life Technologies) using 40 ng of cDNA and the primers pMAD_607FW (Patent P201231427, CSIC) and RTBR2_ex17RV2 (5&#x2032;-GGCTTAGGCATCTATTAGCA-3&#x2032;). PCR consisted of: denaturation step at 94&#x00B0;C for 2 min, followed by 35 cycles 94&#x00B0;C-30 s, 60&#x00B0;C-30 s and 72&#x00B0;C-1 min/kb, and a final extension step at 72&#x00B0;C for 5 min. Transcripts were sequenced at the Macrogen Spain facility.\u003C/p>\r\n\u003Cp class=\"mb0\">In order to relatively quantify all transcripts, semi-quantitative fluorescent RT-PCRs were undertaken in triplicate with the primers pMAD_607FW (FAM-labeled) and RTBR2_ex17RV2 and Platinum Taq DNA polymerase (Life Technologies) under standard conditions except that 26 cycles were herein applied (\u003Ca href=\"#B2\">Acedo et al., 2015\u003C/a>). FAM-labeled products were run with LIZ-1200 Size Standard at the Macrogen facility and analyzed with the Peak Scanner software V1.0 (Life Technologies). Only peak heights &#x2265; 50 RFU (Relative Fluorescence Units) were considered.\u003C/p>\r\n\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\r\n\u003Ch3 class=\"pt0\">Minigene Construction and ESE Mapping\u003C/h3>\r\n\u003Cp class=\"mb0\">The minigene MGBR2_14-20 had previously been used to study variants of exons 16, 17, and 18, proving that it is a reliable and robust tool to functionally assay splicing variants (\u003Ca href=\"#B16\">Fraile-Bethencourt et al., 2017\u003C/a>, \u003Ca href=\"#B17\">2018\u003C/a>; \u003Ca href=\"#B29\">Montalban et al., 2018\u003C/a>). The MGBR2_14-20 is a 10.7 Kb construct which, after transfection in MCF-7 cells, produces a transcript with the following structure: V1-BRCA2_exons from 14 to 20-V2 (1,806 nt) (\u003Ca href=\"#F1\">Figure 1\u003C/a>). To study exons 14 and 15, cDNA was amplified with a forward primer located in V1 (pMAD_607FW) and a reverse primer located in exon 17 (RTBR2_Ex17RV2), with an expected transcript size of 1028 nt (\u003Ca href=\"#F1\">Figures 1B,C\u003C/a>).\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 1\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg\" name=\"figure1\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg\" alt=\"www.frontiersin.org\" id=\"F1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 1.\u003C/strong> Minigene MGBR2_14-20. \u003Cb>(A)\u003C/b> Schematic representation of MGBR2_14-20. BRCA2 exons 14&#x2013;20 are represented in blue boxes. Red lines represented the shortened introns. \u003Cb>(B)\u003C/b> Expected MGBR2_14-20 transcript (1,806 nt) and the amplified RT-PCR product. Specific amplification primers are shown as red arrows. \u003Cb>(C)\u003C/b> Capillary electrophoresis result of the functional assay of the wild type MGBR2_14-20 in MCF-7 cells. The full-length transcript is shown as a blue peak. The Genescan Liz-1200 size standard is shown as orange/faint peaks. Fragment sizes (nt) and relative fluorescent units are indicated on the \u003Ci>x\u003C/i>- and \u003Ci>y\u003C/i>-axes, respectively.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">To map ESEs, 30-nt overlapping microdeletions were performed along the first and the last 55-nt of exons 14 and 15 (\u003Ca href=\"#B2\">Acedo et al., 2015\u003C/a>), always preserving the splice site conserved positions (the first 2 nt and the last 3 nt of the exon). None of the deletions but one altered splicing, suggesting the absence of \u003Ci>cis\u003C/i>-regulatory motifs within these segments. Only exon 15 deletion c.7463_7492 impaired splicing generating a major aberrant transcript (62%) with a deletion of 83 nt [&#x0394;(E15p83)]. This transcript was caused by use of a cryptic 3&#x2032;ss 83-nt downstream, which is stronger than the canonical one, according to Max Ent Scan (MES; 6.18 vs. 5.16) (\u003Ca href=\"#F2\">Figure 2\u003C/a>). To determine which ESEs were implied in exon 15 recognition, siRNA experiments against the main splicing factors (SFSR1, SFSR2, SFSR3, SFSR5, SRSF7, SFSR9, and Tra2&#x03B2;) were accomplished (\u003Ca href=\"#h10\">Supplementary Figure S1\u003C/a>). However, none of them affected the recognition of exons 14 and 15.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 2\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg\" name=\"figure2\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g002.jpg\" alt=\"www.frontiersin.org\" id=\"F2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 2.\u003C/strong> Exon 15 ESE mapping: functional assay of c.7463_7492del positive microdeletion. \u003Cb>(A)\u003C/b> Schematic representation of BRCA2 exons 14 and 15 and the eight microdeletions: 1, c.7010_7039del; 2, c.7035_7064del; 3, c.7378_7407del; 4, c.7402_7432del; 5, c.7438_7467del; 6, c.7463_7492del; 7, c.7561_7590del; 8, c.7586_7615del. \u003Cb>(B)\u003C/b> Capillary electrophoresis and sequence results of functional assays of microdeletion c.7463_7492del in MCF-7 cells.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Ch3>Variant Collection and Bioinformatics Analysis\u003C/h3>\r\n\u003Cp class=\"mb0\">A total of 294 different variants, spread throughout exons 14 and 15 and flanking introns, were collected from the main databases (ClinVar, UMD and BIC) (\u003Ca href=\"#h10\">Supplementary Table S1\u003C/a>). They were analyzed \u003Ci>in silico\u003C/i> with MES and NNSplice for splice site prediction, and with ESE/ESS estimation algorithms integrated in Human Splicing Finder (HSF). Potential splicing variants were selected following these criteria: creation or disruption of splice sites (according to MES or NNSplice); disruption of the branch point; disruption of the polypyrimidine tract; elimination of enhancers or creation of silencers. Some of the selected variants had a combined effect, for example, they were predicted to simultaneously create an ESS and removed an ESE. A total of 53 candidate variants (&#x223C;18%) that included 19 intronic, 18 missense, 5 nonsense, 8 synonymous, and 3 frameshift variants were selected (\u003Ca href=\"#T1\">Table 1\u003C/a>). According to their previous clinical classification, the selection contained: 8 benign or likely benign variants, 30 VUS and 15 pathogenic or likely pathogenic variants.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">TABLE 1\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg\" name=\"table1\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t001.jpg\" alt=\"www.frontiersin.org\" id=\"T1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Table 1.\u003C/strong> Bioinformatics analysis of \u003Ci>BRCA2\u003C/i> exons 14 and 15 selected variants.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">Bioinformatics indicated that 13 variants disrupted the natural splice sites, three decreased their scores (one disrupted the polypyrimidine tract), 11 created new splice sites, one decreased the branch point score (HSF: 79.34&#x2192;55.5), three altered intronic splicing elements (ISEs and ISSs) and 22 altered exonic splicing elements (ESEs and ESSs) (\u003Ca href=\"#T1\">Table 1\u003C/a>). Exceptionally, variants c.7008-5T &#x003E; C (ivs13-5T &#x003E; C) and c.7435+5T &#x003E; C (ivs14+5T &#x003E; C) were also selected because, even though the bioinformatics did not show significant score changes (MES: 10.37&#x2192;8.48 and 5.64&#x2192;5.56, respectively), these positions are relevant for exon recognition. Thus, c.7008-5T &#x003E; C is the closest position of the polypyrimidine tract to the canonical acceptor site, and c.7435+5T &#x003E; C is part of the consensus 5&#x2032;ss sequence and +5 changes were previously associated with disease (\u003Ca href=\"#B37\">Sharma et al., 2014\u003C/a>; \u003Ca href=\"#B29\">Montalban et al., 2018\u003C/a>).\u003C/p>\r\n\u003Ch3>Functional Splicing Assays Using the Minigene MGBR2_14-20\u003C/h3>\r\n\u003Cp class=\"mb0\">A total of 52 variants were genetically engineered in the wt MGBR2_14-20 by using specific primers (\u003Ca href=\"#h10\">Supplementary Table S2\u003C/a>). Despite 53 variants were initially selected, mutagenesis experiments did not work for c.7598C &#x003E; G variant. The 52 mutant minigenes were checked by Sanger sequencing and assayed in MCF-7 cells. Results showed that 12 of them (23%) altered splicing (\u003Ca href=\"#T2\">Table 2\u003C/a> and \u003Ca href=\"#F3\">Figure 3\u003C/a>), seven of which had previously been classified as pathogenic and five as VUS (\u003Ca href=\"#T3\">Table 3\u003C/a>). Among these 12 variants, there were 9 intronic, 2 missense and 1 nonsense changes. Functionally, the 9 intronic variants (c.7008-3C &#x003E; G, c.7008-2A &#x003E; T, c.7008-1G &#x003E; A, c.7435+1G &#x003E; C, c.7436-2A &#x003E; T, c.7436-1G &#x003E; A, c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G) disrupted the natural splice sites, the two missense changes (c.7177A &#x003E; G and c.7447A &#x003E; G) triggered the use of \u003Ci>de novo\u003C/i> splice sites and originated other transcripts, and the nonsense one (c.7501C &#x003E; T) probably altered SREs despite it was primarily selected because of the creation of a new 5&#x2032;ss (\u003Ca href=\"#T1\">Table 1\u003C/a>). According to \u003Ca href=\"#B43\">Vall&#x00E9;e et al. (2016)\u003C/a>, nine variants induced severe splicing disruptions as they produced more than 60% of aberrant transcripts, ranging from 92.8 to 100% (\u003Ca href=\"#T3\">Table 3\u003C/a>).\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">TABLE 2\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg\" name=\"table2\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t002.jpg\" alt=\"www.frontiersin.org\" id=\"T2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Table 2.\u003C/strong> Quantification of the transcripts found by capillary electrophoresis after functional assays of \u003Ci>BRCA2\u003C/i> exons 14 and 15 variants.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine mb15\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 3\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg\" name=\"figure3\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g003.jpg\" alt=\"www.frontiersin.org\" id=\"F3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 3.\u003C/strong> Functional assays of the BRCA2 exons 14 and 15 variants using the MGBR2_14-minigene. \u003Cb>(A)\u003C/b> Exon 14 variants. \u003Cb>(B)\u003C/b> Exon 15 variants. On the left, capillary electropherograms are shown. Transcripts were amplified using pMAD_607FW-FAM and RTBR2_Ex17RV2. Labeled transcripts are shown as blue peaks, LIZ1200 was used as size standard (orange peaks). The expected size of the full length transcript is 1028 nt (1018&#x2013;1019 nt according to Peak Scanner). On the right, splicing patterns are represented. While blue boxes are natural exons, red boxes represent aberrant exons; dashed black and red lines show canonical and aberrant splicing events, respectively.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine mb15\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">TABLE 3\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg\" name=\"table3\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t003.jpg\" alt=\"www.frontiersin.org\" id=\"T3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Table 3.\u003C/strong> Classification of spliceogenic variants.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Ch4>Acceptor Site Variants\u003C/h4>\r\n\u003Cp class=\"mb15\">Exon 14 3&#x2032;ss was affected by c.7008-3C &#x003E; G, c.7008-2A &#x003E; T, and c.7008-1G &#x003E; A, whereas c.7008-5T &#x003E; C only produced the canonical transcript (\u003Ca href=\"#T2\">Table 2\u003C/a>). Curiously, while the main outcome of c.7008-3C &#x003E; G was exon skipping (&#x0394;E14), the variants c.7008-2A &#x003E; T and c.7008-1G &#x003E; A produced mostly the aberrant transcript &#x0394;(E14p10), in which a cryptic 3&#x2032;ss was recognized by the spliceosome 10-nt downstream. This cryptic 3&#x2032;ss was not detected by NNSplice or MES tools. The loss of 10-nt at the beginning of exon 14 would generate a PTC 27 codons downstream (p.Thr2337Asnfs\u003Csup>&#x2217;\u003C/sup>27). Our results also revealed the use of another cryptic 3&#x2032;ss (MES = 4.44) within exon 14, located 246-nt downstream the natural one, originating the transcript &#x0394;(E14p246) (13%) in the c.7008-3C &#x003E; G assay (\u003Ca href=\"#T2\">Table 2\u003C/a>). The transcript &#x0394;(E14p246) led to an in-frame deletion of 82 amino acids from position p.2337 to p.2418 (p.Thr2337_Arg2418del).\u003C/p>\r\n\u003Cp class=\"mb0\">The branch point (c.7436-22C &#x003E; T), polypyrimidine tract (c.7436-14T &#x003E; G) and &#x2212;4 (c.7436-4A &#x003E; G, c.7436-4A &#x003E; T) variants of exon 15 did not impair splicing. Other exon 15 acceptor variants, such as c.7436-2A &#x003E; T and c.7436-1G &#x003E; A, mainly caused isoform &#x0394;(E15p13) through use of a cryptic acceptor 13-nt downstream (\u003Ca href=\"#T2\">Table 2\u003C/a>). The use of this cryptic acceptor would provoke a frameshift deletion, leading to a PTC in the protein (p.Asp2479Valfs\u003Csup>&#x2217;\u003C/sup>41). Like exon 14 cryptic acceptor, this exon 15 cryptic 3&#x2032;ss was not detected by NNSplice or MES. Variant c.7436-1G &#x003E; A also produced the minor transcript &#x0394;E15p83 (3.7%) a 83-nt deletion that introduced a frameshift (p.Asp2479Alafs\u003Csup>&#x2217;\u003C/sup>32) and a PTC 32 codons downstream. This transcript was generated by a cryptic acceptor site 83-nt downstream (MES = 6.28). In summary, we found 5 variants (c.7008-3C &#x003E; G, c.7008-2A &#x003E; T, c.7008-1G &#x003E; A, c.7436-2A &#x003E; T, and c.7436-1G &#x003E; A) that altered 3&#x2032;ss recognition of exons 14 and 15, leading to aberrant splicing (\u003Ca href=\"#T2\">Table 2\u003C/a>). Remarkably, all of them showed the total absence of canonical transcript, except for c.7008-3C &#x003E; G that produced 7% of the full-length transcript. Moreover, our results unveiled exon 14 and 15 cryptic splice sites that are only recognized when natural acceptors are disrupted.\u003C/p>\r\n\u003Ch4>Donor Site Variants\u003C/h4>\r\n\u003Cp class=\"mb0\">Seven variants were predicted to disrupt donor sites: c.7435+1G &#x003E; C, c.7435+3A &#x003E; G, c.7435+5T &#x003E; C, and c.7435+6G &#x003E; A (exon 14) and c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G (exon 15; \u003Ca href=\"#T1\">Table 1\u003C/a>). Among the exon 14 variants, only c.7435+1G &#x003E; C impaired splicing (\u003Ca href=\"#T2\">Table 2\u003C/a>) producing a single transcript with a 5-nt insertion [\u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-i001.jpg\" id=\"I3\" alt=\"www.frontiersin.org\">(E14q5)], due to the recognition of a cryptic 5&#x2032;ss in ivs14. The \u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-i001.jpg\" id=\"I4\" alt=\"www.frontiersin.org\">(E14q5) is an aberrant splicing isoform which leads to PTC (p.Asp2479Glyfs\u003Csup>&#x2217;\u003C/sup>4). Surprisingly, this cryptic donor was not detected by NNSplice software as the canonical one was. Regarding exon 15 donor variants, our results showed that all of them (c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G) produced &#x0394;(E15) as unique transcript (\u003Ca href=\"#T2\">Table 2\u003C/a>), which generates a PTC eight codons downstream (p.Asp2479Alafs\u003Csup>&#x2217;\u003C/sup>8).\u003C/p>\r\n\u003Ch4>Splicing Regulatory Element-Variants\u003C/h4>\r\n\u003Cp class=\"mb0\">A total of 26 SRE variants were selected according to the criteria above described and assayed in MCF-7 cells (\u003Ca href=\"#T1\">Table 1\u003C/a>). Only c.7177A &#x003E; G altered weakly splicing resulting in about 5% of aberrant transcripts (\u003Ca href=\"#T2\">Table 2\u003C/a>). This matches with the creation of a new donor site that was not detected by the splicing prediction software. Conversely, none of the exon 15 SRE-variants impaired splicing even though microdeletion tests had revealed a presumed ESE interval (c.7463_7492).\u003C/p>\r\n\u003Ch4>New Splice Site Variants\u003C/h4>\r\n\u003Cp class=\"mb0\">We have assayed 10 variants of this type, six in exon 14 (c.7030A &#x003E; G, c.7180A &#x003E; T, c.7182A &#x003E; G, c.7203A &#x003E; G, c.7266T &#x003E; A, and c.7418G &#x003E; A) and four in exon 15 (c.7447A &#x003E; G, c.7466A &#x003E; G, c.7501C &#x003E; T, and c.7611_7615delTAAAC) (\u003Ca href=\"#T1\">Table 1\u003C/a>). Results showed that two exon 15 variants (c.7447A &#x003E; G and c.7501C &#x003E; T) slightly disrupted splicing (\u003Ca href=\"#T2\">Table 2\u003C/a>). The variant c.7447A &#x003E; G generated a new acceptor but most of its outcome was a full-length transcript (\u003Ca href=\"#T2\">Table 2\u003C/a>). The variant c.7501C &#x003E; T was predicted to create a new strong donor (NNSplice: &#x003C; 0.4&#x2192;0.96 and MES: 2.44&#x2192;10.19) (\u003Ca href=\"#T1\">Table 1\u003C/a>). However, only 16% of the transcripts made use of this cryptic donor 83-nt upstream of the natural one (\u003Ca href=\"#T2\">Table 2\u003C/a>).\u003C/p>\r\n\u003Ch3>Analysis of Transcripts\u003C/h3>\r\n\u003Cp class=\"mb0\">The so called full-length or canonical transcript (expected size: 1028-nt) was amplified with primers placed on vector exon V1 and BRCA2 exon 17. Apart from the canonical transcript, we have detected other ten different ones (\u003Ca href=\"#F3\">Figure 3\u003C/a>). Aberrant exon 14 splicing produced six different isoforms, but only five of them were characterized: &#x0394;(E14), &#x0394;(E14p10), &#x0394;(E14p246), &#x0394;(E14q256), and \u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-i001.jpg\" id=\"I5\" alt=\"www.frontiersin.org\">(E14q5). A 942-nt transcript of unknown structure could also be detected by capillary electrophoresis. All exon 14 isoforms, except for &#x0394;(E14p246), introduced PTCs into the mRNA. The isoform &#x0394;(E14p246) was seen in up to 13% of the c.7008-3C &#x003E; G transcripts (\u003Ca href=\"#T2\">Table 2\u003C/a>). Exon 15 variants produced 4 different isoforms besides the canonical one: &#x0394;(E15p12), &#x0394;(E15p13), &#x0394;(E15q83), and &#x0394;(E15). The &#x0394;(E15p13), &#x0394;(E15q83) and &#x0394;(E15) isoforms created PTCs while &#x0394;(E15p12) (new acceptor 12-nt downstream) kept the reading frame, although this isoform only accounted for 10% of the transcripts (\u003Ca href=\"#T2\">Table 2\u003C/a>).\u003C/p>\r\n\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\r\n\u003Cp class=\"mb0\">Due to the implementation of Next Generation Sequencing in the clinical setting (\u003Ca href=\"#B39\">Slavin et al., 2015\u003C/a>), a large number of variants have been detected in disease-responsible genes. HBOC and the breast cancer susceptibility genes are not exceptions, where thousands of different variants have been reported although many of them are considered as VUS (\u003Ca href=\"#B41\">Spurdle et al., 2012\u003C/a>; \u003Ca href=\"#B38\">Slavin et al., 2017\u003C/a>). In this context, the functional and clinical classifications pose a challenge for Medical Genetics. We have herein functionally assayed 52 \u003Ci>BRCA2\u003C/i> variants using the minigene MGBR2_14-20, whose reliability had been previously proven (\u003Ca href=\"#B16\">Fraile-Bethencourt et al., 2017\u003C/a>, \u003Ca href=\"#B17\">2018\u003C/a>; \u003Ca href=\"#B29\">Montalban et al., 2018\u003C/a>). We found 12 variants that altered splicing, nine of which would severely alter the protein. This study forms part of a comprehensive study of our group concerning potential splicing \u003Ci>BRCA2\u003C/i> variants, where 22 exons and up to 335 variants have been assayed using three minigenes: MGBR2_2-9 (\u003Ca href=\"#B18\">Fraile-Bethencourt et al., 2019\u003C/a>), MGBR2_14-20 (\u003Ca href=\"#B16\">Fraile-Bethencourt et al., 2017\u003C/a>, \u003Ca href=\"#B17\">2018\u003C/a>) and MGBR2_19-27 (\u003Ca href=\"#B3\">Acedo et al., 2012\u003C/a>, \u003Ca href=\"#B2\">2015\u003C/a>). The following advantages of the minigene technology should be underlined: (i) analysis of a single allele outcome without the interference of the wt counterpart of a patient sample; (ii) simple and fast quantification of generated transcripts by fluorescent capillary electrophoresis with minimum hands-on time versus other proposed methods (\u003Ca href=\"#B15\">Farber-Katz et al., 2018\u003C/a>); (iii) versatility, one single multi-exon minigene allows to assay variants from different exons; (iv) capability of analysis in many cell types to check effects derived from tissue-specific alternative splicing; (v) high reproducibility of splicing physiological/pathological patterns. In fact, we have previously provided many examples of the minigene reproducibility. In the case of \u003Ci>BRCA2\u003C/i> exons 14 and 15, variants c.7008-2A &#x003E; T, c.7617+1G &#x003E; A, and c.7617+2T &#x003E; G displayed similar patterns in patient RNA and minigene assays (\u003Ca href=\"#B45\">Vreeswijk et al., 2009\u003C/a>; \u003Ca href=\"#B9\">Colombo et al., 2013\u003C/a>; \u003Ca href=\"#B11\">de Garibay et al., 2014\u003C/a>). Moreover, another 31 variants of this and other constructs replicated previously reported patient splicing outcomes (\u003Ca href=\"#B2\">Acedo et al., 2015\u003C/a>; \u003Ca href=\"#B16\">Fraile-Bethencourt et al., 2017\u003C/a>, \u003Ca href=\"#B17\">2018\u003C/a>, \u003Ca href=\"#B18\">2019\u003C/a>), confirming that splicing reporters are robust and valuable tools to test the impact of variants on splicing, especially when patient RNA is not available.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">TABLE 4\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg\" name=\"table4\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-t004.jpg\" alt=\"www.frontiersin.org\" id=\"T4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Table 4.\u003C/strong> Summary of spliceogenic variants tested in minigene MGBR2_14-20.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">Here, we have shown that nine variants drastically disrupted the splicing pattern. We found five 3&#x2032;ss disrupting variants, one of which (c.7008-3C &#x003E; G) provoked exon 14 skipping, whereas the rest of them induced the use of cryptic sites (c.7008-2A &#x003E; T, c.7008-1G &#x003E; A, c.7436-2A &#x003E; T, and c.7436-1G &#x003E; A). Moreover, variant c.7435+1G &#x003E; C, which disrupt the exon 14 donor site, provoked the use of a cryptic donor. Curiously, neither c.7435+3A &#x003E; G, c.7435+5T &#x003E; C nor c.7435+6G &#x003E; A, which are also part of the consensus 5&#x2032;ss, affected splicing. This may be due to the low frequency of +5T and +6G at these positions, so that any nucleotide change only equals or improves splice site strength. Conversely, +3A is the main nucleotide at this position (71%) but +3G is also relatively frequent (24%) (\u003Ca href=\"#B49\">Zhang, 1998\u003C/a>). Thus, a substitution A to G might have a reduced or no splicing impact, as it is the case of the c.7435+3A &#x003E; G variant. As a matter of fact, variant c.9501+3A &#x003E; T produced 87% of the canonical transcript (\u003Ca href=\"#B2\">Acedo et al., 2015\u003C/a>). On the other hand, the three variants of exon 15 donor site c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G resulted in exon skipping. In this regard, it was recently recommended the use of a combination of the computational tools HSF plus Splice Site Finder-like to select candidate splice site variants with high sensitivity and specificity (\u003Ca href=\"#B28\">Moles-Fern&#x00E1;ndez et al., 2018\u003C/a>). According to HSF, variants c.7435+3A &#x003E; G, c.7435+5T &#x003E; C, and c.7435+6G &#x003E; A showed only minimal changes of the splice site scores (&#x00B1;1%) so that they should have been excluded from subsequent functional tests.\u003C/p>\r\n\u003Cp class=\"mb0\">Concerning other splicing motifs, minigenes also allow the identification of regulatory sequences (splicing enhancers and silencers) and splicing factors involved in the specific regulation (\u003Ca href=\"#B4\">Baralle and Buratti, 2017\u003C/a>). Indeed, the SRE mapping constitutes an interesting experimental approach since it identifies critical regions for exon recognition. In this context, our group previously found exonic variants that disrupted splicing through elimination of ESEs or creation of \u003Ci>de novo\u003C/i> silencers, such as \u003Ci>BRCA2\u003C/i> variants c.7985C &#x003E; G (predicted missense p.Thr2662Arg) or c.8009C &#x003E; A (predicted nonsense p.Ser2670\u003Csup>&#x2217;\u003C/sup>) (\u003Ca href=\"#B16\">Fraile-Bethencourt et al., 2017\u003C/a>). The splicing assays showed how both variants elicited complete splicing aberrations (mainly exon 18 skipping). However, they were \u003Ci>a priori\u003C/i> classified as missense and nonsense variants, respectively, due to their predicted protein effect. After microdeletion mapping, we have identified a putative ESE-region in exon 15 (c.7463_7492). These ESEs might be involved in exon 15 3&#x2032;ss recognition since their loss produced the use of a cryptic acceptor 83-nt downstream (\u003Ca href=\"#F2\">Figure 2\u003C/a>). Curiously, we did not find any ESE-variants that affected pre-mRNA processing. Only, c.7501C &#x003E; T, which lays near to this presumed ESE interval, provoked a similar outcome to that of r.7463_7492 deletion (\u003Ca href=\"#T2\">Table 2\u003C/a>). In summary, we have tested a total of 117 different variants in minigene MGBR2_14-20, from exons 14&#x2013;18 (\u003Ca href=\"#T4\">Table 4\u003C/a>), 51 of which (43.6%) induced abnormal splicing patterns: 31 disrupted the natural splice sites (16 3&#x2032;ss and 15 5&#x2032;ss), 11 affected SREs, six created \u003Ci>de novo\u003C/i> splice sites and three altered the polypyrimidine tract.\u003C/p>\r\n\u003Ch3>Transcript Interpretation\u003C/h3>\r\n\u003Cp class=\"mb0\">The \u003Ci>BRCA2\u003C/i> exons 14 (c.7008_7435) and 15 (c.7436_7617) encode for amino acids 2336 to p.2539, which are part of the DNA Binding Domain (DBD; p.2459_p.3190). The DBD is the largest conserved region of BRCA2 and is composed of a helical domain (HD), three oligonucleotide binding sites (OB) and a tower domain (TD) (\u003Ca href=\"#B19\">Guidugli et al., 2014\u003C/a>). Specifically, exons 14 and 15 are part of the HD (p.2481_2667) that binds to the protein DSS1 (deleted in split-hand/split-foot syndrome) in the region comprised by the residues 2472&#x2013;2957 (\u003Ca href=\"#B25\">Marston et al., 1999\u003C/a>). Among these residues, a total of 125 are strictly conserved from human to sea urchin. DSS1 is important for BRCA2 stability, since its loss leads to a reduction of BRCA2 levels in human cells (\u003Ca href=\"#B22\">Li et al., 2006\u003C/a>). Moreover, exons 14 and 15 coding region is also recognized by FANCD2 (Fanconi anemia group D2) protein, which binds to the BRCA2 protein between codons 2350 and 2545 (\u003Ca href=\"#B20\">Hussain et al., 2004\u003C/a>). FANCD2, like BRCA2, is one of the 16 proteins that form the Fanconi Anemia complex, aimed to repair DNA interstrand crosslinks. However, it was shown that BRCA2-FANCD2 association has an independent function in the Fanconi Anemia pathway. The BRCA2-FANCD2 complex is involved in the restart of the replication fork, by protecting the nascent DNA strands from degradation (\u003Ca href=\"#B33\">Raghunandan et al., 2015\u003C/a>). Taken together, exons 14 and 15 contain crucial sequences of \u003Ci>BRCA2\u003C/i>, owing to its function in homologous recombination and other relevant biological processes. Moreover, the biological relevance of exons 14 and 15 is supported by the presence of numerous pathological nonsense and frameshift variants at the mutation databases. Hence, the exon 14&#x2013;15 spliceogenic variants that induce PTC-transcripts may be associated with an increased risk of HBOC.\u003C/p>\r\n\u003Ch3>Clinical Interpretation of Spliceogenic Variants\u003C/h3>\r\n\u003Cp class=\"mb15\">Twelve variants altered splicing with different patterns. While some variants caused the total absence of canonical transcript, others originated just &#x223C;5% of aberrant transcripts (\u003Ca href=\"#T2\">Table 2\u003C/a>). Variants c.7008-2A &#x003E; T, c.7008-1G &#x003E; A, c.7435+1G &#x003E; C, c.7436-2A &#x003E; T, c.7436-1G &#x003E; A, c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G did not produce the canonical transcript. Moreover, all the transcripts generated by these variants were frameshift transcripts. Thus, following the criteria of the American College of Medical Genetics and Genomics (ACMG), these eight variants should be classified as pathogenic variants (\u003Ca href=\"#T3\">Table 3\u003C/a>). Variant c.7008-3C &#x003E; G produced &#x0394;(E14) as the major transcript, but the full-length (&#x223C;7%) and the in-frame transcript &#x0394;(E14p246) (&#x223C;13%) were also identified. The &#x0394;(E14p246) isoform contains a deletion of 82 non-conserved amino acids (p.Thr2337_Arg2418del) that form part of the FANCD2 binding site (p.Thr2350_Val2545). At the UMD database, c.7008-3C &#x003E; G is classified as a &#x201C;causal&#x201D; variant because of the skipping of exon 14, but ClinVar shows it as VUS. According to the ACMG criteria, this variant should be cataloged as likely pathogenic (\u003Ca href=\"#T3\">Table 3\u003C/a>). On the other hand, according to the guidelines of the ENIGMA consortium\u003Csup id=\"footnotesuper7\">\u003Ca id=\"note7a\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#note7\">7\u003C/a>\u003C/sup> eight variants should be classified as Class 4 (Likely pathogenic), three as VUS and one as pathogenic, though this is due to its predicted nonsense effect (\u003Ca href=\"#T3\">Table 3\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">On the other hand, missense variants c.7177A &#x003E; G (p.Met2393Val) and c.7447A &#x003E; G (p.Ser2483Gly) produced the canonical transcript as the main outcome and only 5 and 10% of aberrant isoforms, respectively (\u003Ca href=\"#T2\">Table 2\u003C/a>). The canonical transcript generated by these two variants carried missense changes, but \u003Ci>in silico\u003C/i> predictions with the PolyPhen tool\u003Csup id=\"footnotesuper8\">\u003Ca id=\"note8a\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#note8\">8\u003C/a>\u003C/sup> suggested that p.Met2393Val and p.Ser2483Gly were both benign changes. So, following the ACMG criteria, c.7177A &#x003E; G and c.7447A &#x003E; G remain as VUS (\u003Ca href=\"#T3\">Table 3\u003C/a>). Finally, variant c.7501C &#x003E; T generated mainly the canonical transcript (84%) that includes a nonsense change (pathogenic according to ClinVar) so this change should be classified as pathogenic under a combined splicing-protein viewpoint. Altogether, we have re-classified three variants (c.7008-3C &#x003E; G, c.7008-1G &#x003E; A, and c.7436-1G &#x003E; A) from VUS to pathogenic or likely pathogenic, and we have provided further support for the classification of six spliceogenic variants (c.7008-2A &#x003E; T, c.7435+1G &#x003E; C, c.7436-2A &#x003E; T, c.7617+1G &#x003E; A, c.7617+1G &#x003E; T, and c.7617+2T &#x003E; G). Interestingly, c.7617G &#x003E; A is classified as &#x201C;causal&#x201D; in the UMD database\u003Csup id=\"footnotesuper9\">\u003Ca id=\"note9a\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#note9\">9\u003C/a>\u003C/sup> and indicated that causes exon 15 skipping but no functional proofs were provided. However, the functional assay of MGBR2_14-20-c.7617G &#x003E; A only showed the canonical transcript (\u003Ca href=\"#h10\">Supplementary Figure S2\u003C/a>). In fact, NNSplice, HSF and MES estimated just a small decrease (&#x2212;19, &#x2212;11.6, and &#x2212;24%, respectively) of the donor site score. Therefore, c.7617G &#x003E; A behaves as a neutral variant from the splicing perspective. Finally, the minigene MGBR2_14-20 results of 5 exons suggest that a total of 39 spliceogenic variants should be classified as pathogenic or likely pathogenic (\u003Ca href=\"#T4\">Table 4\u003C/a>), lending further support to this strategy for the clinical interpretation of variants.\u003C/p>\r\n\u003Cp class=\"mb0\">In summary, splicing is a finely regulated mechanism which can be altered by any change in the sequence. The disruption of this process might cause serious effects on the protein, from the loss of important domains to the generation of a PTC. Thus, splicing alteration is a common mechanism of gene inactivation, which is often involved in human disease. Here, we have revealed 12 spliceogenic variants of \u003Ci>BRCA2\u003C/i> exons 14 and 15. The minigene based assays offer a relevant information about effects of splicing variants, since they allow to functionally assay almost any DNA change, to quantify all generated transcripts, including very rare ones, and to initially study the splicing regulation. Moreover, we have detected an ESE region that seems to be regulating exon 15 splicing, and therefore constitutes a hypothetical hotspot for putative ESE-mutations. Indeed, pSAD-based minigenes have constituted an invaluable technology to functionally test variants of other disease genes such as \u003Ci>GRN\u003C/i> (Frontotemporal Dementia), \u003Ci>SERPINA1\u003C/i> (Severe alpha-1 antitrypsin deficiency) and \u003Ci>CHD7\u003C/i> (Charge Syndrome) genes (\u003Ca href=\"#B21\">Lara et al., 2014\u003C/a>; \u003Ca href=\"#B44\">Villate et al., 2018\u003C/a>). Altogether, these results highlight, once more, the importance of RNA assays to know the splicing effects of DNA variants to give support to their clinical interpretation and consequently to activate preventive and/or therapeutic interventions.\u003C/p>\r\n\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Author Contributions\u003C/h2>\r\n\u003Cp class=\"mb0\">EF-B contributed to the bioinformatics analysis, minigene construction, manuscript writing, and performed most of the splicing functional assays. BD-G and AV-P participated in minigene construction, mutagenesis experiments, and functional assays. SG-B and MC carried out the data collection of variants and their computer analysis, as well as manuscript editing. EV conceived the study and the experimental design, supervised all the experiments, and wrote the manuscript. All authors contributed to data interpretation, revisions of the manuscript, and approved the final version of the manuscript.\u003C/p>\r\n\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Funding\u003C/h2>\r\n\u003Cp class=\"mb0\">EV&#x2019;s lab was supported by grants from the Spanish Ministry of Science, Innovation and Universities, Plan Nacional de I+D+I 2013-2016, Instituto de Salud Carlos III (PI13/01749 and PI17/00227) co-funded by FEDER from Regional Development European Funds (European Union), and grants CSI090U14 (ORDEN EDU/122/2014) and CSI242P18 (actuaci&#x00F3;n cofinanciada P.O. FEDER 2014-2020 de Castilla y Le&#x00F3;n) from the Consejer&#x00ED;a de Educaci&#x00F3;n, Junta de Castilla y Le&#x00F3;n. EF-B was supported by a predoctoral fellowship from the University of Valladolid and Banco de Santander (2015&#x2013;2019). AV-P was supported by a predoctoral fellowship from Consejer&#x00ED;a de Educaci&#x00F3;n, Junta de Castilla y Le&#x00F3;n (2018&#x2013;2022).\u003C/p>\r\n\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Conflict of Interest Statement\u003C/h2>\r\n\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\r\n\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Acknowledgments\u003C/h2>\r\n\u003Cp class=\"mb0\">We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).\u003C/p>\r\n\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Supplementary Material\u003C/h2>\r\n\u003Cp class=\"mb0\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fgene.2019.00503/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fgene.2019.00503/full#supplementary-material\u003C/a>\u003C/p>\r\n\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>Footnotes\u003C/h2>\r\n\u003Col>\r\n\u003Cli id=\"note1\">\u003Cstrong>\u003Ca style=\"color:gray;\" class=\"footnotetextanchor\" href=\"#note1a\" title=\"\">^\u003C/a>\u003C/strong> \u003Ca style=\"color:gray;\" href=\"https://www.ncbi.nlm.nih.gov/clinvar\">https://www.ncbi.nlm.nih.gov/clinvar\u003C/a>\u003C/li>\r\n\u003Cli id=\"note2\">\u003Cstrong>\u003Ca style=\"color:gray;\" class=\"footnotetextanchor\" href=\"#note2a\" title=\"\">^\u003C/a>\u003C/strong> \u003Ca style=\"color:gray;\" href=\"https://www.ncbi.nlm.nih.gov/clinvar/\">https://www.ncbi.nlm.nih.gov/clinvar/\u003C/a>\u003C/li>\r\n\u003Cli id=\"note3\">\u003Cstrong>\u003Ca style=\"color:gray;\" class=\"footnotetextanchor\" href=\"#note3a\" title=\"\">^\u003C/a>\u003C/strong> \u003Ca style=\"color:gray;\" href=\"http://www.umd.be/BRCA2/\">http://www.umd.be/BRCA2/\u003C/a>\u003C/li>\r\n\u003Cli id=\"note4\">\u003Cstrong>\u003Ca style=\"color:gray;\" class=\"footnotetextanchor\" href=\"#note4a\" title=\"\">^\u003C/a>\u003C/strong> \u003Ca style=\"color:gray;\" href=\"https://research.nhgri.nih.gov/projects/bic/index.shtml\">https://research.nhgri.nih.gov/projects/bic/index.shtml\u003C/a>\u003C/li>\r\n\u003Cli id=\"note5\">\u003Cstrong>\u003Ca style=\"color:gray;\" class=\"footnotetextanchor\" href=\"#note5a\" title=\"\">^\u003C/a>\u003C/strong> \u003Ca style=\"color:gray;\" href=\"http://www.fruitfly.org/seq_tools/splice.html\">http://www.fruitfly.org/seq_tools/splice.html\u003C/a>\u003C/li>\r\n\u003Cli id=\"note6\">\u003Cstrong>\u003Ca style=\"color:gray;\" class=\"footnotetextanchor\" href=\"#note6a\" title=\"\">^\u003C/a>\u003C/strong> \u003Ca style=\"color:gray;\" href=\"http://www.umd.be/HSF3/\">http://www.umd.be/HSF3/\u003C/a>\u003C/li>\r\n\u003Cli id=\"note7\">\u003Cstrong>\u003Ca style=\"color:gray;\" class=\"footnotetextanchor\" href=\"#note7a\" title=\"\">^\u003C/a>\u003C/strong> \u003Ca style=\"color:gray;\" href=\"https://enigmaconsortium.org/library/general-documents/enigma-classification-criteria/\">https://enigmaconsortium.org/library/general-documents/enigma-classification-criteria/\u003C/a>\u003C/li>\r\n\u003Cli id=\"note8\">\u003Cstrong>\u003Ca style=\"color:gray;\" class=\"footnotetextanchor\" href=\"#note8a\" title=\"\">^\u003C/a>\u003C/strong> \u003Ca style=\"color:gray;\" href=\"http://genetics.bwh.harvard.edu/pph2/\">http://genetics.bwh.harvard.edu/pph2/\u003C/a>\u003C/li>\r\n\u003Cli id=\"note9\">\u003Cstrong>\u003Ca style=\"color:gray;\" class=\"footnotetextanchor\" href=\"#note9a\" title=\"\">^\u003C/a>\u003C/strong> \u003Ca style=\"color:gray;\" href=\"https://goo.gl/bG2V4n\">https://goo.gl/bG2V4n\u003C/a>\u003C/li>\r\n\u003C/ol>\r\n\u003Ca id=\"h12\" name=\"h12\">\u003C/a>\u003Ch2>References\u003C/h2>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a>Abramowicz, A., and Gos, M. (2018). Splicing mutations in human genetic disorders: examples, detection, and confirmation. \u003Ci>J. Appl. Genet.\u003C/i> 59, 253&#x2013;268. doi: 10.1007/s13353-018-0444-447\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1007/s13353-018-0444-447\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Splicing+mutations+in+human+genetic+disorders%3A+examples%2C+detection%2C+and+confirmation%2E&#x0026;journal=J%2E+Appl%2E+Genet%2E&#x0026;author=Abramowicz+A.&#x0026;author=and+Gos+M.&#x0026;publication_year=2018&#x0026;volume=59&#x0026;pages=253-268\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a>Acedo, A., Hern&#x00E1;ndez-Moro, C., Curiel-Garc&#x00ED;a, &#x00C1;, D&#x00ED;ez-G&#x00F3;mez, B., and Velasco, E. A. ( (2015). Functional classification of BRCA2 DNA variants by splicing assays in a large minigene with 9 exons. \u003Ci>Hum. Mutat.\u003C/i> 36, 210&#x2013;221. doi: 10.1002/humu.22725\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=25382762\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.22725\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Functional+classification+of+BRCA2+DNA+variants+by+splicing+assays+in+a+large+minigene+with+9+exons%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Acedo+A.&#x0026;author=Hern&#x00E1;ndez-Moro+C.+Curiel-Garc&#x00ED;a&#x0026;author=&#x00C1;+D&#x00ED;ez-G&#x00F3;mez+B.&#x0026;author=and+Velasco+E.+A.&#x0026;publication_year=2015&#x0026;volume=36&#x0026;pages=210-221\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a>Acedo, A., Sanz, D. J., Dur&#x00E1;n, M., Infante, M., P&#x00E9;rez-Cabornero, L., Miner, C., et al. (2012). Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes. \u003Ci>Breast Cancer Res.\u003C/i> 14:R87. doi: 10.1186/bcr3202\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=22632462\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/bcr3202\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Comprehensive+splicing+functional+analysis+of+DNA+variants+of+the+BRCA2+gene+by+hybrid+minigenes%2E&#x0026;journal=Breast+Cancer+Res%2E&#x0026;author=Acedo+A.&#x0026;author=Sanz+D.+J.&#x0026;author=Dur&#x00E1;n+M.&#x0026;author=Infante+M.&#x0026;author=P&#x00E9;rez-Cabornero+L.&#x0026;author=Miner+C.&#x0026;publication_year=2012\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a>Baralle, D., and Buratti, E. (2017). RNA splicing in human disease and in the clinic. \u003Ci>Clin. Sci.\u003C/i> 131, 356&#x2013;368. doi: 10.1042/CS20160211\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=28202748\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1042/CS20160211\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=RNA+splicing+in+human+disease+and+in+the+clinic%2E&#x0026;journal=Clin%2E+Sci%2E&#x0026;author=Baralle+D.&#x0026;author=and+Buratti+E.&#x0026;publication_year=2017&#x0026;volume=131&#x0026;pages=356-368\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a>Beroud, C., Letovsky, S. I., Braastad, C. D., Caputo, S. M., Beaudoux, O., Bignon, Y. J., et al. (2016). BRCA share: a collection of clinical BRCA gene variants. \u003Ci>Hum. Mutat.\u003C/i> 37, 1318&#x2013;1328. doi: 10.1002/humu.23113\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=27633797\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.23113\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA+share%3A+a+collection+of+clinical+BRCA+gene+variants%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Beroud+C.&#x0026;author=Letovsky+S.+I.&#x0026;author=Braastad+C.+D.&#x0026;author=Caputo+S.+M.&#x0026;author=Beaudoux+O.&#x0026;author=Bignon+Y.+J.&#x0026;publication_year=2016&#x0026;volume=37&#x0026;pages=1318-1328\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a>Buys, S. S., Sandbach, J. F., Gammon, A., Patel, G., Kidd, J., Brown, K. L., et al. (2017). A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. \u003Ci>Cancer\u003C/i> 123, 1721&#x2013;1730. doi: 10.1002/cncr.30498\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=28085182\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/cncr.30498\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+study+of+over+35%2C000+women+with+breast+cancer+tested+with+a+25-gene+panel+of+hereditary+cancer+genes%2E&#x0026;journal=Cancer&#x0026;author=Buys+S.+S.&#x0026;author=Sandbach+J.+F.&#x0026;author=Gammon+A.&#x0026;author=Patel+G.&#x0026;author=Kidd+J.&#x0026;author=Brown+K.++L.&#x0026;publication_year=2017&#x0026;volume=123&#x0026;pages=1721-1730\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a>Cartegni, L., Chew, S. L., and Krainer, A. R. (2002). Listening to silence and understanding nonsense: exonic mutations that affect splicing. \u003Ci>Nat. Rev. Genet.\u003C/i> 3, 285&#x2013;298. doi: 10.1038/nrg775\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=11967553\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nrg775\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Listening+to+silence+and+understanding+nonsense%3A+exonic+mutations+that+affect+splicing%2E&#x0026;journal=Nat%2E+Rev%2E++Genet%2E&#x0026;author=Cartegni+L.&#x0026;author=Chew+S.+L.&#x0026;author=and+Krainer+A.+R.&#x0026;publication_year=2002&#x0026;volume=3&#x0026;pages=285-298\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a>Cartegni, L., Wang, J., Zhu, Z., Zhang, M. Q., and Krainer, A. R. (2003). ESEfinder: a web resource to identify exonic splicing enhancers. \u003Ci>Nucleic Acids Res.\u003C/i> 31, 3568&#x2013;3571.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=12824367\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=ESEfinder%3A+a+web+resource+to+identify+exonic+splicing+enhancers%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Cartegni+L.&#x0026;author=Wang+J.&#x0026;author=Zhu+Z.&#x0026;author=Zhang+M.+Q.&#x0026;author=and+Krainer+A.+R.&#x0026;publication_year=2003&#x0026;volume=31&#x0026;pages=3568-3571\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a>Colombo, M., De Vecchi, G., Caleca, L., Foglia, C., Ripamonti, C. B., Ficarazzi, F., et al. (2013). Comparative in vitro and in silico analyses of variants in splicing regions of brca1 and brca2 genes and characterization of novel pathogenic mutations. \u003Ci>PLoS One\u003C/i> 8:e57173. doi: 10.1371/journal.pone.0057173\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=23451180\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pone.0057173\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Comparative+in+vitro+and+in+silico++analyses+of+variants+in+splicing+regions+of+brca1+and+brca2+genes+and+characterization+of+novel+pathogenic+mutations%2E&#x0026;journal=PLoS+One&#x0026;author=Colombo+M.&#x0026;author=De+Vecchi+G.&#x0026;author=Caleca+L.&#x0026;author=Foglia+C.&#x0026;author=Ripamonti+C.++B.&#x0026;author=Ficarazzi+F.&#x0026;publication_year=2013\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a>De Conti, L., Baralle, M., and Buratti, E. (2012). Exon and intron definition in pre-mRNA splicing. \u003Ci>Wiley Interdiscip. Rev. RNA\u003C/i> 4, 49&#x2013;60. doi: 10.1002/wrna.1140\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=23044818\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/wrna.1140\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Exon+and+intron+definition+in+pre-mRNA+splicing%2E&#x0026;journal=Wiley+Interdiscip%2E+Rev%2E+RNA&#x0026;author=De+Conti+L.&#x0026;author=Baralle+M.&#x0026;author=and+Buratti+E.&#x0026;publication_year=2012&#x0026;volume=4&#x0026;pages=49-60\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a>de Garibay, G. R., Acedo, A., Garc&#x00ED;a-Casado, Z., Guti&#x00E9;rrez-Enr&#x00ED;quez, S., Tosar, A., Romero, A., et al. (2014). Capillary electrophoresis analysis of conventional splicing assays: IARC analytical and clinical classification of 31 BRCA2 genetic variants. \u003Ci>Hum. Mutat.\u003C/i> 35, 53&#x2013;57. doi: 10.1002/humu.22456\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=24123850\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.22456\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Capillary+electrophoresis+analysis+of+conventional+splicing+assays%3A+IARC+analytical+and+clinical+classification+of+31+BRCA2+genetic+variants%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=de+Garibay+G.+R.&#x0026;author=Acedo+A.&#x0026;author=Garc&#x00ED;a-Casado+Z.&#x0026;author=Guti&#x00E9;rrez-Enr&#x00ED;quez+S.&#x0026;author=Tosar+A.&#x0026;author=Romero+A.&#x0026;publication_year=2014&#x0026;volume=35&#x0026;pages=53-57\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a>Desmet, F. O., Hamroun, D., Lalande, M., Collod-Beroud, G., Claustres, M., and Beroud, C. (2009). Human Splicing Finder: an online bioinformatics tool to predict splicing signals. \u003Ci>Nucleic Acids Res.\u003C/i> 37:e67. doi: 10.1093/nar/gkp215\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=19339519\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gkp215\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Human+Splicing+Finder%3A+an+online+bioinformatics+tool+to+predict+splicing+signals%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Desmet+F.+O.&#x0026;author=Hamroun+D.&#x0026;author=Lalande+M.&#x0026;author=Collod-Beroud+G.&#x0026;author=Claustres+M.&#x0026;author=and+Beroud+C.&#x0026;publication_year=2009\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a>Eccles, D. M., Mitchell, G., Monteiro, A. N. A., Schmutzler, R., Couch, F. J., Spurdle, A. B., et al. (2015). BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. \u003Ci>Ann. Oncol.\u003C/i> 26, 2057&#x2013;2065. doi: 10.1093/annonc/mdv278\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=26153499\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/annonc/mdv278\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA1+and+BRCA2+genetic+testing-pitfalls+and+recommendations+for+managing+variants+of+uncertain+clinical+significance%2E&#x0026;journal=Ann%2E+Oncol%2E&#x0026;author=Eccles+D.+M.&#x0026;author=Mitchell+G.&#x0026;author=Monteiro+A.+N.+A.&#x0026;author=Schmutzler+R.&#x0026;author=Couch+F.++J.&#x0026;author=Spurdle+A.+B.&#x0026;publication_year=2015&#x0026;volume=26&#x0026;pages=2057-2065\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a>Fackenthal, J. D., Yoshimatsu, T., Zhang, B., de Garibay, G. R., Colombo, M., De Vecchi, G., et al. (2016). Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples. \u003Ci>J. Med. Genet.\u003C/i> 53, 548&#x2013;558. doi: 10.1136/jmedgenet-2015-103570\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=27060066\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/jmedgenet-2015-103570\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Naturally+occurring+BRCA2+alternative+mRNA+splicing+events+in+clinically+relevant+samples%2E&#x0026;journal=J%2E+Med%2E+Genet%2E&#x0026;author=Fackenthal+J.+D.&#x0026;author=Yoshimatsu+T.&#x0026;author=Zhang+B.&#x0026;author=de+Garibay+G.+R.&#x0026;author=Colombo+M.&#x0026;author=De+Vecchi+G.&#x0026;publication_year=2016&#x0026;volume=53&#x0026;pages=548-558\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a>Farber-Katz, S., Hsuan, V., Wu, S., Landrith, T., Vuong, H., Xu, D., et al. (2018). Quantitative Analysis of BRCA1 and BRCA2 Germline Splicing Variants Using a Novel RNA-Massively Parallel Sequencing Assay. \u003Ci>Front. Oncol.\u003C/i> 8:286. doi: 10.3389/fonc.2018.00286\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=30101128\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fonc.2018.00286\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Quantitative+Analysis+of+BRCA1+and+BRCA2+Germline+Splicing+Variants+Using+a+Novel+RNA-Massively+Parallel+Sequencing+Assay%2E&#x0026;journal=Front%2E++Oncol%2E&#x0026;author=Farber-Katz+S.&#x0026;author=Hsuan+V.&#x0026;author=Wu+S.&#x0026;author=Landrith+T.&#x0026;author=Vuong+H.&#x0026;author=Xu+D.&#x0026;publication_year=2018\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a>Fraile-Bethencourt, E., D&#x00ED;ez-G&#x00F3;mez, B., Vel&#x00E1;squez-Zapata, V., Acedo, A., Sanz, D. J., and Velasco, E. A. (2017). Functional classification of DNA variants by hybrid minigenes: identification of 30 spliceogenic variants of BRCA2 exons 17 and 18. \u003Ci>PLoS Genet.\u003C/i> 13:e1006691. doi: 10.1371/journal.pgen.1006691\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=28339459\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pgen.1006691\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Functional+classification+of+DNA+variants+by+hybrid+minigenes%3A+identification+of+30+spliceogenic+variants+of+BRCA2+exons+17+and+18%2E&#x0026;journal=PLoS+Genet%2E&#x0026;author=Fraile-Bethencourt+E.&#x0026;author=D&#x00ED;ez-G&#x00F3;mez+B.&#x0026;author=Vel&#x00E1;squez-Zapata+V.&#x0026;author=Acedo+A.&#x0026;author=Sanz+D.++J.&#x0026;author=and+Velasco+E.++A.&#x0026;publication_year=2017\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a>Fraile-Bethencourt, E., Valenzuela-Palomo, A., D&#x00ED;ez-G&#x00F3;mez, B., Acedo, A., and Velasco, E. A. (2018). Identification of Eight Spliceogenic Variants in BRCA2 Exon 16 by Minigene Assays. \u003Ci>Front. Genet.\u003C/i> 9:188. doi: 10.3389/fgene.2018.00188\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=29881398\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fgene.2018.00188\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Identification+of+Eight+Spliceogenic+Variants+in+BRCA2+Exon+16+by+Minigene+Assays%2E&#x0026;journal=Front%2E++Genet%2E&#x0026;author=Fraile-Bethencourt+E.&#x0026;author=Valenzuela-Palomo+A.&#x0026;author=D&#x00ED;ez-G&#x00F3;mez+B.&#x0026;author=Acedo+A.&#x0026;author=and+Velasco+E.+A.&#x0026;publication_year=2018\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a>Fraile-Bethencourt, E., Valenzuela-Palomo, A., D&#x00ED;ez-G&#x00F3;mez, B., Goina, E., Acedo, A., Buratti, E., et al. (2019). Mis-splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assays. \u003Ci>J. Pathol.\u003C/i> doi: 10.1002/path.5268 [Epub ahead of print].\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=30883759\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/path.5268 [Epub ahead of print].\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Mis-splicing+in+breast+cancer%3A+identification+of+pathogenic+BRCA2+variants+by+systematic+minigene+assays%2E&#x0026;journal=J%2E+Pathol%2E&#x0026;author=Fraile-Bethencourt+E.&#x0026;author=Valenzuela-Palomo+A.&#x0026;author=D&#x00ED;ez-G&#x00F3;mez+B.&#x0026;author=Goina+E.&#x0026;author=Acedo+A.&#x0026;author=Buratti+E.&#x0026;publication_year=2019\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a>Guidugli, L., Carreira, A., Caputo, S. M., Ehlen, A., Galli, A., Monteiro, A. N., et al. (2014). Functional assays for analysis of variants of uncertain significance in BRCA2. \u003Ci>Hum. Mutat.\u003C/i> 35, 151&#x2013;164. doi: 10.1002/humu.22478\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=24323938\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.22478\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Functional+assays+for+analysis+of+variants+of+uncertain+significance+in+BRCA2%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Guidugli+L.&#x0026;author=Carreira+A.&#x0026;author=Caputo+S.+M.&#x0026;author=Ehlen+A.&#x0026;author=Galli+A.&#x0026;author=Monteiro+A.+N.&#x0026;publication_year=2014&#x0026;volume=35&#x0026;pages=151-164\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a>Hussain, S., Wilson, J. B., Medhurst, A. L., Hejna, J., Witt, E., Ananth, S., et al. (2004). Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. \u003Ci>Hum. Mol. Genet.\u003C/i> 13, 1241&#x2013;1248. doi: 10.1093/hmg/ddh135\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=15115758\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/hmg/ddh135\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Direct+interaction+of+FANCD2+with+BRCA2+in+DNA+damage+response+pathways%2E&#x0026;journal=Hum%2E++Mol%2E++Genet%2E&#x0026;author=Hussain+S.&#x0026;author=Wilson+J.++B.&#x0026;author=Medhurst+A.++L.&#x0026;author=Hejna+J.&#x0026;author=Witt+E.&#x0026;author=Ananth+S.&#x0026;publication_year=2004&#x0026;volume=13&#x0026;pages=1241-1248\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a>Lara, B., Mart&#x00ED;nez, M. T., Blanco, I., Hern&#x00E1;ndez-Moro, C., Velasco, E. A., Ferrarotti, I., et al. (2014). Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadrid. \u003Ci>Respir. Res.\u003C/i> 15, 125. doi: 10.1186/s12931-014-0125-y\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=25287719\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s12931-014-0125-y\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Severe+alpha-1+antitrypsin+deficiency+in+composite+heterozygotes+inheriting+a+new+splicing+mutation+QOMadrid%2E&#x0026;journal=Respir%2E+Res%2E&#x0026;author=Lara+B.&#x0026;author=Mart&#x00ED;nez+M.+T.&#x0026;author=Blanco+I.&#x0026;author=Hern&#x00E1;ndez-Moro+C.&#x0026;author=Velasco+E.+A.&#x0026;author=Ferrarotti+I.&#x0026;publication_year=2014&#x0026;volume=15&#x0026;issue=125\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a>Li, J., Zou, C., Bai, Y., Wazer, D. E., Band, V., and Gao, Q. (2006). DSS1 is required for the stability of BRCA2. \u003Ci>Oncogene\u003C/i> 25, 1186&#x2013;1194. doi: 10.1038/sj.onc.1209153\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=16205630\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/sj.onc.1209153\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=DSS1+is+required+for+the+stability+of+BRCA2%2E&#x0026;journal=Oncogene&#x0026;author=Li+J.&#x0026;author=Zou+C.&#x0026;author=Bai+Y.&#x0026;author=Wazer+D.++E.&#x0026;author=Band+V.&#x0026;author=and+Gao+Q.&#x0026;publication_year=2006&#x0026;volume=25&#x0026;pages=1186-1194\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a>L&#x00F3;pez-Bigas, N., Audit, B., Ouzounis, C., Parra, G., and Guig&#x00F3;, R. (2005). Are splicing mutations the most frequent cause of hereditary disease? \u003Ci>FEBS Lett.\u003C/i> 579, 1900&#x2013;1903. doi: 10.1016/j.febslet.2005.02.047\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=15792793\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.febslet.2005.02.047\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Are+splicing+mutations+the+most+frequent+cause+of+hereditary+disease%B4&#x0026;journal=FEBS+Lett%2E&#x0026;author=L&#x00F3;pez-Bigas+N.&#x0026;author=Audit+B.&#x0026;author=Ouzounis+C.&#x0026;author=Parra+G.&#x0026;author=and+Guig&#x00F3;+R.&#x0026;publication_year=2005&#x0026;volume=579&#x0026;pages=1900-1903\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a>Lopez-Perolio, I., Leman, R., Behar, R., Lattimore, V., Pearson, J. F., Cast&#x00E9;ra, L., et al. (2019). Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report. \u003Ci>J. Med. Genet.\u003C/i> 2019, 1&#x2013;9. doi: 10.1136/jmedgenet-2018-105834\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=30890586\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/jmedgenet-2018-105834\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Alternative+splicing+and+ACMG-AMP-2015-based+classification+of+PALB2+genetic+variants%3A+an+ENIGMA+report%2E&#x0026;journal=J%2E+Med%2E+Genet%2E&#x0026;author=Lopez-Perolio+I.&#x0026;author=Leman+R.&#x0026;author=Behar+R.&#x0026;author=Lattimore+V.&#x0026;author=Pearson+J.++F.&#x0026;author=Cast&#x00E9;ra+L.&#x0026;publication_year=2019&#x0026;volume=2019&#x0026;pages=1-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a>Marston, N. J., Richards, W. J., Hughes, D., Bertwistle, D., Marshall, C. J., and Ashworth, A. (1999). Interaction between the Product of the Breast Cancer Susceptibility Gene \u003Ci>BRCA2\u003C/i> and DSS1, a Protein Functionally Conserved from Yeast to Mammals. \u003Ci>Mol. Cell. Biol.\u003C/i> 19, 4633&#x2013;4642. doi: 10.1128/MCB.19.7.4633\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=10373512\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1128/MCB.19.7.4633\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Interaction+between+the+Product+of+the+Breast+Cancer+Susceptibility+Gene+BRCA2+and+DSS1%2C+a+Protein+Functionally+Conserved+from+Yeast+to+Mammals%2E&#x0026;journal=Mol%2E++Cell%2E++Biol%2E&#x0026;author=Marston+N.++J.&#x0026;author=Richards+W.++J.&#x0026;author=Hughes+D.&#x0026;author=Bertwistle+D.&#x0026;author=Marshall+C.++J.&#x0026;author=and+Ashworth+A.&#x0026;publication_year=1999&#x0026;volume=19&#x0026;pages=4633-4642\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a>Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., et al. (2013). Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. \u003Ci>J. Natl. Cancer Inst.\u003C/i> 105, 812&#x2013;822. doi: 10.1093/jnci/djt095\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=23628597\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/jnci/djt095\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Cancer+risks+for+BRCA1+and+BRCA2+mutation+carriers%3A+results+from++prospective+analysis+of+EMBRACE%2E&#x0026;journal=J%2E+Natl%2E+Cancer+Inst%2E&#x0026;author=Mavaddat+N.&#x0026;author=Peock+S.&#x0026;author=Frost+D.&#x0026;author=Ellis+S.&#x0026;author=Platte+R.&#x0026;author=Fineberg+E.&#x0026;publication_year=2013&#x0026;volume=105&#x0026;pages=812-822\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a>Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. \u003Ci>Science\u003C/i> 266, 66&#x2013;71.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=7545954\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+strong+candidate+for+the+breast+and+ovarian+cancer+susceptibility+gene+BRCA1%2E&#x0026;journal=Science&#x0026;author=Miki+Y.&#x0026;author=Swensen+J.&#x0026;author=Shattuck-Eidens+D.&#x0026;author=Futreal+P.+A.&#x0026;author=Harshman+K.&#x0026;author=Tavtigian+S.&#x0026;publication_year=1994&#x0026;volume=266&#x0026;pages=66-71\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a>Moles-Fern&#x00E1;ndez, A., Duran-Lozano, L., Montalban, G., Bonache, S., L&#x00F3;pez-Perolio, I., Men&#x00E9;ndez, M., et al. (2018). Computational tools for splicing defect prediction in breast/ovarian cancer genes: how efficient are they at predicting rna alterations? \u003Ci>Front. Genet.\u003C/i> 9:366. doi: 10.3389/fgene.2018.00366\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=30233647\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fgene.2018.00366\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Computational+tools+for+splicing+defect+prediction+in+breast%2Fovarian+cancer+genes%3A+how+efficient+are+they+at+predicting+rna+alterations%B4&#x0026;journal=Front%2E++Genet%2E&#x0026;author=Moles-Fern&#x00E1;ndez+A.&#x0026;author=Duran-Lozano+L.&#x0026;author=Montalban+G.&#x0026;author=Bonache+S.&#x0026;author=L&#x00F3;pez-Perolio+I.&#x0026;author=Men&#x00E9;ndez+M.&#x0026;publication_year=2018\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a>Montalban, G., Fraile-Bethencourt, E., L&#x00F3;pez-Perolio, I., P&#x00E9;rez-Segura, P., Infante, M., Dur&#x00E1;n, M., et al. (2018). Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.\u003Ci>7976\u003C/i>+5G &#x003E; T as a case study. \u003Ci>Hum. Mutat.\u003C/i> 39, 1155&#x2013;1160. doi: 10.1002/humu.23583\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=29969168\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.23583\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Characterization+of+spliceogenic+variants+located+in+regions+linked+to+high+levels+of+alternative+splicing%3A+BRCA2+c%2E7976%2B5G+>+T+as+a+case+study%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Montalban+G.&#x0026;author=Fraile-Bethencourt+E.&#x0026;author=L&#x00F3;pez-Perolio+I.&#x0026;author=P&#x00E9;rez-Segura+P.&#x0026;author=Infante+M.&#x0026;author=Dur&#x00E1;n+M.&#x0026;publication_year=2018&#x0026;volume=39&#x0026;pages=1155-1160\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a>Nielsen, F. C., van Overeem Hansen, T., and S&#x00F8;rensen, C. S. (2016). Hereditary breast and ovarian cancer: new genes in confined pathways. \u003Ci>Nat. Rev. Cancer\u003C/i> 16, 599&#x2013;612. doi: 10.1038/nrc.2016.72\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=27515922\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nrc.2016.72\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Hereditary+breast+and+ovarian+cancer%3A+new+genes+in+confined+pathways%2E&#x0026;journal=Nat%2E++Rev%2E+Cancer&#x0026;author=Nielsen+F.++C.&#x0026;author=van+Overeem+Hansen+T.&#x0026;author=and+S&#x00F8;rensen+C.++S.&#x0026;publication_year=2016&#x0026;volume=16&#x0026;pages=599-612\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a>Petrucelli, N., Daly, M. B., and Feldman, G. L. (2013). &#x201C;BRCA1 and BRCA2 hereditary breast and ovarian cancer&#x201D;. \u003Ci>GeneReviews\u003Csup>&#x00AE;\u003C/sup>[Internet]\u003C/i> eds MP., Adam, H. H., Ardinger Seattle, WA: University of Washington, Seattle 1&#x2013;11.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=%22BRCA1+and+BRCA2+hereditary+breast+and+ovarian+cancer%22%2E&#x0026;journal=GeneReviews&#xAE;%3B%5BInternet%5D&#x0026;author=Petrucelli+N.&#x0026;author=Daly+M.++B.&#x0026;author=and+Feldman+G.++L.&#x0026;publication_year=2013&#x0026;pages=1-11\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a>Radice, P., De, S. S., Caleca, L., and Tommasi, S. (2011). Unclassified variants in BRCA genes: guidelines for interpretation. \u003Ci>Ann.Oncol.\u003C/i> 22(Suppl. 1), i18&#x2013;i23. doi: 10.1093/annonc/mdq661\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=21285146\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/annonc/mdq661\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Unclassified+variants+in+BRCA+genes%3A+guidelines+for+interpretation%2E&#x0026;journal=Ann%2EOncol%2E&#x0026;author=Radice+P.&#x0026;author=De+S.+S.&#x0026;author=Caleca+L.&#x0026;author=and+Tommasi+S.&#x0026;publication_year=2011&#x0026;pages=i18-i23\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a>Raghunandan, M., Chaudhury, I., Kelich, S. L., Hanenberg, H., and Sobeck, A. (2015). FANCD2. FANCJ and BRCA2 cooperate to promote replication fork recovery independently of the Fanconi Anemia core complex. \u003Ci>Cell Cycle\u003C/i> 14, 342&#x2013;353. doi: 10.4161/15384101.2014.987614\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=25659033\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.4161/15384101.2014.987614\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=FANCD2%2E+FANCJ+and+BRCA2+cooperate+to+promote+replication+fork+recovery+independently+of+the+Fanconi+Anemia+core+complex%2E&#x0026;journal=Cell+Cycle&#x0026;author=Raghunandan+M.&#x0026;author=Chaudhury+I.&#x0026;author=Kelich+S.+L.&#x0026;author=Hanenberg+H.&#x0026;author=and+Sobeck+A.&#x0026;publication_year=2015&#x0026;volume=14&#x0026;pages=342-353\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a>Rebbeck, T. R., Friebel, T. M., Friedman, E., Hamann, U., Huo, D., Kwong, A., et al. (2018). Mutational spectrum in a worldwide study of 29,700 families with \u003Ci>BRCA1\u003C/i> or \u003Ci>BRCA2\u003C/i> mutations. \u003Ci>Hum. Mutat.\u003C/i> 39, 593&#x2013;620. doi: 10.1002/humu.23406\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=29446198\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.23406\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Mutational+spectrum+in+a+worldwide+study+of+29%2C700+families+with+BRCA1+or+BRCA2+mutations%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Rebbeck+T.++R.&#x0026;author=Friebel+T.++M.&#x0026;author=Friedman+E.&#x0026;author=Hamann+U.&#x0026;author=Huo+D.&#x0026;author=Kwong+A.&#x0026;publication_year=2018&#x0026;volume=39&#x0026;pages=593-620\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a>Reese, M. G., Eeckman, F. H., Kulp, D., and Haussler, D. (1997). Improved splice site detection in Genie. \u003Ci>J. Comput. Biol.\u003C/i> 4, 311&#x2013;323. doi: 10.1089/cmb.1997.4.311\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=9278062\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1089/cmb.1997.4.311\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Improved+splice+site+detection+in+Genie%2E&#x0026;journal=J%2E+Comput%2E+Biol%2E&#x0026;author=Reese+M.++G.&#x0026;author=Eeckman+F.++H.&#x0026;author=Kulp+D.&#x0026;author=and+Haussler+D.&#x0026;publication_year=1997&#x0026;volume=4&#x0026;pages=311-323\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a>Ricks, T. K., Chiu, H.-J., Ison, G., Kim, G., McKee, A. E., Kluetz, P., et al. (2015). Successes and challenges of PARP inhibitors in cancer therapy. \u003Ci>Front. Oncol.\u003C/i> 5:222. doi: 10.3389/fonc.2015.00222\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=26528434\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fonc.2015.00222\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Successes+and+challenges+of+PARP+inhibitors+in+cancer+therapy%2E&#x0026;journal=Front%2E++Oncol%2E&#x0026;author=Ricks+T.+K.&#x0026;author=Chiu+H.-J.&#x0026;author=Ison+G.&#x0026;author=Kim+G.&#x0026;author=McKee+A.+E.&#x0026;author=Kluetz+P.&#x0026;publication_year=2015\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a>Sharma, N., Sosnay, P. R., Ramalho, A. S., Douville, C., Franca, A., Gottschalk, L. B., et al. (2014). Experimental assessment of splicing variants using expression minigenes and comparison with in silico predictions. \u003Ci>Hum. Mutat.\u003C/i> 35,1249&#x2013;1259. doi: 10.1002/humu.22624\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=25066652\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.22624\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Experimental+assessment+of+splicing+variants+using+expression+minigenes+and+comparison+with+in+silico+predictions%2E&#x0026;journal=Hum%2E++Mutat%2E&#x0026;author=Sharma+N.&#x0026;author=Sosnay+P.++R.&#x0026;author=Ramalho+A.++S.&#x0026;author=Douville+C.&#x0026;author=Franca+A.&#x0026;author=Gottschalk+L.+B.&#x0026;publication_year=2014&#x0026;volume=35&#x0026;pages=1249-1259\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a>Slavin, T. P., Maxwell, K. N., Lilyquist, J., Vijai, J., Neuhausen, S. L., Hart, S. N., et al. (2017). The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. \u003Ci>NPJ Breast Cancer\u003C/i> 3, 22. doi: 10.1038/s41523-017-0024-8\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=29119134\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41523-017-0024-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=The+contribution+of+pathogenic+variants+in+breast+cancer+susceptibility+genes+to+familial+breast+cancer+risk%2E&#x0026;journal=NPJ+Breast+Cancer&#x0026;author=Slavin+T.+P.&#x0026;author=Maxwell+K.+N.&#x0026;author=Lilyquist+J.&#x0026;author=Vijai+J.&#x0026;author=Neuhausen+S.+L.&#x0026;author=Hart+S.+N.&#x0026;publication_year=2017&#x0026;volume=3&#x0026;issue=22\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a>Slavin, T. P., Niell-Swiller, M., Solomon, I., Nehoray, B., Rybak, C., Blazer, K. R., et al. (2015). Clinical application of multigene panels: challenges of next-generation counseling and cancer risk management. \u003Ci>Front. Oncol.\u003C/i> 5:208. doi: 10.3389/fonc.2015.00208\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=26484312\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fonc.2015.00208\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Clinical+application+of+multigene+panels%3A+challenges+of+next-generation+counseling+and+cancer+risk+management%2E&#x0026;journal=Front%2E+Oncol%2E&#x0026;author=Slavin+T.+P.&#x0026;author=Niell-Swiller+M.&#x0026;author=Solomon+I.&#x0026;author=Nehoray+B.&#x0026;author=Rybak+C.&#x0026;author=Blazer+K.+R.&#x0026;publication_year=2015\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B40\" id=\"B40\">\u003C/a>Spurdle, A. B., Couch, F. J., Hogervorst, F. B. L., Radice, P., and Sinilnikova, O. M. (2008). Prediction and assessment of splicing alterations: implications for clinical testing. \u003Ci>Hum. Mutat.\u003C/i> 29, 1304&#x2013;1313. doi: 10.1002/humu.20901\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=18951448\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.20901\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Prediction+and+assessment+of+splicing+alterations%3A+implications+for+clinical+testing%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Spurdle+A.+B.&#x0026;author=Couch+F.+J.&#x0026;author=Hogervorst+F.+B.+L.&#x0026;author=Radice+P.&#x0026;author=and+Sinilnikova+O.+M.&#x0026;publication_year=2008&#x0026;volume=29&#x0026;pages=1304-1313\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B41\" id=\"B41\">\u003C/a>Spurdle, A. B., Healey, S., Devereau, A., Hogervorst, F. B. L., Monteiro, A. N. A., Nathanson, K. L., et al. (2012). ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. \u003Ci>Hum. Mutat.\u003C/i> 33, 2&#x2013;7. doi: 10.1002/humu.21628\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=21990146\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.21628\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=ENIGMA-evidence-based+network+for+the+interpretation+of+germline+mutant+alleles%3A+an+international+initiative+to+evaluate+risk+and+clinical+significance+associated+with+sequence+variation+in+BRCA1+and+BRCA2+genes%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Spurdle+A.+B.&#x0026;author=Healey+S.&#x0026;author=Devereau+A.&#x0026;author=Hogervorst+F.+B.+L.&#x0026;author=Monteiro+A.+N.++A.&#x0026;author=Nathanson+K.+L.&#x0026;publication_year=2012&#x0026;volume=33&#x0026;pages=2-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B42\" id=\"B42\">\u003C/a>Stratton, M. R., and Rahman, N. (2008). The emerging landscape of breast cancer susceptibility. \u003Ci>Nat. Genet.\u003C/i> 40, 17&#x2013;22.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=The+emerging+landscape+of+breast+cancer+susceptibility%2E&#x0026;journal=Nat%2E+Genet%2E&#x0026;author=Stratton+M.+R.&#x0026;author=and+Rahman+N.&#x0026;publication_year=2008&#x0026;volume=40&#x0026;pages=17-22\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B43\" id=\"B43\">\u003C/a>Vall&#x00E9;e, M. P., Di Sera, T. L., Nix, D. A., Paquette, A. M., Parsons, M. T., Bell, R., et al. (2016). Adding in silico assessment of potential splice aberration to the integrated evaluation of brca gene unclassified variants. \u003Ci>Hum. Mutat.\u003C/i> 37, 627&#x2013;639. doi: 10.1002/humu.22973\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=26913838\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.22973\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Adding+in+silico+assessment+of+potential+splice+aberration+to+the+integrated+evaluation+of+brca+gene+unclassified+variants%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Vall&#x00E9;e+M.+P.&#x0026;author=Di+Sera+T.+L.&#x0026;author=Nix+D.+A.&#x0026;author=Paquette+A.+M.&#x0026;author=Parsons+M.+T.&#x0026;author=Bell+R.&#x0026;publication_year=2016&#x0026;volume=37&#x0026;pages=627-639\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B44\" id=\"B44\">\u003C/a>Villate, O., Ibarluzea, N., Fraile-Bethencourt, E., Valenzuela, A., Velasco, E. A., Grozeva, D., et al. (2018). Functional analyses of a novel splice variant in the CHD7 gene. found by next generation sequencing, confirm its pathogenicity in a spanish patient and diagnose him with CHARGE syndrome. \u003Ci>Front. Genet.\u003C/i> 9, 26&#x2013;31. doi: 10.3389/fgene.2018.00007\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=29434620\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fgene.2018.00007\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Functional+analyses+of+a+novel+splice+variant+in+the+CHD7+gene%2E+found+by+next+generation+sequencing%2C+confirm+its+pathogenicity+in+a+spanish+patient+and+diagnose+him+with+CHARGE+syndrome%2E&#x0026;journal=Front%2E+Genet%2E&#x0026;author=Villate+O.&#x0026;author=Ibarluzea+N.&#x0026;author=Fraile-Bethencourt+E.&#x0026;author=Valenzuela+A.&#x0026;author=Velasco+E.++A.&#x0026;author=Grozeva+D.&#x0026;publication_year=2018&#x0026;volume=9&#x0026;pages=26-31\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B45\" id=\"B45\">\u003C/a>Vreeswijk, M. P. G., Kraan, J. N., van der Klift, H. M., Vink, G. R., Cornelisse, C. J., Wijnen, J. T., et al. (2009). Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. \u003Ci>Hum. Mutat.\u003C/i> 30, 107&#x2013;114. doi: 10.1002/humu.20811\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=18693280\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.20811\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Intronic+variants+in+BRCA1+and+BRCA2+that+affect+RNA+splicing+can+be+reliably+selected+by+splice-site+prediction+programs%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Vreeswijk+M.++P.++G.&#x0026;author=Kraan+J.++N.&#x0026;author=van+der+Klift+H.++M.&#x0026;author=Vink+G.++R.&#x0026;author=Cornelisse+C.+J.&#x0026;author=Wijnen+J.+T.&#x0026;publication_year=2009&#x0026;volume=30&#x0026;pages=107-114\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B46\" id=\"B46\">\u003C/a>Wang, G.-S., and Cooper, T. A. (2007). Splicing in disease: disruption of the splicing code and the decoding machinery. \u003Ci>Nat. Rev. Genet.\u003C/i> 8, 749&#x2013;761. doi: 10.1038/nrg2164\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=17726481\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nrg2164\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Splicing+in+disease%3A+disruption+of+the+splicing+code+and+the+decoding+machinery%2E&#x0026;journal=Nat%2E+Rev%2E+Genet%2E&#x0026;author=Wang+G.-S.&#x0026;author=and+Cooper+T.+A.&#x0026;publication_year=2007&#x0026;volume=8&#x0026;pages=749-761\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B47\" id=\"B47\">\u003C/a>Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. \u003Ci>Nature\u003C/i> 378, 789&#x2013;792. doi: 10.1038/378789a0\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=8524414\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/378789a0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Identification+of+the+breast+cancer+susceptibility+gene+BRCA2%2E&#x0026;journal=Nature&#x0026;author=Wooster+R.&#x0026;author=Bignell+G.&#x0026;author=Lancaster+J.&#x0026;author=Swift+S.&#x0026;author=Seal+S.&#x0026;author=Mangion+J.&#x0026;publication_year=1995&#x0026;volume=378&#x0026;pages=789-792\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B48\" id=\"B48\">\u003C/a>Yeo, G., and Burge, C. B. (2004). Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. \u003Ci>J. Comput. Biol.\u003C/i> 11, 377&#x2013;394. doi: 10.1089/1066527041410418\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=15285897\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1089/1066527041410418\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Maximum+entropy+modeling+of+short+sequence+motifs+with+applications+to+RNA+splicing+signals%2E&#x0026;journal=J%2E+Comput%2E+Biol%2E&#x0026;author=Yeo+G.&#x0026;author=and+Burge+C.++B.&#x0026;publication_year=2004&#x0026;volume=11&#x0026;pages=377-394\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B49\" id=\"B49\">\u003C/a>Zhang, M. Q. (1998). Statistical features of human exons and their flanking regions. \u003Ci>Hum. Mol. Genet.\u003C/i> 7, 919&#x2013;932. doi: 10.1093/hmg/7.5.919\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x0026;Cmd=ShowDetailView&#x0026;TermToSearch=9536098\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/hmg/7.5.919\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Statistical+features+of+human+exons+and+their+flanking+regions%2E&#x0026;journal=Hum%2E+Mol%2E+Genet%2E&#x0026;author=Zhang+M.+Q.&#x0026;publication_year=1998&#x0026;volume=7&#x0026;pages=919-932\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003C/div>\r\n\u003Cdiv class=\"thinLineM20\">\u003C/div>\r\n\u003Cdiv class=\"AbstractSummary\">\r\n\u003Cp>\u003Cspan>Keywords\u003C/span>: breast cancer, BRCA2, DNA variants, splicing, hybrid minigenes\u003C/p>\r\n\u003Cp>\u003Cspan>Citation:\u003C/span> Fraile-Bethencourt E, Valenzuela-Palomo A, D&#x00ED;ez-G&#x00F3;mez B, Caloca MJ, G&#x00F3;mez-Barrero S and Velasco EA (2019) Minigene Splicing Assays Identify 12 Spliceogenic Variants of \u003Ci>BRCA2\u003C/i> Exons 14 and 15. \u003Ci>Front. Genet.\u003C/i> 10:503. doi: 10.3389/fgene.2019.00503\u003C/p>\r\n\u003Cp id=\"timestamps\">\r\n\u003Cspan>Received:\u003C/span> 05 February 2019; \u003Cspan>Accepted:\u003C/span> 07 May 2019;\u003Cbr>\u003Cspan>Published:\u003C/span> 28 May 2019.\u003C/p>\r\n\u003Cdiv>\r\n\u003Cp>Edited by:\u003C/p>\r\n\u003Ca href=\"https://loop.frontiersin.org/people/143042/overview\">Naoyuki Kataoka\u003C/a>, The University of Tokyo, Japan\u003C/div>\r\n\u003Cdiv>\r\n\u003Cp>Reviewed by:\u003C/p>\r\n\u003Ca href=\"https://loop.frontiersin.org/people/302927/overview\">Logan Walker\u003C/a>, University of Otago, New Zealand\u003Cbr>\r\n\u003Ca href=\"https://loop.frontiersin.org/people/132589/overview\">Katarzyna Gaweda-Walerych\u003C/a>, Mossakowski Medical Research Centre (PAN), Poland\u003Cbr>\r\n\u003Ca href=\"https://loop.frontiersin.org/people/290253/overview\">Mads Thomassen\u003C/a>, Odense University Hospital, Denmark\u003C/div>\r\n\u003Cp>\u003Cspan>Copyright\u003C/span> &#x00A9; 2019 Fraile-Bethencourt, Valenzuela-Palomo, D&#x00ED;ez-G&#x00F3;mez, Caloca, G&#x00F3;mez-Barrero and Velasco. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\r\n\u003Cp>\u003Cspan>*Correspondence:\u003C/span> Eladio A. Velasco, \u003Ca id=\"encmail\">ZWF2ZWxzYW1AaWJnbS51dmEuZXM=\u003C/a>\u003C/p>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003C/div>\r\n","\u003Cul class=\"flyoutJournal\">\r\n\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h3\">Materials and Methods\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h6\">Author Contributions\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h7\">Funding\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h8\">Conflict of Interest Statement\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h9\">Acknowledgments\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h10\">Supplementary Material\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h11\">Footnotes\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h12\">References\u003C/a>\u003C/li>\r\n\u003C/ul>\r\n",[647,652,658,661,667],{"name":648,"fileServerPackageEntryId":19,"fileServerId":649,"fileServerVersionNumber":374,"type":650},"EPUB.epub","452814/epub",{"code":651,"name":651},"EPUB",{"name":653,"fileServerPackageEntryId":654,"fileServerId":655,"fileServerVersionNumber":374,"type":656},"fgene-10-00503.pdf","fgene-10-00503/fgene-10-00503.pdf","452814/pubmed-zip",{"code":657,"name":657},"PDF",{"name":653,"fileServerPackageEntryId":19,"fileServerId":659,"fileServerVersionNumber":374,"type":660},"452814/publishers-proof/pdf",{"code":657,"name":657},{"name":662,"fileServerPackageEntryId":663,"fileServerId":655,"fileServerVersionNumber":374,"type":664},"fgene-10-00503.xml","fgene-10-00503/fgene-10-00503.xml",{"code":665,"name":666},"NLM_XML","XML",{"name":668,"fileServerPackageEntryId":19,"fileServerId":669,"fileServerVersionNumber":374,"type":670},"Provisional PDF.pdf","452814/provisional-pdf",{"code":657,"name":657},"v3",{"title":673,"link":674,"meta":678,"script":789},"Frontiers | Minigene Splicing Assays Identify 12 Spliceogenic Variants of BRCA2 Exons 14 and 15",[675],{"rel":676,"href":677},"canonical","https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/full",[679,682,685,687,690,694,697,701,704,707,710,712,714,716,718,720,723,726,728,731,734,736,739,742,745,748,751,755,759,762,764,767,769,772,775,778,781,784,786],{"hid":680,"property":680,"name":680,"content":681},"description","A relevant fraction of BRCA2 variants is associated with splicing alterations and with an increased risk of hereditary breast and ovarian cancer (HBOC). In t...",{"hid":683,"property":683,"name":684,"content":673},"og:title","title",{"hid":686,"property":686,"name":680,"content":681},"og:description",{"hid":688,"name":688,"content":689},"keywords","breast  cancer,BRCA2,DNA variants,Aberrant splicing,Minigenes",{"hid":691,"property":691,"name":692,"content":693},"og:site_name","site_name","Frontiers",{"hid":695,"property":695,"name":367,"content":696},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/452814/fgene-10-00503-HTML/image_m/fgene-10-00503-g001.jpg",{"hid":698,"property":698,"name":699,"content":700},"og:type","type","article",{"hid":702,"property":702,"name":703,"content":677},"og:url","url",{"hid":705,"name":705,"content":706},"twitter:card","summary_large_image",{"hid":708,"name":708,"content":709},"citation_volume","10",{"hid":711,"name":711,"content":116},"citation_journal_title",{"hid":713,"name":713,"content":693},"citation_publisher",{"hid":715,"name":715,"content":627},"citation_journal_abbrev",{"hid":717,"name":717,"content":628},"citation_issn",{"hid":719,"name":719,"content":518},"citation_doi",{"hid":721,"name":721,"content":722},"citation_firstpage","452814",{"hid":724,"name":724,"content":725},"citation_language","English",{"hid":727,"name":727,"content":519},"citation_title",{"hid":729,"name":729,"content":730},"citation_keywords","breast  cancer; BRCA2; DNA variants; Aberrant splicing; Minigenes",{"hid":732,"name":732,"content":733},"citation_abstract","A relevant fraction of BRCA2 variants is associated with splicing alterations and with an increased risk of hereditary breast and ovarian cancer (HBOC). In this work, we have carried out a thorough study of variants from BRCA2 exons 14 and 15 reported at mutation databases.A total of 294 variants from exons 14 and 15 and flanking intronic sequences were analysed with the online splicing tools NNSplice and Human Splicing Finder. Fifty-three out of these 294 variants were selected as candidate splicing variants. All variants but one, were introduced into the minigene MGBR2_ex14-20 (with exons 14 to 20) by site-directed mutagenesis and assayed in MCF-7 cells. Twelve of the remaining 52 variants (23.1%) impaired splicing at different degrees, yielding from 5% to 100% of aberrant transcripts. Nine variants affected the natural acceptor or donor sites of both exons and three affected putative enhancers or silencers. Fluorescent capillary electrophoresis revealed at least ten different anomalous transcripts: (E14q5),  (E14p10), (E14p246), (E14q256), (E14), (E15p12), (E15p13), (E15p83), (E15) and a 942-nt fragment of unknown structure. All transcripts, except for (E14q256) and (E15p12), are expected to truncate the BRCA2 protein. Nine variants induced severe splicing aberrations with more than 90% of abnormal transcripts. Thus, according to the guidelines of the American College of Medical Genetics and Genomics, eight variants should be classified as pathogenic (c.7008-2A>T, c.7008-1G>A, c.7435+1G>C, c.7436-2A>T, c.7436-2A>G, c.7617+1G>A, c.7617+1G>T and c.7617+2T>G), one as likely pathogenic (c.7008-3C>G) and three remain as variants of uncertain clinical significance or VUS (c.7177A>G, c.7447A>G and c.7501C>T).In conclusion, functional assays by minigenes constitute a valuable strategy to primarily check the splicing impact of DNA variants and their clinical interpretation. While bioinformatics predictions of splice site variants were accurate, those of enhancer or silencer variants were poor (only 3/23 spliceogenic variants) which showed weak impacts on splicing (~5 to 16% of aberrant isoforms). So, the Exonic Splicing Enhancer and Silencer (ESE and ESS, respectively) prediction algorithms require further improvement.",{"hid":735,"name":735,"content":533},"citation_article_type",{"hid":737,"name":737,"content":738},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/pdf",{"hid":740,"name":740,"content":741},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00503/xml",{"hid":743,"name":743,"content":744},"citation_fulltext_world_readable","yes",{"hid":746,"name":746,"content":747},"citation_online_date","2019/05/07",{"hid":749,"name":749,"content":750},"citation_publication_date","2019/05/28",{"hid":752,"name":753,"content":754},"citation_author_0","citation_author","Fraile-Bethencourt, Eugenia ",{"hid":756,"name":757,"content":758},"citation_author_institution_0","citation_author_institution","Splicing and Genetic Susceptibility to Cancer, Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain",{"hid":760,"name":753,"content":761},"citation_author_1","Valenzuela-Palomo, Alberto ",{"hid":763,"name":757,"content":758},"citation_author_institution_1",{"hid":765,"name":753,"content":766},"citation_author_2","Dez-Gmez, Beatriz ",{"hid":768,"name":757,"content":758},"citation_author_institution_2",{"hid":770,"name":753,"content":771},"citation_author_3","Caloca, Mara Jos ",{"hid":773,"name":757,"content":774},"citation_author_institution_3","Instituto de Biologa y Gentica Molecular (CSIC-UVa), Spain",{"hid":776,"name":753,"content":777},"citation_author_4","Gmez-Barrero, Susana ",{"hid":779,"name":757,"content":780},"citation_author_institution_4","VISAVET-Universidad Complutense de Madrid, Spain",{"hid":782,"name":753,"content":783},"citation_author_5","Velasco, Eladio A. ",{"hid":785,"name":757,"content":758},"citation_author_institution_5",{"hid":787,"name":787,"content":788},"dc.identifier","doi:10.3389/fgene.2019.00503",[790,793,795,797,799],{"src":791,"body":13,"type":792,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":794,"body":13,"type":792,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":796,"body":13,"type":792,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":798,"body":13,"type":792,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fgene.2019.00503?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":800,"body":13,"type":792,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":802,"articleHubArticlesList":803,"canJournalHasArticleHub":359,"articleDoiList":804},{},[],[],{"title":19,"image":-1,"breadcrumbs":806,"linksCollection":807,"metricsCollection":809},[],{"total":371,"items":808},[],{"total":371,"items":810},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fgene.2019.00503?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>